

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ABALOPARATIDE

Products Affected

- TYMLOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 MONTHS
Other Criteria	OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ABATACEPT IV

Products Affected

- ORENCIA INTRAVENOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	RA, PJIA, PSA: INITIAL: 6 MOS, RENEWAL: 12 MOS. ACUTE GRAFT VERSUS HOST DISEASE (AGVHD): 1 MO.
Other Criteria	INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. RENEWAL: RA, PJIA, PSA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ABATACEPT SQ

Products Affected

- ORENCIA CLICKJECT
- ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PJIA, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ABEMACICLIB

Products Affected

- VERZENIO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ABIRATERONE

Products Affected

- *abiraterone acetate*
- *abirtega*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC HIGH-RISK CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC), METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

ABIRATERONE SUBMICRONIZED

Products Affected

- ABIRATERONE ACETATE MICRONIZED
- YONSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ACALABRUTINIB

Products Affected

- CALQUENCE ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ACORAMIDIS

Products Affected

- ATTRUBY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CARDIOMYOPATHY OF WILD TYPE OR VARIANT TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM): INITIAL: 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS I, II, OR III HEART FAILURE, AND 2) DIAGNOSIS CONFIRMED BY (A) BONE SCAN (SCINTIGRAPHY) STRONGLY POSITIVE FOR MYOCARDIAL UPTAKE OF TC-99M-PYP, OR (B) BIOPSY OF TISSUE OF AFFECTED ORGAN(S) (CARDIAC AND POSSIBLY NON-CARDIAC SITES) TO CONFIRM AMYLOID PRESENCE AND CHEMICAL TYPING TO CONFIRM PRESENCE OF TRANSTHYRETIN (TTR) PROTEIN.
Age Restrictions	
Prescriber Restrictions	ATTR-CM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST, ATTR SPECIALIST, OR MEDICAL GENETICIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	ATTR-CM: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER ATTR-CM TTR STABILIZERS (E.G., TAFAMIDIS).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ADAGRASIB

Products Affected

- KRAZATI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ADALIMUMAB

Products Affected

- HUMIRA (2 PEN) SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA (2 SYRINGE) SUBCUTANEOUS PREFILLED SYRINGE KIT 10 MG/0.1ML, 20 MG/0.2ML, 40 MG/0.4ML, 40 MG/0.8ML
- HUMIRA-CD/UC/HS STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PED<40KG CROHNS STARTER
- HUMIRA-PED>=40KG CROHNS START
- HUMIRA-PED>=40KG UC STARTER SUBCUTANEOUS AUTO-INJECTOR KIT
- HUMIRA-PSORIASIS/UVEIT STARTER SUBCUTANEOUS AUTO-INJECTOR KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST.
Coverage Duration	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ADALIMUMAB-AATY

Products Affected

- *adalimumab-aaty (1 pen) auto-injector kit 40 mg/0.4ml subcutaneous*
- *adalimumab-aaty (1 pen) subcutaneous auto-injector kit 80 mg/0.8ml*
- *adalimumab-aaty (2 pen)*
- *adalimumab-aaty (2 syringe)*
- *adalimumab-aaty cd/uc/hs start*
- *YUFLYMA (1 PEN)*
- *YUFLYMA (2 SYRINGE)*
- *YUFLYMA-CD/UC/HS STARTER*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST.
Coverage Duration	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ADALIMUMAB-ADBIM

Products Affected

- CYLTEZO (2 PEN)
- CYLTEZO (2 SYRINGE)
- CYLTEZO-CD/UC/HS STARTER
- CYLTEZO-PSORIASIS/UV STARTER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST.
Coverage Duration	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	(PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ADALIMUMAB-BWWD

Products Affected

- HADLIMA
- HADLIMA PUSHTOUCH

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: RA, PJIA, ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST OR RHEUMATOLOGIST. PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH GASTROENTEROLOGIST. UVEITIS: PRESCRIBED BY OR IN CONSULTATION WITH OPHTHALMOLOGIST.
Coverage Duration	INITIAL: RA, PSO, PJIA, AS, PSA, CD, UC, UVEITIS: 6 MONTHS, HS: 12 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RHEUMATOID ARTHRITIS (RA): TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. UVEITIS: DOES NOT HAVE ISOLATED ANTERIOR UVEITIS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), PSA, AS, PSO, HS, UVEITIS: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

AFATINIB

Products Affected

- GILOTRIF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ALECTINIB

Products Affected

- ALECENSA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ALPELISIB-PIQRAY

Products Affected

- PIQRAY (200 MG DAILY DOSE)
- PIQRAY (250 MG DAILY DOSE)
- PIQRAY (300 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

AMIKACIN LIPOSOMAL INH

Products Affected

- ARIKAYCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE: RENEWAL: 1) NO POSITIVE MAC SPUTUM CULTURE AFTER CONSECUTIVE NEGATIVE CULTURES, AND 2) IMPROVEMENT IN SYMPTOMS. ADDITIONALLY, FOR FIRST RENEWAL, APPROVAL REQUIRES AT LEAST ONE NEGATIVE SPUTUM CULTURE FOR MAC BY SIX MONTHS OF ARIKAYCE TREATMENT. FOR SECOND AND SUBSEQUENT RENEWALS, APPROVAL REQUIRES AT LEAST THREE NEGATIVE SPUTUM CULTURES FOR MAC BY 12 MONTHS OF ARIKAYCE TREATMENT.
Age Restrictions	
Prescriber Restrictions	MAC LUNG DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR INFECTIOUS DISEASE SPECIALIST.
Coverage Duration	INITIAL/RENEWAL: 6 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

AMIVANTAMAB-HYALURONIDASE-LPUJ

Products Affected

- RYBREVANT FASPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

AMIVANTAMAB-VMJW

Products Affected

- RYBREVANT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ANAKINRA

Products Affected

- KINERET SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED ADULTS.
Required Medical Information	INITIAL: CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES. DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS.
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	RA: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. CAPS, DIRA: LIFETIME.
Other Criteria	INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS:

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: RA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

APALUTAMIDE

Products Affected

- ERLEADA ORAL TABLET 240 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC), METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

APOMORPHINE - ONAPGO

Products Affected

- ONAPGO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PD: RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

APREMILAST

Products Affected

- OTEZLA
- OTEZLA XR
- OTEZLA/OTEZLA XR INITIATION PK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: MILD PLAQUE PSORIASIS (PSO): 1) PSORIASIS COVERING LESS THAN 3 PERCENT OF BODY SURFACE AREA (BSA), 2) STATIC PHYSICIAN GLOBAL ASSESSMENT (SPGA) SCORE OF 2, OR 3) PSORIASIS AREA AND SEVERITY INDEX (PASI) SCORE OF 2 TO 9. MODERATE TO SEVERE PSO: PSORIASIS COVERING 3 PERCENT OR MORE OF BSA, OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. BEHCETS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: MILD PSO: TRIAL OF OR CONTRAINDICATION TO ONE CONVENTIONAL SYSTEMIC THERAPY (E.G., METHOTREXATE, ACITRETIN, CYCLOSPORINE) OR ONE CONVENTIONAL TOPICAL THERAPY (E.G., TOPICAL CORTICOSTEROIDS). MODERATE TO SEVERE PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR,

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	OR JAK INHIBITOR FOR THE SAME INDICATION. BEHCETS DISEASE: 1) HAS ORAL ULCERS OR A HISTORY OF RECURRENT ORAL ULCERS BASED ON CLINICAL SYMPTOMS, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OR MORE CONSERVATIVE TREATMENTS (E.G., COLCHICINE, TOPICAL CORTICOSTEROID, ORAL CORTICOSTEROID). INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ALL INDICATIONS: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ARIMOCLOMOL

Products Affected

- MIPLYFFA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	NIEMANN-PICK DISEASE TYPE C (NPC): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH NEUROLOGIST OR GENETICIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	NPC: RENEWAL: IMPROVEMENT OR SLOWING OF DISEASE PROGRESSION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ASCIMINIB

Products Affected

- SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED OR T315I MUTATION PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND SCEMBLIX IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ATOGEPANT

Products Affected

- QULIPTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

AVACOPAN

Products Affected

- TAVNEOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	ANTI-NEUTROPHIL CYTOPLASMIC AUTOANTIBODY (ANCA)-ASSOCIATED VASCULITIS: INITIAL: ANCA SEROPOSITIVE (ANTI-PR3 OR ANTI-MPO).
Age Restrictions	
Prescriber Restrictions	ANCA-ASSOCIATED VASCULITIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 6 MONTHS.
Other Criteria	ANCA-ASSOCIATED VASCULITIS: RENEWAL: CONTINUES TO BENEFIT FROM THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

AVAPRITINIB

Products Affected

- AYVAKIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

AVUTOMETINIB-DEFACTINIB

Products Affected

- AVMAPKI FAKZYNJA CO-PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

AXATILIMAB-CSFR

Products Affected

- NIKTIMVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CHRONIC GRAFT VS HOST DISEASE (CGVHD): 1) FAILURE OF AT LEAST TWO LINES OF SYSTEMIC THERAPY, ONE OF WHICH MUST BE A TRIAL OF OR CONTRAINDICATION TO JAKAFI, AND 2) NO CONCURRENT USE WITH JAKAFI, REZUROCK, OR IMBRUVICA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

AXITINIB

Products Affected

- INLYTA ORAL TABLET 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

AZACITIDINE

Products Affected

- ONUREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

AZTREONAM INHALED

Products Affected

- CAYSTON

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	7 YEARS OF AGE OR OLDER
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

BEDAQUILINE

Products Affected

- SIRTURO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 WEEKS
Other Criteria	N/A
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

BELIMUMAB

Products Affected

- BENLYSTA SUBCUTANEOUS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. LUPUS NEPHRITIS (LN): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR NEPHROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: SLE: CURRENTLY TAKING CORTICOSTEROIDS, ANTIMALARIALS, NSAIDS, OR IMMUNOSUPPRESSIVE AGENTS. RENEWAL: SLE: PATIENT HAD CLINICAL IMPROVEMENT. LN: IMPROVEMENT IN RENAL RESPONSE FROM BASELINE LABORATORY VALUES (I.E., EGFR OR PROTEINURIA) AND/OR CLINICAL PARAMETERS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

BELUMOSUDIL

Products Affected

- REZUROCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CHRONIC GRAFT VS HOST DISEASE (CGVHD): 1) FAILURE OF AT LEAST TWO LINES OF SYSTEMIC THERAPY, ONE OF WHICH MUST BE A TRIAL OF OR CONTRAINDICATION TO JAKAFI, AND 2) NO CONCURRENT USE WITH JAKAFI, NIKTIMVO, OR IMBRUVICA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

BELZUTIFAN

Products Affected

- WELIREG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

BENDAMUSTINE

Products Affected

- BENDAMUSTINE HCL
INTRA VENOUS SOLUTION
- *bendamustine hcl intravenous solution
reconstituted*
- BENDEKA
- VIVIMUSTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

BENRALIZUMAB

Products Affected

- FASENRA
- FASENRA PEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
Age Restrictions	
Prescriber Restrictions	INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE.
Coverage Duration	ASTHMA, EGPA: INITIAL/RENEWAL: 12 MO. HYPEREOSINOPHILIC SYNDROME (HES): 12 MO.
Other Criteria	INITIAL: ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE, OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS, OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION.

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	RENEWAL: ASTHMA: 1) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): REDUCTION IN EGPA SYMPTOMS COMPARED TO BASELINE OR ABILITY TO REDUCE/ELIMINATE CORTICOSTEROID USE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

BEVACIZUMAB-BVZR

Products Affected

- ZIRABEV

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

BEXAROTENE

Products Affected

- *bexarotene*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

BINIMETINIB

Products Affected

- MEKTOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

BORTEZOMIB

Products Affected

- BORTEZOMIB INJECTION
- BORUZU

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

BOSENTAN

Products Affected

- bosentan oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PAH: INITIAL: 1) DOES NOT HAVE ELEVATED LIVER ENZYMES (ALT, AST) MORE THAN 3 TIMES UPPER LIMIT OF NORMAL (ULN) OR INCREASE IN BILIRUBIN BY 2 OR MORE TIMES ULN, AND 2) NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE. RENEWAL: NO CONCURRENT USE WITH CYCLOSPORINE A OR GLYBURIDE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

BOSUTINIB

Products Affected

- BOSULIF ORAL CAPSULE 100 MG, 500 MG
- *bosutinib oral tablet 100 mg, 400 mg, 500 mg*
- BOSULIF ORAL TABLET 100 MG, 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND THERAPY IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

BRIGATINIB

Products Affected

- ALUNBRIG ORAL TABLET 180 MG, 30 MG, 90 MG
- ALUNBRIG ORAL TABLET THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

C1 ESTERASE INHIBITOR-HAEGARDA

Products Affected

- HAEGARDA SUBCUTANEOUS
SOLUTION RECONSTITUTED 2000
UNIT, 3000 UNIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HEREDITARY ANGIOEDEMA (HAE): INITIAL: 1) TYPE III HAE, OR 2) TYPE I OR II HAE CONFIRMED BY ONE OF THE FOLLOWING COMPLEMENT TESTS: C1-INH PROTEIN LEVELS, C4 PROTEIN LEVELS, C1-INH FUNCTIONAL LEVELS, C1Q.
Age Restrictions	
Prescriber Restrictions	HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, IMMUNOLOGIST, ALLERGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	HAE: INITIAL/RENEWAL: NOT ON CONCURRENT TREATMENT WITH ALTERNATIVE PROPHYLACTIC AGENT FOR HAE ATTACKS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

CABOZANTINIB CAPSULE

Products Affected

- COMETRIQ (100 MG DAILY DOSE)
ORAL KIT 80 & 20 MG
- COMETRIQ (140 MG DAILY DOSE)
ORAL KIT 3 X 20 MG & 80 MG
- COMETRIQ (60 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

CABOZANTINIB TABLET

Products Affected

- CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

CANNABIDIOL

Products Affected

- EPIDIOLEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: DRAVET SYNDROME (DS), LENNOX-GASTAUT SYNDROME (LGS), TUBEROUS SCLEROSIS COMPLEX (TSC): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: LGS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

CAPIVASERTIB

Products Affected

- TRUQAP ORAL TABLET 200 MG
- TRUQAP ORAL TABLET THERAPY PACK 160 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

CAPMATINIB

Products Affected

- TABRECTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

CARGLUMIC ACID

Products Affected

- carglumic acid oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ACUTE OR CHRONIC HYPERAMMONEMIA (HA) DUE TO N ACETYLGUTAMATE SYNTHASE (NAGS) DEFICIENCY: NAGS GENE MUTATION IS CONFIRMED BY BIOCHEMICAL OR GENETIC TESTING. ACUTE HA DUE TO PROPIONIC ACIDEMIA (PA): 1) CONFIRMED BY ELEVATED METHYLCITRIC ACID AND NORMAL METHYLMALONIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE PCCA OR PCCB GENE. ACUTE HA DUE TO METHYLMALONIC ACIDEMIA (MMA): 1) CONFIRMED BY ELEVATED METHYLMALONIC ACID, METHYLCITRIC ACID, OR 2) GENETIC TESTING CONFIRMS MUTATION IN THE MMUT, MMA, MMAB OR MMADHC GENES.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ACUTE HA DUE TO NAGS/PA/MMA: 7 DAYS. CHRONIC HA DUE TO NAGS: INITIAL: 6 MOS, RENEWAL: 12 MOS.
Other Criteria	RENEWAL: CHRONIC HA DUE TO NAGS: PATIENT HAS SHOWN CLINICAL IMPROVEMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

CERITINIB

Products Affected

- ZYKADIA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

CERTOLIZUMAB PEGOL

Products Affected

- CIMZIA (1 SYRINGE)
- CIMZIA (2 SYRINGE)
- CIMZIA SUBCUTANEOUS KIT 2 X 200 MG
- CIMZIA-STARTER

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. PSA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA,

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, XELJANZ, RINVOQ, SKYRIZI, TREMFYA, ORENCIA, OTEZLA. AS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ. CD: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, RINVOQ, SKYRIZI, TREMFYA. PSO: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: COSENTYX, HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, SELARSDI/YESINTEK/USTEKINUMAB-AAUZ, SKYRIZI, TREMFYA, OTEZLA. NR-AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ IR, ORENCIA, RINVOQ. INITIAL FOR RA, PSA, PSO, AS, CD, PJIA: TRIAL OF OR CONTRAINDICATION TO THE STEP AGENTS IS NOT REQUIRED IF THE PATIENT IS PREGNANT, BREASTFEEDING, OR TRYING TO BECOME PREGNANT. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL FOR RA, PSA, AS, PSO, NR-AXSPA, PJIA: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

CETUXIMAB

Products Affected

- ERBITUX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

CLOBAZAM-SYMPAZAN

Products Affected

- SYMPAZAN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: LENNOX-GASTAUT SYNDROME (LGS): THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	LGS: INITIAL: CONTRAINDICATION TO OR UNABLE TO SWALLOW CLOBAZAM TABLETS OR SUSPENSION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

COBIMETINIB

Products Affected

- COTELLIC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

CRIZOTINIB CAPSULE

Products Affected

- XALKORI ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

CRIZOTINIB PELLETS

Products Affected

- XALKORI ORAL CAPSULE SPRINKLE
150 MG, 20 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	NON-SMALL CELL LUNG CANCER (NSCLC), ANAPLASTIC LARGE CELL LYMPHOMA (ALCL), INFLAMMATORY MYOFIBROBLASTIC TUMOR (IMT): UNABLE TO SWALLOW CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DABRAFENIB CAPSULES

Products Affected

- TAFINLAR ORAL CAPSULE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

DABRAFENIB SUSPENSION

Products Affected

- TAFINLAR ORAL TABLET SOLUBLE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNABLE TO SWALLOW TAFINLAR CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

DACOMITINIB

Products Affected

- VIZIMPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE-INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DALFAMPRIDINE

Products Affected

- dalfampridine er*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	MULTIPLE SCLEROSIS (MS): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	MS: INITIAL: HAS SYMPTOMS OF A WALKING DISABILITY (E.G., MILD TO MODERATE BILATERAL LOWER EXTREMITY WEAKNESS, UNILATERAL WEAKNESS PLUS LOWER EXTREMITY OR TRUNCAL ATAXIA). RENEWAL: IMPROVEMENT IN WALKING ABILITY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DAROLUTAMIDE

Products Affected

- NUBEQA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC), METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DASATINIB

Products Affected

- dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND DASATINIB IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

DATOPOTAMAB DERUXTECAN-DLNK

Products Affected

- DATROWAY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

DECITABINE/CEDAZURIDINE

Products Affected

- INQOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DEFERASIROX

Products Affected

- *deferasirox granules*
- *deferasirox oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 1000 MCG/L. CHRONIC IRON OVERLOAD IN NON-TRANSFUSION DEPENDENT THALASSEMIA (NTDT): 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS), AND 2) LIVER IRON CONCENTRATION (LIC) OF 5 MG FE/G OF LIVER DRY WEIGHT OR GREATER. RENEWAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS: SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 500 MCG/L. NTDT: 1) SERUM FERRITIN LEVEL CONSISTENTLY ABOVE 300 MCG/L (AT LEAST TWO LAB VALUES IN THE PREVIOUS THREE MONTHS) OR 2) LIC OF 3 MG FE/G OF LIVER DRY WEIGHT OR GREATER.
Age Restrictions	
Prescriber Restrictions	INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS OR NTDT: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR HEMATOLOGIST/ONCOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: CHRONIC IRON OVERLOAD DUE TO BLOOD TRANSFUSIONS OR NTDT: DEFERASIROX SPRINKLE PACKETS: TRIAL OF OR CONTRAINDICATION TO GENERIC DEFERASIROX ORAL TABLET OR TABLET FOR ORAL SUSPENSION.
Indications	All FDA-approved Indications.
Off Label Uses	

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

DENOSUMAB-BMWO - OSENVELT

Products Affected

- OSENVELT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DEUTETRABENAZINE

Products Affected

- AUSTEDO ORAL TABLET 12 MG, 6 MG, 9 MG
- AUSTEDO XR ORAL TABLET EXTENDED RELEASE 24 HOUR 12 MG, 18 MG, 24 MG, 30 MG, 36 MG, 42 MG, 48 MG, 6 MG
- AUSTEDO XR PATIENT TITRATION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HUNTINGTON DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST. TARDIVE DYSKINESIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST.
Coverage Duration	12 MONTHS
Other Criteria	TARDIVE DYSKINESIA: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DEXTROMETHORPHAN QUINIDINE

Products Affected

- dextromethorphan-quinidine*
- NUEDEXTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

DICLOFENAC TOPICAL SOLUTION

Products Affected

- diclofenac sodium external solution 2 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	OSTEOARTHRITIS OF THE KNEE: TRIAL OF OR CONTRAINDICATION TO A FORMULARY VERSION OF DICLOFENAC SODIUM 1.5% TOPICAL DROPS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DICLOFENAC-FLECTOR

Products Affected

- diclofenac epolamine external*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DIMETHYL FUMARATE

Products Affected

- *dimethyl fumarate oral capsule delayed release 120 mg, 240 mg*
- *dimethyl fumarate starter pack oral capsule delayed release therapy pack*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

DIROXIMEL FUMARATE

Products Affected

- VUMERITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DORDAVIPRONE

Products Affected

- MODEYSO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DOSTARLIMAB-GXLY

Products Affected

- JEMPERLI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DRONABINOL CAPSULE

Products Affected

- dronabinol oral capsule*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	NAUSEA AND VOMITING ASSOCIATED WITH CANCER CHEMOTHERAPY: TRIAL OF OR CONTRAINDICATION TO ONE ANTIEMETIC THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DROXIDOPA

Products Affected

- droxidopa*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	NEUROGENIC ORTHOSTATIC HYPOTENSION (NOH): INITIAL: 1) BASELINE BLOOD PRESSURE READINGS WHILE THE PATIENT IS SITTING AND ALSO WITHIN 3 MINUTES OF STANDING FROM A SUPINE POSITION. 2) A DECREASE OF AT LEAST 20 MMHG IN SYSTOLIC BLOOD PRESSURE OR 10 MMHG DIASTOLIC BLOOD PRESSURE WITHIN THREE MINUTES AFTER STANDING FROM A SITTING POSITION.
Age Restrictions	
Prescriber Restrictions	NOH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR CARDIOLOGIST.
Coverage Duration	INITIAL: 3 MONTHS RENEWAL: 12 MONTHS
Other Criteria	NOH: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DUPILUMAB

Products Affected

- DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: EOSINOPHILIC ASTHMA: BLOOD EOSINOPHIL LEVEL OF 150 TO 1500 CELLS/MCL WITHIN THE PAST 12 MONTHS. EOSINOPHILIC ESOPHAGITIS (EOE): DIAGNOSIS CONFIRMED BY ESOPHAGOGASTRODUODENOSCOPY (EGD) WITH BIOPSY.
Age Restrictions	
Prescriber Restrictions	INITIAL: AD, PN, CSU: PRESCRIBED OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED OR IN CONSULTATION WITH ALLERGIST OR PULMONOLOGIST. CRSWNP: PRESCRIBED OR IN CONSULTATION WITH OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOE: PRESCRIBED OR IN CONSULTATION WITH GASTROENTEROLOGIST, ALLERGIST, OR IMMUNOLOGIST. COPD: PRESCRIBED OR IN CONSULTATION WITH PULMONOLOGIST. RENEWAL: CSU: PRESCRIBED OR IN CONSULTATION WITH ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
Coverage Duration	BP, AFRS: 12 MO. AD/CRSWNP/EOE/PN/CSU: INITIAL/RENEWAL: 6 MO/12 MO. ASTHMA/COPD: INIT/RENEW: 12 MO.
Other Criteria	INITIAL: AD: TRIAL OF OR CONTRAINDICATION TO ONE TOPICAL (CORTICOSTEROID, CALCINEURIN INHIBITOR, PDE4 INHIBITOR, AHR AGONIST OR JAK INHIBITOR). ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY-TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	LEAST 3 DAYS WITHIN THE PAST 12 MONTHS, OR ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: (A) DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, (B) ANY NIGHT WAKING DUE TO ASTHMA, (C) SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, (D) ANY ACTIVITY LIMITATION DUE TO ASTHMA. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) EVIDENCE OF NASAL POLYPS BY DIRECT EXAMINATION, ENDOSCOPY, OR SINUS CT SCAN, AND 3) INADEQUATELY CONTROLLED DISEASE. PRURIGO NODULARIS (PN): CHRONIC PRURITUS (ITCH MORE THAN 6 WEEKS), MULTIPLE PRURIGINOUS LESIONS, AND HISTORY OR SIGN OF A PROLONGED SCRATCHING BEHAVIOR. EOSINOPHILIC COPD: USED IN COMBINATION WITH A LAMA/LABA/ICS. CHRONIC SPONTANEOUS URTICARIA (CSU): 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE AND 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS. INITIAL/RENEWAL : ALL INDICATIONS EXCEPT BULLOUS PEMPHIGOID (BP): NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: AD, CRSWNP, EOE: IMPROVEMENT WHILE ON THERAPY. ASTHMA: 1) CONTINUED USE OF ICS AND ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, OR (D) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS. PN: IMPROVEMENT OR REDUCTION OF PRURITUS OR PRURIGINOUS LESIONS. EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, AND 2) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: (A) REDUCTION IN COPD EXACERBATIONS FROM BASELINE, OR

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	(B) REDUCTION IN SEVERITY OR FREQUENCY OF COPD-RELATED SYMPTOMS. CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

DUVELISIB

Products Affected

- COPIKTRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

EFLORNITHINE

Products Affected

- IWILFIN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ELACESTRANT

Products Affected

- ORSERDU ORAL TABLET 345 MG, 86 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ELAPEGADEMASE-LVLR

Products Affected

- REVCOVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	ADENOSINE DEAMINASE SEVERE COMBINED IMMUNE DEFICIENCY (ADA-SCID): INITIAL: ADA-SCID AS MANIFESTED BY: 1) CONFIRMATORY GENETIC TEST, OR 2) SUGGESTIVE LABORATORY FINDINGS (E.G., ELEVATED DEOXYADENOSINE NUCLEOTIDE [DAXP] LEVELS, LYMPHOPENIA) AND HALLMARK SIGNS/SYMPTOMS (E.G., RECURRENT INFECTIONS, FAILURE TO THRIVE, PERSISTENT DIARRHEA).
Age Restrictions	
Prescriber Restrictions	ADA-SCID: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH IMMUNOLOGIST, HEMATOLOGIST/ONCOLOGIST, OR PHYSICIAN SPECIALIZING IN INHERITED METABOLIC DISORDERS.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	ADA-SCID: RENEWAL: 1) IMPROVEMENT OR MAINTENANCE OF IMMUNE FUNCTION FROM BASELINE, AND 2) HAS NOT RECEIVED SUCCESSFUL HCT OR GENE THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ELEXACFTOR-TEZACFTOR-IVACFTOR

Products Affected

- TRIKAFTA ORAL TABLET THERAPY • TRIKAFTA ORAL THERAPY PACK PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CYSTIC FIBROSIS (CF): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: LIFETIME.
Other Criteria	CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ELRANATAMAB-BCMM

Products Affected

- ELREXFIO SUBCUTANEOUS
SOLUTION 44 MG/1.1ML, 76
MG/1.9ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	RELAPSED OR REFRACTORY MULTIPLE MYELOMA: RENEWAL: 1) HAS RECEIVED AT LEAST 24 WEEKS OF TREATMENT WITH ELREXFIO, AND 2) HAS RESPONDED TO TREATMENT (PARTIAL RESPONSE OR BETTER), AND HAS MAINTAINED THIS RESPONSE FOR AT LEAST 2 MONTHS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ELTROMBOPAG - ALVAIZ

Products Affected

- ALVAIZ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT IS LESS THAN $30 \times 10^9/L$, OR 2) PLATELET COUNT IS LESS THAN $50 \times 10^9/L$ AND HAD A PRIOR BLEEDING EVENT.
Age Restrictions	
Prescriber Restrictions	INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.
Coverage Duration	ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.
Other Criteria	INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS). RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNT FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ELTROMBOPAG - PROMACTA

Products Affected

- *eltrombopag olamine oral packet 12.5 mg, 25 mg*
- *eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PERSISTENT OR CHRONIC IMMUNE THROMBOCYTOPENIA (ITP): INITIAL: 1) PLATELET COUNT OF LESS THAN $30 \times 10^9/L$, OR 2) PLATELET COUNT OF LESS THAN $50 \times 10^9/L$ AND A PRIOR BLEEDING EVENT.
Age Restrictions	
Prescriber Restrictions	INITIAL: ITP: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR IMMUNOLOGIST.
Coverage Duration	ITP: INITIAL: 6 MO, RENEWAL: 12 MO. HEPATITIS C, SEVERE APLASTIC ANEMIA: 12 MO.
Other Criteria	INITIAL: ITP: 1) TRIAL OF OR CONTRAINDICATION TO ONE CORTICOSTEROID OR IMMUNOGLOBULIN, OR HAD AN INSUFFICIENT RESPONSE TO SPLENECTOMY, AND 2) NO CONCURRENT USE WITH OTHER THROMBOPOIETIN RECEPTOR AGONISTS (TPO-RAS). ALL INDICATIONS: ELTROMBOPAG ORAL SUSPENSION PACKETS: TRIAL OF A FORMULARY VERSION OF ELTROMBOPAG TABLET OR PATIENT IS UNABLE TO TOLERATE TABLET FORMULATION. RENEWAL: ITP: 1) IMPROVEMENT IN PLATELET COUNTS FROM BASELINE OR REDUCTION IN BLEEDING EVENTS, AND 2) NO CONCURRENT USE WITH OTHER TPO-RAS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ENASIDENIB

Products Affected

- IDHIFA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ENCORAFENIB

Products Affected

- BRAFTOVI ORAL CAPSULE 75 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

ENSARTINIB

Products Affected

- ENSACOVE ORAL CAPSULE 100 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

ENTRECTINIB CAPSULES

Products Affected

- ROZLYTREK ORAL CAPSULE 100 MG, 200 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ENTRECTINIB PELLETS

Products Affected

- ROZLYTREK ORAL PACKET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), SOLID TUMORS: 1) TRIAL OF OR CONTRAINDICATION TO ROZLYTREK CAPSULES MADE INTO AN ORAL SUSPENSION, AND 2) DIFFICULTY OR UNABLE TO SWALLOW CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ENZALUTAMIDE

Products Affected

- XTANDI ORAL CAPSULE
- XTANDI ORAL TABLET 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	NON-METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (NMCSPC): HIGH RISK FOR METASTASIS (I.E. PSA DOUBLING TIME OF 9 MONTHS OR LESS). METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), NON-METASTATIC CRPC (NMCRPC), METASTATIC CSPC (MCSPC), NMCSPC: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

EPCORITAMAB-BYSP

Products Affected

- EPKINLY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

EPOETIN ALFA-EPBX

Products Affected

- RETACRIT INJECTION SOLUTION UNIT/ML, 4000 UNIT/ML, 40000
10000 UNIT/ML, 10000 UNIT/ML(1ML), UNIT/ML
2000 UNIT/ML, 20000 UNIT/ML, 3000

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: CHRONIC KIDNEY DISEASE (CKD), ANEMIA RELATED TO ZIDOVUDINE, OR CANCER CHEMOTHERAPY: HEMOGLOBIN LEVEL IS LESS THAN 10G/DL. ELECTIVE, NON-CARDIAC, NON-VASCULAR SURGERY: HEMOGLOBIN LEVEL IS 13G/DL OR LESS. RENEWAL: 1) CKD IN ADULTS NOT ON DIALYSIS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS REACHED 10G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 2) CKD IN PEDIATRIC PATIENTS: (A) HEMOGLOBIN LEVEL IS LESS THAN 10G/DL, OR (B) HEMOGLOBIN LEVEL HAS APPROACHED OR EXCEEDS 12G/DL AND THE DOSE IS BEING OR HAS BEEN REDUCED/INTERRUPTED TO DECREASE THE NEED FOR BLOOD TRANSFUSIONS. 3) ANEMIA RELATED TO ZIDOVUDINE: HEMOGLOBIN LEVEL BETWEEN 10G/DL AND 12G/DL. 4) CANCER CHEMOTHERAPY: (A) HEMOGLOBIN LEVEL IS LESS THAN 10 G/DL, OR (B) HEMOGLOBIN LEVEL DOES NOT EXCEED A LEVEL NEEDED TO AVOID RBC TRANSFUSION.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ANEMIA FROM CHEMO/CKD WITHOUT DIALYSIS/ZIDOVUDINE: INITIAL/RENEWAL: 12 MONTHS. SURGERY: 1 MONTH.
Other Criteria	RENEWAL: CKD: NOT RECEIVING DIALYSIS TREATMENT. THIS DRUG MAY BE EITHER BUNDLED WITH AND COVERED UNDER END STAGE RENAL DISEASE DIALYSIS RELATED SERVICES OR

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	COVERED UNDER MEDICARE D DEPENDING UPON THE CIRCUMSTANCES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

ERDAFITINIB

Products Affected

- BALVERSA ORAL TABLET 3 MG, 4 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ERENUMAB-AOOE

Products Affected

- AIMOVIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ERLOTINIB

Products Affected

- erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ESKETAMINE

Products Affected

- SPRAVATO (56 MG DOSE)
- SPRAVATO (84 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: TREATMENT-RESISTANT DEPRESSION (TRD), MAJOR DEPRESSIVE DISORDER (MDD): PRESCRIBED BY OR IN CONSULTATION WITH A PSYCHIATRIST OR OTHER REMS-CERTIFIED PROVIDER.
Coverage Duration	INITIAL: TRD: 3 MONTHS. MDD: 4 WEEKS. RENEWAL: TRD, MDD: 12 MONTHS.
Other Criteria	INITIAL: TRD, MDD: 1) NON-PSYCHOTIC, UNIPOLAR DEPRESSION, AND 2) NO ACTIVE SUBSTANCE ABUSE. RENEWAL: TRD, MDD: DEMONSTRATED CLINICAL BENEFIT (IMPROVEMENT IN DEPRESSION) COMPARED TO BASELINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ETANERCEPT

Products Affected

- ENBREL MINI
- ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML
- ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE
- ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA), ANKYLOSING SPONDYLITIS (AS): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ALL INDICATIONS: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

EVEROLIMUS-AFINITOR

Products Affected

- *everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *yulithira oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*
- *torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

EVEROLIMUS-AFINITOR DISPERZ

Products Affected

- everolimus oral tablet soluble*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

FECAL MICROBIOTA CAPSULE

Products Affected

- VOWST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	30 DAYS
Other Criteria	CLOSTRIDIODES DIFFICILE INFECTION (CDI): 1) HAS NOT PREVIOUSLY RECEIVED VOWST: COMPLETION OF ANTIBIOTIC TREATMENT FOR RECURRENT CDI (AT LEAST 3 CDI EPISODES), OR 2) PREVIOUSLY RECEIVED VOWST: (A) TREATMENT FAILURE (DEFINED AS THE PRESENCE OF CDI DIARRHEA WITHIN 8 WEEKS OF FIRST DOSE OF VOWST AND A POSITIVE STOOL TEST FOR C. DIFFICILE), AND (B) HAS NOT RECEIVED MORE THAN ONE TREATMENT COURSE OF VOWST WHICH WAS AT LEAST 12 DAYS AND NOT MORE THAN 8 WEEKS PRIOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

FEDRATINIB

Products Affected

- INREBIC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	MYELOFIBROSIS: INITIAL: TRIAL OF OR CONTRAINDICATION TO JAKAFI (RUXOLITINIB). RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

FENFLURAMINE

Products Affected

- FINTEPLA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: DRAVET SYNDROME, LENNOX-GASTAUT SYNDROME (LGS): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: LGS: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING ANTIEPILEPTIC MEDICATIONS: RUFINAMIDE, FELBAMATE, CLOBAZAM, TOPIRAMATE, LAMOTRIGINE, CLONAZEPAM.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

FENTANYL CITRATE

Products Affected

- fentanyl citrate buccal lozenge on a handle*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CANCER RELATED PAIN: 1) CURRENTLY ON A MAINTENANCE DOSE OF CONTROLLED-RELEASE OPIOID PAIN MEDICATION, AND 2) TRIAL OF OR CONTRAINDICATION TO AT LEAST ONE IMMEDIATE-RELEASE ORAL OPIOID PAIN AGENT OR PATIENT HAS DIFFICULTY SWALLOWING TABLETS/CAPSULES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

FEZOLINETANT

Products Affected

- VEOZAH

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	MENOPAUSAL VASOMOTOR SYMPTOMS (VMS): INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO HORMONAL THERAPY (E.G., ESTRADIOL TRANSDERMAL PATCH, ORAL CONJUGATED ESTROGENS), 2) LABORATORY TESTING TO ESTABLISH BASELINE HEPATIC FUNCTION AND CONTINUED MONITORING OF THESE VALUES IN ACCORDANCE WITH THE FDA CURRENT LABEL RECOMMENDATION, AND 3) NO CONCURRENT USE WITH ANOTHER HORMONAL (E.G., PREMPRO) OR NON-HORMONAL (E.G., BRISDELLE) AGENT FOR VMS. RENEWAL: 1) CONTINUED NEED FOR VMS TREATMENT (PERSISTENT HOT FLASHES), 2) REDUCTION IN VMS FREQUENCY OR SEVERITY DUE TO VEOZAH TREATMENT, AND 3) NO NEW SYMPTOMS OF LIVER INJURY AND/OR WORSENING LAB VALUES (E.G., ALT, AST, TOTAL BILIRUBIN).
Indications	All FDA-approved Indications.
Off Label Uses	

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

FILGRASTIM-AAFI

Products Affected

- NIVESTYM

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

FINERENONE

Products Affected

- KERENDIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: HEART FAILURE (HF): 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS II-IV, AND 2) LEFT VENTRICULAR EJECTION FRACTION OF AT LEAST 40 PERCENT NOT DUE TO AN UNDERLYING CAUSE (E.G., INFILTRATIVE CARDIOMYOPATHY, HYPERTROPHIC CARDIOMYOPATHY, VALVULAR DISEASE, PERICARDIAL DISEASE, HIGH-OUTPUT HEART FAILURE).
Age Restrictions	
Prescriber Restrictions	INITIAL: HF: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST.
Coverage Duration	INITIAL/RENEWAL:12 MONTHS
Other Criteria	CHRONIC KIDNEY DISEASE (CKD) ASSOCIATED WITH TYPE 2 DIABETES (T2D): INITIAL: HISTORY OF AND WILL CONTINUE ON, HAS A CONTRAINDICATION, OR INTOLERANCE TO AN ANGIOTENSIN CONVERTING ENZYME INHIBITOR (ACE-I) OR AN ANGIOTENSIN RECEPTOR BLOCKER (ARB). HF: INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER MINERALOCORTICOID (ALDOSTERONE) RECEPTOR ANTAGONIST.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

FINGOLIMOD

Products Affected

- fingolimod hcl*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

FOSCARBIDOPA-FOSLEVODOPA

Products Affected

- VYALEV SUBCUTANEOUS SOLUTION 12-240 MG/ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PARKINSONS DISEASE (PD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL: 12 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	PD: INITIAL: ONE OF THE FOLLOWING: 1) UNABLE TO SWALLOW EXTENDED-RELEASE (ER) TABLETS OR ADMINISTER ER CAPSULES VIA A FEEDING TUBE, OR 2) FAILURE TO ADHERE OR TOLERATE VIA A FEEDING TUBE AN ORAL CARBIDOPA/LEVODOPA REGIMEN. RENEWAL: IMPROVEMENT IN MOTOR SYMPTOMS WHILE ON THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

FRUQUINTINIB

Products Affected

- FRUZAQLA ORAL CAPSULE 1 MG, 5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

FUTIBATINIB

Products Affected

- LYTGobi (12 MG DAILY DOSE)
- LYTGobi (16 MG DAILY DOSE)
- LYTGobi (20 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INTRAHEPATIC CHOLANGIOCARCINOMA (ICCA): COMPLETE A COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

GALCANEZUMAB-GNLM

Products Affected

- EMGALITY
- EMGALITY (300 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: MIGRAINE PREVENTION: 6 MOS. EPISODIC CLUSTER HEADACHE: 3 MOS. RENEWAL (ALL): 12 MOS.
Other Criteria	MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY. EPISODIC CLUSTER HEADACHE: RENEWAL: IMPROVEMENT IN EPISODIC CLUSTER HEADACHE FREQUENCY AS COMPARED TO BASELINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

GANAXOLONE

Products Affected

- ZTALMY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

GEFITINIB

Products Affected

- gefitinib*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC) WITH EGFR MUTATION: NOT ON CONCURRENT THERAPY WITH AN EGFR TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

GEPIRONE

Products Affected

- EXXUA
- EXXUA TITRATION PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	MAJOR DEPRESSIVE DISORDER: INITIAL: TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENTS: TRINTELLIX AND ONE GENERIC ANTIDEPRESSANT. INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER 5-HT1A RECEPTOR AGONIST (E.G., BUSPIRONE). RENEWAL: RESPONSE TO OR REMISSION OF DEPRESSIVE SYMPTOMS WITH THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

GILTERITINIB

Products Affected

- XOSPATA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

GLASDEGIB

Products Affected

- DAURISMO ORAL TABLET 100 MG,
25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

GLATIRAMER

Products Affected

- *glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*
- *glatopa subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

GLECAPREVIR/PIBRENTASVIR

Products Affected

- MAVYRET ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) INTOLERANCE OR CONTRAINDICATION TO ONE OF THE PREFERRED FORMULARY AGENTS: HARVONI OR EPCLUSA, WHEN THESE AGENTS ARE CONSIDERED ACCEPTABLE FOR TREATMENT OF THE SPECIFIC GENOTYPE PER AASLD/IDSA GUIDANCE, 3) NO CONCURRENT USE WITH THE FOLLOWING AGENTS: RIFAMPIN, ATAZANAVIR, CARBAMAZEPINE, EFAVIRENZ, DARUNAVIR, LOPINAVIR, RITONAVIR, ATORVASTATIN, LOVASTATIN, SIMVASTATIN, ROSUVASTATIN AT DOSES GREATER THAN 10MG, CYCLOSPORINE AT DOSES GREATER THAN 100MG PER DAY, MEDICATIONS CONTAINING MORE THAN 20MCG OF ETHINYL ESTRADIOL, EPCLUSA, HARVONI, VOSEVI, OR ZEPATIER, AND 4) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD PUGH B OR C).
Indications	All FDA-approved Indications.
Off Label Uses	

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

GLP1-DULAGLUTIDE

Products Affected

- TRULICITY SUBCUTANEOUS
SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

GLP1-SEMAGLUTIDE

Products Affected

- OZEMPIC
- OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML
- OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML
- OZEMPIC (2 MG/DOSE)
- RYBELSUS
- RYBELSUS (FORMULATION R2)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

GLP1-TIRZEPATIDE

Products Affected

- MOUNJARO SUBCUTANEOUS
SOLUTION AUTO-INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS.
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

GOSERELIN

Products Affected

- ZOLADEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
Coverage Duration	STAGE B2-C PROSTATIC CARCINOMA: 4 MOS. ENDOMETRIOSIS: 6 MOS PER LIFETIME. ALL OTHERS: 12 MONTHS.
Other Criteria	ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 6 MONTHS OF TREATMENT PER LIFETIME.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

GUSELKUMAB

Products Affected

- TREMFYA INTRAVENOUS
- TREMFYA ONE-PRESS
SUBCUTANEOUS SOLUTION PEN-INJECTOR
- TREMFYA PEN SUBCUTANEOUS
SOLUTION AUTO-INJECTOR 200
MG/2ML
- TREMFYA SUBCUTANEOUS
SOLUTION PREFILLED SYRINGE
- TREMFYA-CD/UC INDUCTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSO, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

HIGH RISK DRUGS IN THE ELDERLY - CYPROHEPTADINE

Products Affected

- *cyproheptadine hcl oral syrup 2 mg/5ml*
- *cyproheptadine hcl oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING ADDITIONAL CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

HIGH RISK DRUGS IN THE ELDERLY - BUTALBITAL-CONTAINING AGENTS

Products Affected

- *butalbital-apap-caff-cod oral capsule 50-325-40-30 mg*
- *butalbital-apap-caffeine oral capsule*
- *butalbital-apap-caffeine oral tablet 50-325-40 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PREScriBER ACKNOWLEDGEMENT/AWARENESS DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING ADDITIONAL CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

HIGH RISK DRUGS IN THE ELDERLY - CHLORDIAZEPOXIDE-CLIDINIUM

Products Affected

- chlordiazepoxide-clidinium*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING ADDITIONAL CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

HIGH RISK DRUGS IN THE ELDERLY - DIPYRIDAMOLE

Products Affected

- *dipyridamole oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING ADDITIONAL CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

HIGH RISK DRUGS IN THE ELDERLY - ESTRADIOL-NORETHINDRONE

Products Affected

- *abigale*
- *estradiol-norethindrone acet*
- *mimvey*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	VULVAR/VAGINAL ATROPHY, OSTEOPOROSIS, AND VASOMOTOR SYMPTOMS OF MENOPAUSE: PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HYPOESTROGENISM TREATMENT AND HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING ADDITIONAL CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

HIGH RISK DRUGS IN THE ELDERLY - ESTROGEN-MEDROXYPROGESTERONE

Products Affected

- PREMPHASE
- PREMPRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING ADDITIONAL CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

HIGH RISK DRUGS IN THE ELDERLY - GLYBURIDE FORMULATIONS

Products Affected

- *glyburide micronized*
- *glyburide oral*
- *glyburide-metformin*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	TYPE 2 DIABETES MELLITUS (DM): 1) TRIAL OF OR CONTRAINDICATION TO GLIMEPIRIDE OR GLIPIZIDE, OR 2) PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS ARE APPROVED WITHOUT REQUIRING ADDITIONAL CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

HIGH RISK DRUGS IN THE ELDERLY - PHENOBARBITAL

Products Affected

- *phenobarbital oral elixir 20 mg/5ml*
- *phenobarbital oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	EPILEPSY/SEIZURES: PATIENTS WHO ARE NEWLY PRESCRIBED PHENOBARBITAL: 1) HAS NOT RESPONDED TO AT LEAST ONE ANTICONVULSANT, OR 2) PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING ADDITIONAL CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

HIGH RISK DRUGS IN THE ELDERLY - PROMETHAZINE

Products Affected

- *promethazine hcl injection solution 25 mg/ml*
- *promethazine hcl oral tablet*
- *promethazine hcl rectal suppository 25 mg*
- *promethegan rectal suppository 12.5 mg, 25 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRURITUS/URTICARIA/SEASONAL/PERENNIAL ALLERGY: 1) TRIAL OF OR CONTRAINDICATION TO A NON-SEDATING ANTIHISTAMINE SUCH AS LEVOCETIRIZINE, OR 2) PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. NAUSEA AND VOMITING: PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH-RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS REQUIRE PHYSICIAN ATTESTATION THAT REQUESTED MEDICATION IS USED TO TREAT A DIAGNOSIS UNRELATED TO THE TERMINAL ILLNESS OR RELATED CONDITION, AND ARE APPROVED WITHOUT TRIAL OF FORMULARY ALTERNATIVES NOR REQUIRING PRESCRIBER ACKNOWLEDGEMENT.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

HIGH RISK DRUGS IN THE ELDERLY - SCOPOLAMINE

Products Affected

- *scopolamine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS REQUIRE PHYSICIAN ATTESTATION THAT REQUESTED MEDICATION IS USED TO TREAT A DIAGNOSIS UNRELATED TO THE TERMINAL ILLNESS OR RELATED CONDITION, AND ARE APPROVED WITHOUT REQUIRING PRESCRIBER ACKNOWLEDGEMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

HIGH RISK DRUGS IN THE ELDERLY- DIPHENOXYLATE-ATROPINE

Products Affected

- *diphenoxylate-atropine oral tablet 2.5-0.025 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PREScriBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING ADDITIONAL CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

HIGH RISK DRUGS IN THE ELDERLY- INDOMETHACIN

Products Affected

- *indomethacin oral capsule 25 mg, 50 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING ADDITIONAL CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

HIGH RISK DRUGS IN THE ELDERLY- MEGESTROL

Products Affected

- *megestrol acetate oral suspension 40 mg/ml, 625 mg/5ml*
- *megestrol acetate oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING ADDITIONAL CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

HIGH RISK DRUGS IN THE ELDERLY- PAROXETINE

Products Affected

- *paroxetine hcl*
- *paroxetine hcl er*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	APPROPRIATE HIGH RISK MEDICATION USE: 65 YEARS OF AGE OR OLDER. PA NOT REQUIRED FOR AGE 0-64 YEARS.
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	PRESCRIBER ACKNOWLEDGEMENT/AWARENESS THAT THE DRUG IS CONSIDERED HIGH RISK FOR PATIENTS 65 YEARS AND OLDER. HOSPICE PATIENTS WILL BE APPROVED WITHOUT REQUIRING ADDITIONAL CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

IBRUTINIB

Products Affected

- IMBRUVICA ORAL CAPSULE 140 MG, 70 MG
- IMBRUVICA ORAL TABLET 140 MG, 280 MG, 420 MG
- IMBRUVICA ORAL SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CHRONIC GRAFT VS HOST DISEASE (CGVHD): NO CONCURRENT USE WITH JAKAFI, NIKTIMVO, OR REZUROCK.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ICATIBANT

Products Affected

- *icatibant acetate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HEREDITARY ANGIOEDEMA (HAE): INITIAL: 1) TYPE III HAE, OR 2) TYPE I OR II HAE CONFIRMED BY ONE OF THE FOLLOWING COMPLEMENT TESTS: C1-INH PROTEIN LEVELS, C4 PROTEIN LEVELS, C1-INH FUNCTIONAL LEVELS, C1Q.
Age Restrictions	
Prescriber Restrictions	HAE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, IMMUNOLOGIST, HEMATOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	HAE: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER MEDICATIONS FOR THE TREATMENT OF ACUTE HAE ATTACKS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

IDELALISIB

Products Affected

- ZYDELIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

IMATINIB

Products Affected

- *imatinib mesylate oral tablet 100 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.
Other Criteria	PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

IMATINIB SOLUTION

Products Affected

- IMKELDI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ADJUVANT GASTROINTESTINAL STROMAL TUMOR TREATMENT: 36 MONTHS. ALL OTHER DIAGNOSES: 12 MONTHS.
Other Criteria	PHILADELPHIA CHROMOSOME POSITIVE CHRONIC MYELOID LEUKEMIA: PATIENT HAS NOT RECEIVED A PREVIOUS TREATMENT WITH ANOTHER TYROSINE KINASE INHIBITOR. ALL INDICATIONS: UNABLE TO SWALLOW GENERIC IMATINIB TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

IMETELSTAT

Products Affected

- RYTELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

IMLUNESTRANT

Products Affected

- INLURIYO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

INAVOLISIB

Products Affected

- ITOVEBI ORAL TABLET 3 MG, 9 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

INSULIN SUPPLIES PAYMENT DETERMINATION

Products Affected

- 1ST TIER UNIFINE PENTIPS 29G X 12MM
- 1ST TIER UNIFINE PENTIPS 31G X 5 MM
- 1ST TIER UNIFINE PENTIPS 31G X 6 MM
- 1ST TIER UNIFINE PENTIPS 31G X 8 MM
- 1ST TIER UNIFINE PENTIPS 32G X 4 MM
- 1ST TIER UNIFINE PENTIPS 32G X 6 MM
- 1ST TIER UNIFINE PENTIPS 33G X 4 MM
- 1ST TIER UNIFINE PENTIPS PLUS 29G X 12MM
- 1ST TIER UNIFINE PENTIPS PLUS 31G X 5 MM
- 1ST TIER UNIFINE PENTIPS PLUS 31G X 6 MM
- 1ST TIER UNIFINE PENTIPS PLUS 31G X 8 MM
- 1ST TIER UNIFINE PENTIPS PLUS 32G X 4 MM
- 1ST TIER UNIFINE PENTIPS PLUS 33G X 4 MM
- ABOUTTIME PEN NEEDLE 30G X 8 MM
- ABOUTTIME PEN NEEDLE 31G X 5 MM
- ABOUTTIME PEN NEEDLE 31G X 8 MM
- ABOUTTIME PEN NEEDLE 32G X 4 MM
- ADVOCATE ALCOHOL PREP PADS PAD 70 %
- ADVOCATE INSULIN PEN NEEDLE 32G X 4 MM
- ADVOCATE INSULIN PEN NEEDLES 29G X 12.7MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 5 MM
- ADVOCATE INSULIN PEN NEEDLES 31G X 8 MM
- ADVOCATE INSULIN PEN NEEDLES 33G X 4 MM
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ADVOCATE INSULIN SYRINGE 29G X 1/2" 1 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 30G X 5/16" 1 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ADVOCATE INSULIN SYRINGE 31G X 5/16" 1 ML
- ALCOHOL PADS PAD 70 %
- ALCOHOL PREP PAD
- ALCOHOL PREP PAD 70 %
- ALCOHOL PREP PADS PAD 70 %
- ALCOHOL SWABS PAD
- ALCOHOL SWABS PAD 70 %
- AQ INSULIN SYRINGE 29G X 1/2" 1 ML

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

- AQ INSULIN SYRINGE 30G X 5/16" 0.5 ML
- AQ INSULIN SYRINGE 31G X 5/16" 1 ML
- AQINJECT PEN NEEDLE 31G X 5 MM
- AQINJECT PEN NEEDLE 32G X 4 MM
- ASSURE ID DUO PRO PEN NEEDLES 31G X 5 MM
- ASSURE ID INSULIN SAFETY SYR 29G X 1/2" 1 ML
- ASSURE ID PRO PEN NEEDLES 30G X 5 MM
- ASSURE ID SAFETY PEN NEEDLES 30G X 8 MM
- AUM ALCOHOL PREP PADS PAD 70 %
- AUM INSULIN SAFETY PEN NEEDLE 31G X 4 MM
- AUM INSULIN SAFETY PEN NEEDLE 31G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 6 MM
- AUM MINI INSULIN PEN NEEDLE 32G X 8 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 4 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 5 MM
- AUM MINI INSULIN PEN NEEDLE 33G X 6 MM
- AUM PEN NEEDLE 32G X 4 MM
- AUM PEN NEEDLE 32G X 5 MM
- AUM PEN NEEDLE 32G X 6 MM
- AUM PEN NEEDLE 33G X 4 MM
- AUM PEN NEEDLE 33G X 5 MM
- AUM PEN NEEDLE 33G X 6 MM
- AUM READYGARD DUO PEN NEEDLE 32G X 4 MM
- AUM SAFETY PEN NEEDLE 31G X 4 MM
- AUM SAFETY PEN NEEDLE 31G X 5 MM
- AURORA PEN NEEDLES 29G X 12MM
- AURORA PEN NEEDLES 31G X 6 MM
- AURORA PEN NEEDLES 31G X 8 MM
- AUTOKEEPER SAFETY PEN NEEDLE 30G X 5 MM
- AUTOKEEPER SAFETY PEN NEEDLE 30G X 8 MM
- BD AUTOSHIELD DUO 30G X 5 MM
- BD ECLIPSE SYRINGE 30G X 1/2" 1 ML
- BD INS SYR ULTRAFINE 1/2UNIT 31G X 5/16" 0.3 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.3 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 0.5 ML
- BD INSULIN SYR ULTRAFINE II 31G X 5/16" 1 ML
- BD INSULIN SYRINGE 27.5G X 5/8" 2 ML
- BD INSULIN SYRINGE 27G X 1/2" 1 ML
- BD INSULIN SYRINGE 29G X 1/2" 0.3 ML
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 0.5 ML (RX)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE HALF-UNIT 31G X 5/16" 0.3 ML
- BD INSULIN SYRINGE MICROFINE 27G X 5/8" 1 ML
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 0.5 ML

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (OTC)
- BD INSULIN SYRINGE MICROFINE 28G X 1/2" 1 ML (RX)
- BD INSULIN SYRINGE U-100 1 ML
- BD INSULIN SYRINGE U/F 30G X 1/2" 1 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 29G X 1/2" 0.5 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 0.5 ML
- BD INSULIN SYRINGE ULTRAFINE 30G X 1/2" 1 ML
- BD INSULIN SYRINGE ULTRAFINE 31G X 5/16" 0.3 ML
- BD INSULIN SYRINGE ULTRAFINE 31G X 5/16" 0.5 ML
- BD INSULIN SYRINGE ULTRAFINE 31G X 5/16" 1 ML
- BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM
- BD PEN NEEDLE MINI U/F 31G X 5 MM
- BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM
- BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM
- BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM
- BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM
- BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM
- BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.3 ML
- BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.3 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 0.5 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64" 1 ML
- BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8" 1 ML
- BD SWAB SINGLE USE REGULAR PAD
- BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 0.5 ML
- BD VEO INSULIN SYR ULTRAFINE 31G X 15/64" 1 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.3 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 0.5 ML
- BD VEO INSULIN SYRINGE U/F 31G X 15/64" 1 ML
- CAREFINE PEN NEEDLES 29G X 12MM
- CAREFINE PEN NEEDLES 30G X 8 MM
- CAREFINE PEN NEEDLES 31G X 6 MM
- CAREFINE PEN NEEDLES 31G X 8 MM
- CAREFINE PEN NEEDLES 32G X 4 MM
- CAREFINE PEN NEEDLES 32G X 5 MM
- CAREFINE PEN NEEDLES 32G X 6 MM

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- | | |
|--|---|
| • CAREONE INSULIN SYRINGE 30G X 1/2" 0.3 ML | • CARETOUCH PEN NEEDLES 31G X 5 MM |
| • CAREONE INSULIN SYRINGE 30G X 1/2" 0.5 ML | • CARETOUCH PEN NEEDLES 31G X 6 MM |
| • CAREONE INSULIN SYRINGE 30G X 1/2" 1 ML | • CARETOUCH PEN NEEDLES 31G X 8 MM |
| • CAREONE INSULIN SYRINGE 31G X 5/16" 0.3 ML | • CARETOUCH PEN NEEDLES 32G X 4 MM |
| • CAREONE INSULIN SYRINGE 31G X 5/16" 0.5 ML | • CARETOUCH PEN NEEDLES 32G X 5 MM |
| • CAREONE INSULIN SYRINGE 31G X 5/16" 1 ML | • CARETOUCH PEN NEEDLES 33G X 4 MM |
| • CAREONE UNIFINE PENTIPS PLUS 29G X 12MM | • CLEVER CHOICE COMFORT EZ 29G X 12MM |
| • CAREONE UNIFINE PENTIPS PLUS 31G X 5 MM | • CLEVER CHOICE COMFORT EZ 33G X 4 MM |
| • CAREONE UNIFINE PENTIPS PLUS 31G X 6 MM | • CLICKFINE PEN NEEDLES 31G X 5 MM |
| • CAREONE UNIFINE PENTIPS PLUS 31G X 8 MM | • CLICKFINE PEN NEEDLES 31G X 6 MM |
| • CAREONE UNIFINE PENTIPS PLUS 32G X 4 MM | • CLICKFINE PEN NEEDLES 31G X 8 MM |
| • CAREONE UNIFINE PENTIPS PLUS 33G X 4 MM | • CLICKFINE PEN NEEDLES 32G X 4 MM |
| • CARETOUCH ALCOHOL PREP PAD 70 % | • COMFORT ASSIST INSULIN SYRINGE 29G X 1/2" 1 ML |
| • CARETOUCH INSULIN SYRINGE 28G X 5/16" 1 ML | • COMFORT ASSIST INSULIN SYRINGE 31G X 5/16" 0.3 ML |
| • CARETOUCH INSULIN SYRINGE 29G X 5/16" 1 ML | • COMFORT EZ INSULIN SYRINGE 27G X 1/2" 1 ML |
| • CARETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML | • COMFORT EZ INSULIN SYRINGE 28G X 1/2" 0.5 ML |
| • CARETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML | • COMFORT EZ INSULIN SYRINGE 28G X 1/2" 1 ML |
| • CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML | • COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.3 ML |
| • CARETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML | • COMFORT EZ INSULIN SYRINGE 29G X 1/2" 0.5 ML |
| • CARETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML | • COMFORT EZ INSULIN SYRINGE 29G X 1/2" 1 ML |
| • CARETOUCH PEN NEEDLES 29G X 12MM | • COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.3 ML |

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 30G X 1/2" 1 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 30G X 5/16" 1 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 31G X 15/64" 1 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.3 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 0.5 ML
- COMFORT EZ INSULIN SYRINGE 31G X 5/16" 1 ML
- COMFORT EZ MICRO PEN NEEDLES 32G X 4 MM
- COMFORT EZ PEN NEEDLES 31G X 5 MM
- COMFORT EZ PEN NEEDLES 31G X 6 MM
- COMFORT EZ PEN NEEDLES 31G X 8 MM
- COMFORT EZ PEN NEEDLES 32G X 4 MM
- COMFORT EZ PEN NEEDLES 32G X 5 MM
- COMFORT EZ PEN NEEDLES 32G X 6 MM
- COMFORT EZ PEN NEEDLES 32G X 8 MM
- COMFORT EZ PEN NEEDLES 33G X 4 MM
- COMFORT EZ PEN NEEDLES 33G X 5 MM
- COMFORT EZ PEN NEEDLES 33G X 6 MM
- COMFORT EZ PEN NEEDLES 33G X 8 MM
- COMFORT EZ PRO PEN NEEDLES 30G X 8 MM
- COMFORT EZ PRO PEN NEEDLES 31G X 4 MM
- COMFORT EZ PRO PEN NEEDLES 31G X 5 MM
- COMFORT EZ SHORT PEN NEEDLES 31G X 8 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM
- COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM
- COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM
- COMFORT TOUCH INSULIN PEN NEED 33G X 4 MM
- COMFORT TOUCH INSULIN PEN NEED 33G X 5 MM
- COMFORT TOUCH INSULIN PEN NEED 33G X 6 MM
- CURITY ALCOHOL PREPS PAD 70 %
- CURITY ALL PURPOSE SPONGES PAD 2"X2"
- CURITY GAUZE PAD 2"X2"
- CURITY GAUZE SPONGE PAD 2"X2"
- CURITY SPONGES PAD 2"X2"
- CVS ALCOHOL PREP PADS PAD 70 %
- CVS GAUZE PAD 2"X2"

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- CVS GAUZE STERILE PAD 2"X2"
- *cvx isopropyl alcohol wipes*
- CVS PREP PAD 70 %
- DERMACEA GAUZE SPONGE PAD 2"X2"
- DERMACEA IV DRAIN SPONGES PAD 2"X2"
- DERMACEA NON-WOVEN SPONGES PAD 2"X2"
- DERMACEA TYPE VII GAUZE PAD 2"X2"
- DIATHRIVE PEN NEEDLE 31G X 5 MM
- DIATHRIVE PEN NEEDLE 31G X 6 MM
- DIATHRIVE PEN NEEDLE 31G X 8 MM
- DIATHRIVE PEN NEEDLE 32G X 4 MM
- DROPLET INSULIN SYRINGE 29G X 1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 29G X 1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 29G X 1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 1/2" 1 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 15/64" 1 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 0.3 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 0.5 ML
- DROPLET INSULIN SYRINGE 30G X 5/16" 1 ML
- DROPLET MICRON 34G X 3.5 MM
- DROPLET PEN NEEDLES 29G X 10MM
- DROPLET PEN NEEDLES 29G X 12MM
- DROPLET PEN NEEDLES 30G X 8 MM
- DROPLET PEN NEEDLES 31G X 5 MM
- DROPLET PEN NEEDLES 31G X 6 MM
- DROPLET PEN NEEDLES 31G X 8 MM
- DROPLET PEN NEEDLES 32G X 4 MM
- DROPLET PEN NEEDLES 32G X 5 MM
- DROPLET PEN NEEDLES 32G X 6 MM
- DROPLET PEN NEEDLES 32G X 8 MM
- DROPSAFE ALCOHOL PREP PAD 70 %
- DROPSAFE AUTOPROTECT DUO 31G X 4 MM
- DROPSAFE AUTOPROTECT DUO 31G X 5 MM
- DROPSAFE AUTOPROTECT DUO 31G X 8 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 5 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 6 MM
- DROPSAFE SAFETY PEN NEEDLES 31G X 8 MM

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- | | |
|--|---|
| • DROPSAFE SAFETY SYRINGE/NEEDLE 29G X 1/2" 1 ML | • EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.3 ML | • EASY COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 0.5 ML | • EASY COMFORT INSULIN SYRINGE 32G X 5/16" 0.5 ML |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64" 1 ML | • EASY COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.3 ML | • EASY COMFORT PEN NEEDLES 29G X 4MM |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 0.5 ML | • EASY COMFORT PEN NEEDLES 29G X 5MM |
| • DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16" 1 ML | • EASY COMFORT PEN NEEDLES 31G X 5 MM |
| • DRUG MART UNIFINE PENTIPS 29G X 12MM | • EASY COMFORT PEN NEEDLES 31G X 6 MM |
| • DRUG MART UNIFINE PENTIPS 31G X 6 MM | • EASY COMFORT PEN NEEDLES 31G X 8 MM |
| • DRUG MART UNIFINE PENTIPS 31G X 8 MM | • EASY COMFORT PEN NEEDLES 32G X 4 MM |
| • DRUG MART UNIFINE PENTIPS PLUS 32G X 4 MM | • EASY COMFORT PEN NEEDLES 33G X 4 MM |
| • EASY COMFORT ALCOHOL PADS PAD | • EASY COMFORT PEN NEEDLES 33G X 5 MM |
| • EASY COMFORT INSULIN SYRINGE 29G X 5/16" 0.5 ML | • EASY COMFORT PEN NEEDLES 33G X 6 MM |
| • EASY COMFORT INSULIN SYRINGE 29G X 5/16" 1 ML | • EASY GLIDE PEN NEEDLES 33G X 4 MM |
| • EASY COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML | • EASY TOUCH ALCOHOL PREP MEDIUM PAD 70 % |
| • EASY COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML | • EASY TOUCH FLIPLOCK INSULIN SY 29G X 1/2" 1 ML |
| • EASY COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML | • EASY TOUCH FLIPLOCK INSULIN SY 30G X 1/2" 1 ML |
| • EASY COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML | • EASY TOUCH FLIPLOCK INSULIN SY 30G X 5/16" 1 ML |
| • EASY COMFORT INSULIN SYRINGE 31G X 1/2" 0.3 ML | • EASY TOUCH FLIPLOCK INSULIN SY 31G X 5/16" 1 ML |
| • EASY COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML | • EASY TOUCH FLIPLOCK SAFETY SYR 27G X 1/2" 1 ML |
| | • EASY TOUCH INSULIN BARRELS U-100 1 ML |

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

- | | |
|--|--|
| • EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 0.5 ML | • EASY TOUCH PEN NEEDLES 30G X 5 MM |
| • EASY TOUCH INSULIN SAFETY SYR 29G X 1/2" 1 ML | • EASY TOUCH PEN NEEDLES 30G X 6 MM |
| • EASY TOUCH INSULIN SAFETY SYR 30G X 1/2" 1 ML | • EASY TOUCH PEN NEEDLES 30G X 8 MM |
| • EASY TOUCH INSULIN SAFETY SYR 30G X 5/16" 0.5 ML | • EASY TOUCH PEN NEEDLES 31G X 5 MM |
| • EASY TOUCH INSULIN SYRINGE 27G X 1/2" 0.5 ML | • EASY TOUCH PEN NEEDLES 31G X 6 MM |
| • EASY TOUCH INSULIN SYRINGE 27G X 1/2" 1 ML | • EASY TOUCH PEN NEEDLES 31G X 8 MM |
| • EASY TOUCH INSULIN SYRINGE 27G X 5/8" 1 ML | • EASY TOUCH PEN NEEDLES 32G X 4 MM |
| • EASY TOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML | • EASY TOUCH PEN NEEDLES 32G X 5 MM |
| • EASY TOUCH INSULIN SYRINGE 28G X 1/2" 1 ML | • EASY TOUCH PEN NEEDLES 32G X 6 MM |
| • EASY TOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML | • EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM |
| • EASY TOUCH INSULIN SYRINGE 29G X 1/2" 1 ML | • EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM |
| • EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.3 ML | • EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM |
| • EASY TOUCH INSULIN SYRINGE 30G X 1/2" 0.5 ML | • EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2" 1 ML |
| • EASY TOUCH INSULIN SYRINGE 30G X 1/2" 1 ML | • EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2" 1 ML |
| • EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML | • EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16" 1 ML |
| • EASY TOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML | • EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16" 1 ML |
| • EASY TOUCH INSULIN SYRINGE 30G X 5/16" 1 ML | • EMBECTA AUTOSHIELD DUO 30G X 5 MM |
| • EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML | • EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64" 0.3 ML |
| • EASY TOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML | • EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16" 0.3 ML |
| • EASY TOUCH INSULIN SYRINGE 31G X 5/16" 1 ML | • EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.3 ML |
| • EASY TOUCH PEN NEEDLES 29G X 12MM | • EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 0.5 ML |

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

- EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2" 1 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64" 1 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 0.3 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 0.5 ML
- EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16" 1 ML
- EMBECTA INSULIN SYRINGE 28G X 1/2" 0.5 ML
- EMBECTA INSULIN SYRINGE 28G X 1/2" 1 ML (OTC)
- EMBECTA INSULIN SYRINGE 28G X 1/2" 1 ML (RX)
- EMBECTA INSULIN SYRINGE U-100 27G X 5/8" 1 ML
- EMBECTA INSULIN SYRINGE U-500
- EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM
- EMBECTA PEN NEEDLE NANO 32G X 4 MM
- EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM
- EMBECTA PEN NEEDLE ULTRAFINE 31G X 5 MM
- EMBECTA PEN NEEDLE ULTRAFINE 31G X 8 MM
- EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM
- EMBRACE PEN NEEDLES 29G X 12MM
- EMBRACE PEN NEEDLES 30G X 5 MM
- EMBRACE PEN NEEDLES 30G X 8 MM
- EMBRACE PEN NEEDLES 31G X 5 MM
- EMBRACE PEN NEEDLES 31G X 6 MM
- EMBRACE PEN NEEDLES 31G X 8 MM
- EMBRACE PEN NEEDLES 32G X 4 MM
- EMBRACE PEN NEEDLES 32G X 6 MM
- EQL ALCOHOL SWABS PAD 70 %
- EQL GAUZE PAD 2"X2"
- EQL INSULIN SYRINGE 29G X 1/2" 0.3 ML
- EQL INSULIN SYRINGE 29G X 1/2" 0.5 ML
- EQL INSULIN SYRINGE 29G X 1/2" 1 ML
- EQL INSULIN SYRINGE 30G X 5/16" 0.3 ML
- EQL INSULIN SYRINGE 30G X 5/16" 0.5 ML
- EQL INSULIN SYRINGE 30G X 5/16" 1 ML
- EQL INSULIN SYRINGE 31G X 5/16" 0.3 ML
- EQL INSULIN SYRINGE 31G X 5/16" 0.5 ML
- EQL INSULIN SYRINGE 31G X 5/16" 1 ML
- EXEL COMFORT POINT PEN NEEDLE 29G X 12MM
- FIFTY50 ALCOHOL PREP PAD 70 %
- FIFTY50 PEN NEEDLES 31G X 5 MM
- FIFTY50 PEN NEEDLES 31G X 8 MM
- FIFTY50 PEN NEEDLES 32G X 4 MM
- FIFTY50 PEN NEEDLES 32G X 6 MM
- FIFTY50 SUPERIOR COMFORT SYR 31G X 5/16" 0.3 ML
- FIFTY50 SUPERIOR COMFORT SYR 31G X 5/16" 0.5 ML
- FIFTY50 SUPERIOR COMFORT SYR 31G X 5/16" 1 ML
- GAUZE PADS PAD 2"X2"

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- GAUZE TYPE VII MEDI-PAK PAD 2"X2"
- GLOBAL ALCOHOL PREP EASE
- GLOBAL EASE INJECT PEN NEEDLES 29G X 12MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 5 MM
- GLOBAL EASE INJECT PEN NEEDLES 31G X 8 MM
- GLOBAL EASE INJECT PEN NEEDLES 32G X 4 MM
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.3 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 0.5 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64" 1 ML
- GLOBAL EASY GLIDE INSULIN SYR 31G X 5/16" 0.3 ML
- GLOBAL EASY GLIDE PEN NEEDLES 32G X 4 MM
- GLOBAL INJECT EASE INSULIN SYR 28G X 1/2" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 28G X 1/2" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 29G X 1/2" 0.3 ML
- GLOBAL INJECT EASE INSULIN SYR 29G X 1/2" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 29G X 1/2" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 1/2" 0.3 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 1/2" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 1/2" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 5/16" 0.3 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 5/16" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 30G X 5/16" 1 ML
- GLOBAL INJECT EASE INSULIN SYR 31G X 5/16" 0.3 ML
- GLOBAL INJECT EASE INSULIN SYR 31G X 5/16" 0.5 ML
- GLOBAL INJECT EASE INSULIN SYR 31G X 5/16" 1 ML
- GLOBAL INSULIN SYRINGES 30G X 1/2" 0.3 ML
- GLOBAL INSULIN SYRINGES 30G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 1/2" 1 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 30G X 5/16" 1 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- GLUCOPRO INSULIN SYRINGE 31G X 5/16" 1 ML
- GNP ALCOHOL SWABS PAD 70 %
- GNP CLICKFINE PEN NEEDLES 31G X 6 MM
- GNP CLICKFINE PEN NEEDLES 31G X 8 MM
- GNP INSULIN SYRINGE 28G X 1/2" 0.5 ML
- GNP INSULIN SYRINGE 29G X 1/2" 0.3 ML
- GNP INSULIN SYRINGE 29G X 1/2" 0.5 ML

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

- | | |
|---|---|
| • GNP INSULIN SYRINGE 29G X 1/2" 1 ML | • GNP ULTIGUARD SAFEPACK NEEDLE 31G X 8 MM |
| • GNP INSULIN SYRINGE 30G X 5/16" 0.3 ML | • GNP ULTIGUARD SAFEPACK NEEDLE 32G X 4 MM |
| • GNP INSULIN SYRINGE 30G X 5/16" 0.5 ML | • GNP ULTIGUARD SAFEPACK NEEDLE 32G X 6 MM |
| • GNP INSULIN SYRINGE 30G X 5/16" 1 ML | • GNP ULTRA COM INSULIN SYRINGE 28G X 1/2" 1 ML |
| • GNP INSULIN SYRINGE 31G X 5/16" 0.3 ML | • GOODSENSE ALCOHOL SWABS PAD 70 % |
| • GNP INSULIN SYRINGE 31G X 5/16" 0.5 ML | • GOODSENSE CLICKFINE PEN NEEDLE 31G X 5 MM |
| • GNP INSULIN SYRINGE 31G X 5/16" 1 ML | • GOODSENSE PEN NEEDLE PENFINE 31G X 5 MM |
| • GNP INSULIN SYRINGES 28GX1/2" 28G X 1/2" 1 ML | • GOODSENSE PEN NEEDLE PENFINE 31G X 8 MM |
| • GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 0.5 ML | • GOODSENSE PEN NEEDLE PENFINE 32G X 4 MM |
| • GNP INSULIN SYRINGES 29GX1/2" 29G X 1/2" 1 ML | • GOODSENSE PEN NEEDLE PENFINE 32G X 6 MM |
| • GNP INSULIN SYRINGES 30G X 5/16" 1 ML | • H-E-B INCONTROL ALCOHOL PAD |
| • GNP INSULIN SYRINGES 30GX5/16" 30G X 5/16" 0.3 ML | • H-E-B INCONTROL PEN NEEDLES 29G X 12MM |
| • GNP INSULIN SYRINGES 31GX5/16" 31G X 5/16" 0.3 ML | • H-E-B INCONTROL PEN NEEDLES 31G X 5 MM |
| • GNP PEN NEEDLES 31G X 5 MM | • H-E-B INCONTROL PEN NEEDLES 31G X 6 MM |
| • GNP PEN NEEDLES 31G X 8 MM | • H-E-B INCONTROL PEN NEEDLES 31G X 8 MM |
| • GNP PEN NEEDLES 32G X 4 MM | • H-E-B INCONTROL PEN NEEDLES 32G X 4 MM |
| • GNP PEN NEEDLES 32G X 6 MM | • H-E-B INCONTROL UNIFINE PENTIP 31G X 5 MM |
| • GNP STERILE GAUZE PAD 2"X2" | • H-E-B INCONTROL UNIFINE PENTIP 31G X 6 MM |
| • GNP ULTICARE PEN NEEDLES 31G X 5 MM | • H-E-B INCONTROL UNIFINE PENTIP 31G X 8 MM |
| • GNP ULTICARE PEN NEEDLES 31G X 8 MM | • H-E-B INCONTROL UNIFINE PENTIP 32G X 4 MM |
| • GNP ULTICARE PEN NEEDLES 32G X 4 MM | • H-E-B INCONTROL UNIFINE PENTIP 33G X 4 MM |
| • GNP ULTICARE PEN NEEDLES 32G X 6 MM | |
| • GNP ULTIGUARD SAFEPACK NEEDLE 31G X 5 MM | |

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- | | |
|--|---|
| • HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.3 ML | • INSULIN SYRINGE 31G X 5/16" 0.3 ML |
| • HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 0.5 ML | • INSULIN SYRINGE 31G X 5/16" 0.5 ML |
| • HEALTHWISE INSULIN SYR/NEEDLE 30G X 5/16" 1 ML | • INSULIN SYRINGE 31G X 5/16" 1 ML |
| • HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.3 ML | • INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 0.5 ML (OTC) |
| • HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 0.5 ML | • INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 0.5 ML (RX) |
| • HEALTHWISE INSULIN SYR/NEEDLE 31G X 5/16" 1 ML | • INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 1 ML (OTC) |
| • HEALTHWISE MICRON PEN NEEDLES 32G X 4 MM | • INSULIN SYRINGE-NEEDLE U-100 27G X 1/2" 1 ML (RX) |
| • HEALTHWISE SHORT PEN NEEDLES 31G X 5 MM | • INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 0.5 ML (OTC) |
| • HEALTHWISE SHORT PEN NEEDLES 31G X 8 MM | • INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 0.5 ML (RX) |
| • HM STERILE PADS PAD 2"X2" | • INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 1 ML (OTC) |
| • HM ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML | • INSULIN SYRINGE-NEEDLE U-100 28G X 1/2" 1 ML (RX) |
| • HM ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML | • INSULIN SYRINGE-NEEDLE U-100 29G X 1/2" 0.5 ML (OTC) |
| • HM ULTICARE MINI PEN NEEDLES 31G X 5 MM | • INSULIN SYRINGE-NEEDLE U-100 29G X 1/2" 0.5 ML (RX) |
| • HM ULTICARE SHORT PEN NEEDLES 31G X 8 MM | • INSULIN SYRINGE-NEEDLE U-100 29G X 1/2" 1 ML (OTC) |
| • INCONTROL ULTICARE PEN NEEDLES 31G X 6 MM | • INSULIN SYRINGE-NEEDLE U-100 29G X 1/2" 1 ML (RX) |
| • INCONTROL ULTICARE PEN NEEDLES 31G X 8 MM | • INSULIN SYRINGE-NEEDLE U-100 30G X 1/2" 1 ML (OTC) |
| • INCONTROL ULTICARE PEN NEEDLES 32G X 4 MM | • INSULIN SYRINGE-NEEDLE U-100 30G X 1/2" 1 ML (RX) |
| • INSULIN SYRINGE 28G X 1/2" 0.5 ML | • INSULIN SYRINGE-NEEDLE U-100 30G X 5/16" 0.3 ML |
| • INSULIN SYRINGE 29G X 1/2" 0.3 ML | • INSULIN SYRINGE-NEEDLE U-100 30G X 5/16" 0.5 ML (OTC) |
| • INSULIN SYRINGE 29G X 1/2" 0.5 ML | • INSULIN SYRINGE-NEEDLE U-100 30G X 5/16" 0.5 ML (RX) |
| • INSULIN SYRINGE 29G X 1/2" 1 ML | • INSULIN SYRINGE-NEEDLE U-100 30G X 5/16" 1 ML |
| • INSULIN SYRINGE 30G X 5/16" 0.3 ML | |
| • INSULIN SYRINGE 30G X 5/16" 0.5 ML | |
| • INSULIN SYRINGE 30G X 5/16" 1 ML | |

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

- | | |
|--|--|
| • INSULIN SYRINGE-NEEDLE U-100
31G X 1/4" 0.3 ML | • KMART VALU INSULIN SYRINGE
29G U-100 1 ML |
| • INSULIN SYRINGE-NEEDLE U-100
31G X 1/4" 0.5 ML | • KMART VALU INSULIN SYRINGE
30G U-100 0.3 ML |
| • INSULIN SYRINGE-NEEDLE U-100
31G X 1/4" 1 ML | • KMART VALU INSULIN SYRINGE
30G U-100 0.5 ML |
| • INSULIN SYRINGE-NEEDLE U-100
31G X 5/16" 0.3 ML | • KMART VALU INSULIN SYRINGE
30G U-100 1 ML |
| • INSULIN SYRINGE-NEEDLE U-100
31G X 5/16" 0.5 ML (OTC) | • KROGER INSULIN SYRINGE 29G X
1/2" 0.3 ML |
| • INSULIN SYRINGE-NEEDLE U-100
31G X 5/16" 0.5 ML (RX) | • KROGER INSULIN SYRINGE 29G X
1/2" 0.5 ML |
| • INSULIN SYRINGE-NEEDLE U-100
31G X 5/16" 1 ML (OTC) | • KROGER INSULIN SYRINGE 29G X
1/2" 1 ML |
| • INSULIN SYRINGE-NEEDLE U-100
31G X 5/16" 1 ML (RX) | • KROGER INSULIN SYRINGE 30G X
5/16" 0.3 ML |
| • INSUPEN PEN NEEDLES 29G X 12MM | • KROGER INSULIN SYRINGE 30G X
5/16" 0.5 ML |
| • INSUPEN PEN NEEDLES 31G X 5 MM | • KROGER INSULIN SYRINGE 30G X
5/16" 1 ML |
| • INSUPEN PEN NEEDLES 31G X 8 MM | • KROGER INSULIN SYRINGE 31G X
5/16" 0.3 ML |
| • INSUPEN PEN NEEDLES 32G X 4 MM | • KROGER INSULIN SYRINGE 31G X
5/16" 0.5 ML |
| • INSUPEN PEN NEEDLES 33G X 4 MM | • KROGER INSULIN SYRINGE 31G X
5/16" 1 ML |
| • INSUPEN SENSITIVE 32G X 6 MM | • KROGER PEN NEEDLES 29G X 12MM |
| • INSUPEN SENSITIVE 32G X 8 MM | • KROGER PEN NEEDLES 31G X 5 MM |
| • INSUPEN ULTRAFIN 30G X 8 MM | • KROGER PEN NEEDLES 31G X 6 MM |
| • INSUPEN ULTRAFIN 31G X 6 MM | • KROGER PEN NEEDLES 31G X 8 MM |
| • INSUPEN ULTRAFIN 31G X 8 MM | • KROGER PEN NEEDLES 32G X 4 MM |
| • INSUPEN32G EXTR3ME 32G X 6 MM | • KROGER PEN NEEDLES 33G X 4 MM |
| • J & J GAUZE PAD 2"X2" | • LEADER INSULIN SYRINGE 28G X
1/2" 0.5 ML |
| • KENDALL HYDROPHILIC FOAM
DRESS PAD 2"X2" | • LEADER INSULIN SYRINGE 28G X
1/2" 1 ML |
| • KENDALL HYDROPHILIC FOAM
PLUS PAD 2"X2" | • LEADER INSULIN SYRINGE 29G X
1/2" 0.3 ML |
| • KINRAY INSULIN SYRINGE 29G X
1/2" 0.5 ML | • LEADER INSULIN SYRINGE 29G X
1/2" 0.5 ML |
| • KINRAY INSULIN SYRINGE 31G X
5/16" 0.3 ML | • LEADER INSULIN SYRINGE 29G X
1/2" 1 ML |
| • KINRAY INSULIN SYRINGE 31G X
5/16" 0.5 ML | |
| • KINRAY INSULIN SYRINGE 31G X
5/16" 1 ML | |
| • KMART VALU INSULIN SYRINGE
29G U-100 0.5 ML | |

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- | | |
|--|--|
| • LEADER INSULIN SYRINGE 30G X 5/16" 0.3 ML | • LITETOUCH INSULIN SYRINGE 31G X 5/16" 1 ML |
| • LEADER INSULIN SYRINGE 30G X 5/16" 0.5 ML | • LITETOUCH PEN NEEDLES 29G X 12.7MM |
| • LEADER INSULIN SYRINGE 30G X 5/16" 1 ML | • LITETOUCH PEN NEEDLES 31G X 5 MM |
| • LEADER INSULIN SYRINGE 31G X 5/16" 0.3 ML | • LITETOUCH PEN NEEDLES 31G X 6 MM |
| • LEADER INSULIN SYRINGE 31G X 5/16" 0.5 ML | • LITETOUCH PEN NEEDLES 31G X 8 MM |
| • LEADER INSULIN SYRINGE 31G X 5/16" 1 ML | • LITETOUCH PEN NEEDLES 32G X 4 MM |
| • LEADER UNIFINE PENTIPS 31G X 5 MM | • LONGS INSULIN SYRINGE 31G X 5/16" 0.5 ML |
| • LEADER UNIFINE PENTIPS 32G X 4 MM | • MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.3 ML |
| • LEADER UNIFINE PENTIPS PLUS 31G X 5 MM | • MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 0.5 ML |
| • LEADER UNIFINE PENTIPS PLUS 31G X 8 MM | • MAGELLAN INSULIN SAFETY SYR 29G X 1/2" 1 ML |
| • LEADER UNIFINE PENTIPS PLUS 32G X 4 MM | • MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.3 ML |
| • LITETOUCH INSULIN SYRINGE 28G X 1/2" 0.5 ML | • MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 0.5 ML |
| • LITETOUCH INSULIN SYRINGE 28G X 1/2" 1 ML | • MAGELLAN INSULIN SAFETY SYR 30G X 5/16" 1 ML |
| • LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.3 ML | • MARATHON MEDICAL PENTIPS 29G X 12MM |
| • LITETOUCH INSULIN SYRINGE 29G X 1/2" 0.5 ML | • MARATHON MEDICAL PENTIPS 31G X 5 MM |
| • LITETOUCH INSULIN SYRINGE 29G X 1/2" 1 ML | • MARATHON MEDICAL PENTIPS 31G X 8 MM |
| • LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.3 ML | • MARATHON MEDICAL PENTIPS 32G X 4 MM |
| • LITETOUCH INSULIN SYRINGE 30G X 5/16" 0.5 ML | • MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML |
| • LITETOUCH INSULIN SYRINGE 30G X 5/16" 1 ML | • MAXI-COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML |
| • LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.3 ML | • MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM |
| • LITETOUCH INSULIN SYRINGE 31G X 5/16" 0.5 ML | • MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM |

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- MAXICOMFORT II PEN NEEDLE 31G X 6 MM
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 0.5 ML
- MAXICOMFORT SYR 27G X 1/2" 27G X 1/2" 1 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MEDIC INSULIN SYRINGE 30G X 5/16" 0.5 ML
- MEDICINE SHOPPE PEN NEEDLES 29G X 12MM
- MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM
- MEDPURA ALCOHOL PADS 70 % EXTERNAL
- MEIJER ALCOHOL SWABS PAD 70 %
- MEIJER PEN NEEDLES 29G X 12MM
- MEIJER PEN NEEDLES 31G X 6 MM
- MEIJER PEN NEEDLES 31G X 8 MM
- MICRODOT PEN NEEDLE 31G X 6 MM
- MICRODOT PEN NEEDLE 32G X 4 MM
- MICRODOT PEN NEEDLE 33G X 4 MM
- MIRASORB SPONGES 2"X2"
- MM INSULIN SYRINGE/NEEDLE 30G X 5/16" 0.3 ML
- MM INSULIN SYRINGE/NEEDLE 30G X 5/16" 0.5 ML
- MM INSULIN SYRINGE/NEEDLE 30G X 5/16" 1 ML
- MM INSULIN SYRINGE/NEEDLE 31G X 5/16" 0.3 ML
- MM INSULIN SYRINGE/NEEDLE 31G X 5/16" 0.5 ML
- MM INSULIN SYRINGE/NEEDLE 31G X 5/16" 1 ML
- MM PEN NEEDLES 31G X 5 MM
- MM PEN NEEDLES 31G X 6 MM
- MM PEN NEEDLES 31G X 8 MM
- MM PEN NEEDLES 32G X 4 MM
- MONOJECT INSULIN SYRINGE 25G X 5/8" 1 ML
- MONOJECT INSULIN SYRINGE 27G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 27G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 28G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- MONOJECT INSULIN SYRINGE 29G X 1/2" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- MONOJECT INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 1 ML (OTC)
- MONOJECT INSULIN SYRINGE 30G X 5/16" 1 ML (RX)
- MONOJECT INSULIN SYRINGE 31G X 5/16" 1 ML
- MONOJECT INSULIN SYRINGE U-100 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 0.5 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 1 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2" 1 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 0.3 ML

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 0.5 ML
- MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2" 1 ML
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.3 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.5 ML (OTC)
- MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16" 0.5 ML (RX)
- MONOJECT ULTRA COMFORT SYRINGE 31G X 5/16" 0.3 ML
- MONOJECT ULTRA COMFORT SYRINGE 31G X 5/16" 0.5 ML
- MS INSULIN SYRINGE 31G X 5/16" 0.3 ML
- MS INSULIN SYRINGE 31G X 5/16" 0.5 ML
- MS INSULIN SYRINGE 31G X 5/16" 1 ML
- NOVOFINE AUTOCOVER PEN NEEDLE 30G X 8 MM
- NOVOFINE PEN NEEDLE 32G X 6 MM
- NOVOFINE PLUS PEN NEEDLE 32G X 4 MM
- PC UNIFINE PENTIPS 31G X 5 MM
- PC UNIFINE PENTIPS 31G X 6 MM
- PC UNIFINE PENTIPS 31G X 8 MM
- PEN NEEDLE/5-BEVEL TIP 31G X 8 MM
- PEN NEEDLE/5-BEVEL TIP 32G X 4 MM
- PEN NEEDLES 29G X 12MM
- PEN NEEDLES 30G X 5 MM (OTC)
- PEN NEEDLES 30G X 5 MM (RX)
- PEN NEEDLES 30G X 8 MM
- PEN NEEDLES 31G X 5 MM (OTC)
- PEN NEEDLES 31G X 5 MM (RX)
- PEN NEEDLES 31G X 6 MM
- PEN NEEDLES 31G X 8 MM (OTC)
- PEN NEEDLES 31G X 8 MM (RX)
- PEN NEEDLES 32G X 4 MM (OTC)
- PEN NEEDLES 32G X 4 MM (RX)
- PEN NEEDLES 32G X 6 MM
- PENTIPS 29G X 12MM (OTC)
- PENTIPS 29G X 12MM (RX)
- PENTIPS 31G X 5 MM (OTC)
- PENTIPS 31G X 5 MM (RX)
- PENTIPS 31G X 6 MM
- PENTIPS 31G X 8 MM (OTC)
- PENTIPS 31G X 8 MM (RX)
- PENTIPS 32G X 4 MM (OTC)
- PENTIPS 32G X 4 MM (RX)
- PENTIPS 32G X 6 MM
- PENTIPS GENERIC PEN NEEDLES 29G X 12MM
- PENTIPS GENERIC PEN NEEDLES 31G X 5 MM
- PENTIPS GENERIC PEN NEEDLES 31G X 6 MM
- PENTIPS GENERIC PEN NEEDLES 31G X 8 MM
- PENTIPS GENERIC PEN NEEDLES 32G X 4 MM
- PENTIPS GENERIC PEN NEEDLES 32G X 6 MM
- PHARMACIST CHOICE ALCOHOL PAD
- PIP PEN NEEDLES 31G X 5MM 31G X 5 MM
- PIP PEN NEEDLES 32G X 4MM 32G X 4 MM
- PRECISION SURE-DOSE SYRINGE 30G X 5/16" 0.3 ML
- PREFERRED PLUS INSULIN SYRINGE 28G X 1/2" 0.5 ML
- PREFERRED PLUS INSULIN SYRINGE 28G X 1/2" 1 ML

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

- PREFERRED PLUS INSULIN SYRINGE 29G X 1/2" 0.3 ML
- PREFERRED PLUS INSULIN SYRINGE 29G X 1/2" 0.5 ML
- PREFERRED PLUS INSULIN SYRINGE 29G X 1/2" 1 ML
- PREFERRED PLUS INSULIN SYRINGE 30G X 5/16" 0.3 ML
- PREFERRED PLUS INSULIN SYRINGE 30G X 5/16" 0.5 ML
- PREFERRED PLUS INSULIN SYRINGE 30G X 5/16" 1 ML
- PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM
- PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM
- PREVENT SAFETY PEN NEEDLES 31G X 6 MM
- PREVENT SAFETY PEN NEEDLES 31G X 8 MM
- PRO COMFORT ALCOHOL PAD 70 %
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- PRO COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- PRO COMFORT PEN NEEDLES 32G X 4 MM
- PRO COMFORT PEN NEEDLES 32G X 5 MM
- PRO COMFORT PEN NEEDLES 32G X 6 MM
- PRO COMFORT PEN NEEDLES 32G X 8 MM
- PRO COMFORT SAFETY PEN NEEDLE 31G X 5 MM
- PRO COMFORT SAFETY PEN NEEDLE 31G X 6 MM
- PRO COMFORT SAFETY PEN NEEDLE 32G X 4 MM
- PX EXTRA SHORT PEN NEEDLES 31G X 6 MM
- PX INSULIN SYRINGE 30G X 1/2" 0.5 ML
- PX MINI PEN NEEDLES 31G X 5 MM
- PX PEN NEEDLE 29G X 12MM
- PX PEN NEEDLE 31G X 8 MM
- PX SHORTLENGTH PEN NEEDLES 31G X 8 MM
- QC ALCOHOL
- QC ALCOHOL SWABS PAD 70 %
- QC BORDER ISLAND GAUZE PAD 2"X2"
- QC PEN NEEDLES 29G X 12MM
- QC PEN NEEDLES 31G X 6 MM
- QC PEN NEEDLES 31G X 8 MM
- QC UNIFINE PENTIPS 32G X 4 MM

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- QUICK TOUCH INSULIN PEN NEEDLE 29G X 12.7MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 31G X 8 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 32G X 8 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 4 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 5 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 6 MM
- QUICK TOUCH INSULIN PEN NEEDLE 33G X 8 MM
- RA ALCOHOL SWABS PAD 70 %
- RA INSULIN SYRINGE 29G X 1/2" 0.5 ML
- RA INSULIN SYRINGE 29G X 1/2" 1 ML
- RA INSULIN SYRINGE 30G X 5/16" 0.5 ML
- RA INSULIN SYRINGE 30G X 5/16" 1 ML
- *ra isopropyl alcohol wipes*
- RA PEN NEEDLES 31G X 5 MM
- RA PEN NEEDLES 31G X 8 MM
- RA STERILE PAD 2"X2"
- RAYA SURE PEN NEEDLE 29G X 12MM
- RAYA SURE PEN NEEDLE 31G X 4 MM
- RAYA SURE PEN NEEDLE 31G X 5 MM
- RAYA SURE PEN NEEDLE 31G X 6 MM
- RAYA SURE PEN NEEDLE 31G X 8 MM
- REALITY INSULIN SYRINGE 28G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 28G X 1/2" 1 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 0.5 ML
- REALITY INSULIN SYRINGE 29G X 1/2" 1 ML
- REALITY SWABS PAD
- RELI-ON INSULIN SYRINGE 29G 0.3 ML
- RELION ALCOHOL SWABS PAD
- RELION ALCOHOL SWABS PAD 70 %
- RELION INSULIN SYRINGE 29G X 1/2" 0.5 ML
- RELION INSULIN SYRINGE 31G X 15/64" 0.3 ML
- RELION INSULIN SYRINGE 31G X 15/64" 0.5 ML
- RELION INSULIN SYRINGE 31G X 15/64" 1 ML
- RELION INSULIN SYRINGE 31G X 5/16" 0.3 ML
- RELION INSULIN SYRINGE 31G X 5/16" 0.5 ML
- RELION INSULIN SYRINGE 31G X 5/16" 1 ML
- RELION MINI PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 29G X 12MM
- RELION PEN NEEDLES 31G X 6 MM
- RELION PEN NEEDLES 31G X 8 MM
- RELION PEN NEEDLES 32G X 4 MM

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- RELION SHORT PEN NEEDLES 31G X 8 MM
- RESTORE CONTACT LAYER PAD 2"X2"
- SAFETY PEN NEEDLES 30G X 5 MM
- SAFETY PEN NEEDLES 30G X 8 MM
- SAPS CARE ALCOHOL PREP PAD 70 %
- SAPS HEALTH ALCOHOL PREP PAD 70 %
- SAPS HEALTH CARE ALCOHOL PREP PAD 70 %
- SB ALCOHOL PREP PAD 70 %
- SB INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SB INSULIN SYRINGE 29G X 1/2" 1 ML
- SB INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SB INSULIN SYRINGE 30G X 5/16" 1 ML
- SB INSULIN SYRINGE 31G X 5/16" 1 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SECURESAFE INSULIN SYRINGE 29G X 1/2" 1 ML
- SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM
- SECURESAFE SAFETY PEN NEEDLES 31G X 5 MM
- SM STERILE PAD 2"X2"
- STERILE GAUZE PAD 2"X2"
- STERILE PAD 2"X2"
- SURE COMFORT ALCOHOL PREP PAD 70 %
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 28G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 29G X 1/2" 1 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 1/4" 1 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.3 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- SURE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- SURE COMFORT PEN NEEDLES 29G X 12.7MM
- SURE COMFORT PEN NEEDLES 30G X 8 MM
- SURE COMFORT PEN NEEDLES 31G X 5 MM
- SURE COMFORT PEN NEEDLES 31G X 6 MM
- SURE COMFORT PEN NEEDLES 31G X 8 MM
- SURE COMFORT PEN NEEDLES 32G X 4 MM (OTC)
- SURE COMFORT PEN NEEDLES 32G X 4 MM (RX)

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- SURE COMFORT PEN NEEDLES 32G X 6 MM
- SURGICAL GAUZE SPONGE PAD 2"X2"
- TECHLITE INSULIN SYRINGE 30G X 1/2" 1 ML
- TECHLITE INSULIN SYRINGE 31G X 15/64" 0.3 ML
- TECHLITE INSULIN SYRINGE 31G X 15/64" 0.5 ML
- TECHLITE INSULIN SYRINGE 31G X 15/64" 1 ML
- TECHLITE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- TECHLITE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TECHLITE INSULIN SYRINGE 31G X 5/16" 1 ML
- TECHLITE PEN NEEDLES 29G X 12MM
- TECHLITE PEN NEEDLES 31G X 5 MM
- TECHLITE PEN NEEDLES 31G X 8 MM
- TECHLITE PEN NEEDLES 32G X 4 MM
- TECHLITE PEN NEEDLES 32G X 6 MM
- TECHLITE PLUS PEN NEEDLES 32G X 4 MM
- TEGADERM FOAM PAD 2"X2"
- TODAYS HEALTH PEN NEEDLES 29G X 12MM
- TODAYS HEALTH SHORT PEN NEEDLE 31G X 8 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 6 MM
- TOPCARE CLICKFINE PEN NEEDLES 31G X 8 MM
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 29G X 1/2" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 30G X 5/16" 1 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.3 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 0.5 ML
- TOPCARE ULTRA COMFORT INS SYR 31G X 5/16" 1 ML
- TOPFINE INSULIN PEN NEEDLE 32G X 4 MM
- TRUE COMFORT ALCOHOL PREP PADS PAD 70 %
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 1/2" 1 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 30G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 0.5 ML
- TRUE COMFORT INSULIN SYRINGE 31G X 5/16" 1 ML
- TRUE COMFORT INSULIN SYRINGE 32G X 5/16" 1 ML
- TRUE COMFORT PEN NEEDLES 31G X 5 MM
- TRUE COMFORT PEN NEEDLES 31G X 6 MM
- TRUE COMFORT PEN NEEDLES 32G X 4 MM
- TRUE COMFORT PRO ALCOHOL PREP PAD 70 %

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

- | | |
|--|--|
| • TRUE COMFORT PRO INSULIN SYR
30G X 1/2" 0.5 ML | • TRUEPLUS 5-BEVEL PEN NEEDLES
31G X 5 MM |
| • TRUE COMFORT PRO INSULIN SYR
30G X 1/2" 1 ML | • TRUEPLUS 5-BEVEL PEN NEEDLES
31G X 6 MM |
| • TRUE COMFORT PRO INSULIN SYR
30G X 5/16" 0.5 ML | • TRUEPLUS 5-BEVEL PEN NEEDLES
31G X 8 MM |
| • TRUE COMFORT PRO INSULIN SYR
30G X 5/16" 1 ML | • TRUEPLUS 5-BEVEL PEN NEEDLES
32G X 4 MM |
| • TRUE COMFORT PRO INSULIN SYR
31G X 5/16" 0.5 ML | • TRUEPLUS INSULIN SYRINGE 28G X
1/2" 0.5 ML |
| • TRUE COMFORT PRO INSULIN SYR
31G X 5/16" 1 ML | • TRUEPLUS INSULIN SYRINGE 28G X
1/2" 1 ML |
| • TRUE COMFORT PRO INSULIN SYR
32G X 5/16" 0.5 ML | • TRUEPLUS INSULIN SYRINGE 29G X
1/2" 0.3 ML |
| • TRUE COMFORT PRO INSULIN SYR
32G X 5/16" 1 ML | • TRUEPLUS INSULIN SYRINGE 29G X
1/2" 0.5 ML |
| • TRUE COMFORT PRO PEN NEEDLES
31G X 5 MM | • TRUEPLUS INSULIN SYRINGE 29G X
1/2" 1 ML |
| • TRUE COMFORT PRO PEN NEEDLES
31G X 6 MM | • TRUEPLUS INSULIN SYRINGE 30G X
5/16" 0.3 ML |
| • TRUE COMFORT PRO PEN NEEDLES
31G X 8 MM | • TRUEPLUS INSULIN SYRINGE 30G X
5/16" 0.5 ML |
| • TRUE COMFORT PRO PEN NEEDLES
32G X 4 MM | • TRUEPLUS INSULIN SYRINGE 30G X
5/16" 1 ML |
| • TRUE COMFORT PRO PEN NEEDLES
32G X 5 MM | • TRUEPLUS INSULIN SYRINGE 31G X
5/16" 0.3 ML |
| • TRUE COMFORT PRO PEN NEEDLES
32G X 6 MM | • TRUEPLUS INSULIN SYRINGE 31G X
5/16" 0.5 ML |
| • TRUE COMFORT PRO PEN NEEDLES
33G X 4 MM | • TRUEPLUS INSULIN SYRINGE 31G X
5/16" 1 ML |
| • TRUE COMFORT PRO PEN NEEDLES
33G X 5 MM | • TRUEPLUS PEN NEEDLES 29G X
12MM |
| • TRUE COMFORT PRO PEN NEEDLES
33G X 6 MM | • TRUEPLUS PEN NEEDLES 31G X 5
MM |
| • TRUE COMFORT SAFETY PEN
NEEDLE 31G X 5 MM | • TRUEPLUS PEN NEEDLES 31G X 6
MM |
| • TRUE COMFORT SAFETY PEN
NEEDLE 31G X 6 MM | • TRUEPLUS PEN NEEDLES 31G X 8
MM |
| • TRUE COMFORT SAFETY PEN
NEEDLE 32G X 4 MM | • TRUEPLUS PEN NEEDLES 32G X 4
MM |
| • TRUEPLUS 5-BEVEL PEN NEEDLES
29G X 12.7MM | • ULTICARE ALCOHOL SWABS PAD |

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

- | | |
|---|---|
| • ULTICARE ALCOHOL SWABS PAD 70 % | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (OTC) |
| • ULTICARE INSULIN SAFETY SYR 29G X 1/2" 0.5 ML | • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.5 ML (RX) |
| • ULTICARE INSULIN SAFETY SYR 29G X 1/2" 1 ML | • ULTICARE INSULIN SYRINGE 31G X 5/16" 1 ML |
| • ULTICARE INSULIN SYR 1/2 UNIT 31G X 1/4" 0.3 ML | • ULTICARE MICRO PEN NEEDLES 31G X 6 MM |
| • ULTICARE INSULIN SYRINGE 28G X 1/2" 0.5 ML | • ULTICARE MICRO PEN NEEDLES 31G X 8 MM |
| • ULTICARE INSULIN SYRINGE 28G X 1/2" 1 ML | • ULTICARE MICRO PEN NEEDLES 32G X 4 MM |
| • ULTICARE INSULIN SYRINGE 29G X 1/2" 0.3 ML | • ULTICARE MINI PEN NEEDLES 30G X 5 MM |
| • ULTICARE INSULIN SYRINGE 29G X 1/2" 0.5 ML | • ULTICARE MINI PEN NEEDLES 31G X 6 MM |
| • ULTICARE INSULIN SYRINGE 29G X 1/2" 1 ML | • ULTICARE MINI PEN NEEDLES 32G X 6 MM |
| • ULTICARE INSULIN SYRINGE 30G X 1/2" 0.3 ML | • ULTICARE PEN NEEDLES 29G X 12.7MM (OTC) |
| • ULTICARE INSULIN SYRINGE 30G X 1/2" 0.5 ML | • ULTICARE PEN NEEDLES 29G X 12.7MM (RX) |
| • ULTICARE INSULIN SYRINGE 30G X 1/2" 1 ML | • ULTICARE PEN NEEDLES 31G X 5 MM |
| • ULTICARE INSULIN SYRINGE 30G X 5/16" 0.3 ML | • ULTICARE SHORT PEN NEEDLES 30G X 8 MM |
| • ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (OTC) | • ULTICARE SHORT PEN NEEDLES 31G X 8 MM (OTC) |
| • ULTICARE INSULIN SYRINGE 30G X 5/16" 0.5 ML (RX) | • ULTICARE SHORT PEN NEEDLES 31G X 8 MM (RX) |
| • ULTICARE INSULIN SYRINGE 30G X 5/16" 1 ML | • ULTIGUARD SAFEPACK PEN NEEDLE 29G X 12.7MM |
| • ULTICARE INSULIN SYRINGE 31G X 1/4" 0.3 ML | • ULTIGUARD SAFEPACK PEN NEEDLE 31G X 5 MM |
| • ULTICARE INSULIN SYRINGE 31G X 1/4" 0.5 ML | • ULTIGUARD SAFEPACK PEN NEEDLE 31G X 6 MM |
| • ULTICARE INSULIN SYRINGE 31G X 1/4" 1 ML | • ULTIGUARD SAFEPACK PEN NEEDLE 31G X 8 MM |
| • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (OTC) | • ULTIGUARD SAFEPACK PEN NEEDLE 32G X 4 MM |
| • ULTICARE INSULIN SYRINGE 31G X 5/16" 0.3 ML (RX) | • ULTIGUARD SAFEPACK PEN NEEDLE 32G X 6 MM |

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

- ULTIGUARD SAFEPAK SYR/NEEDLE 30G X 1/2" 0.3 ML
- ULTIGUARD SAFEPAK SYR/NEEDLE 30G X 1/2" 0.5 ML
- ULTIGUARD SAFEPAK SYR/NEEDLE 30G X 1/2" 1 ML
- ULTIGUARD SAFEPAK SYR/NEEDLE 31G X 5/16" 0.3 ML
- ULTIGUARD SAFEPAK SYR/NEEDLE 31G X 5/16" 0.5 ML
- ULTIGUARD SAFEPAK SYR/NEEDLE 31G X 5/16" 1 ML
- ULTILET ALCOHOL SWABS PAD
- ULTILET PEN NEEDLE 29G X 12.7MM
- ULTILET PEN NEEDLE 31G X 5 MM
- ULTILET PEN NEEDLE 31G X 8 MM
- ULTILET PEN NEEDLE 32G X 4 MM
- ULTRA COMFORT INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN PEN NEEDLES 29G X 12MM
- ULTRA FLO INSULIN PEN NEEDLES 31G X 5 MM
- ULTRA FLO INSULIN PEN NEEDLES 31G X 8 MM
- ULTRA FLO INSULIN PEN NEEDLES 32G X 4 MM
- ULTRA FLO INSULIN PEN NEEDLES 33G X 4 MM
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYR 1/2 UNIT 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRA FLO INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRA THIN PEN NEEDLES 32G X 4 MM
- ULTRA-CARE ALCOHOL PREP PADS PAD 70 %
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 30G X 5/16" 1 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.3 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 0.5 ML
- ULTRA-THIN II INS SYR SHORT 31G X 5/16" 1 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 0.5 ML
- ULTRA-THIN II INSULIN SYRINGE 29G X 1/2" 1 ML
- ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM
- ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- ULTRA-THIN II PEN NEEDLES 29G X 12.7MM
- ULTRACARE INSULIN SYRINGE 30G X 1/2" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 1/2" 1 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 30G X 5/16" 1 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.3 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 0.5 ML
- ULTRACARE INSULIN SYRINGE 31G X 5/16" 1 ML
- ULTRACARE PEN NEEDLES 31G X 5 MM
- ULTRACARE PEN NEEDLES 31G X 6 MM
- ULTRACARE PEN NEEDLES 31G X 8 MM
- ULTRACARE PEN NEEDLES 32G X 4 MM
- ULTRACARE PEN NEEDLES 32G X 5 MM
- ULTRACARE PEN NEEDLES 32G X 6 MM
- ULTRACARE PEN NEEDLES 33G X 4 MM
- UNIFINE OTC PEN NEEDLES 31G X 5 MM
- UNIFINE OTC PEN NEEDLES 32G X 4 MM
- UNIFINE PENTIPS 29G X 12MM
- UNIFINE PENTIPS 30G X 5 MM
- UNIFINE PENTIPS 31G X 5 MM
- UNIFINE PENTIPS 31G X 6 MM
- UNIFINE PENTIPS 31G X 8 MM
- UNIFINE PENTIPS 32G X 4 MM
- UNIFINE PENTIPS 33G X 4 MM
- UNIFINE PENTIPS PLUS 29G X 12MM
- UNIFINE PENTIPS PLUS 30G X 5 MM
- UNIFINE PENTIPS PLUS 31G X 5 MM
- UNIFINE PENTIPS PLUS 31G X 6 MM
- UNIFINE PENTIPS PLUS 31G X 8 MM
- UNIFINE PENTIPS PLUS 32G X 4 MM
- UNIFINE PENTIPS PLUS 33G X 4 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 5 MM
- UNIFINE PROTECT PEN NEEDLE 30G X 8 MM
- UNIFINE PROTECT PEN NEEDLE 32G X 4 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM
- UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM
- UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM
- UNIFINE ULTRA PEN NEEDLE 29G X 12MM
- UNIFINE ULTRA PEN NEEDLE 31G X 5 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 6 MM
- UNIFINE ULTRA PEN NEEDLE 31G X 8 MM
- UNIFINE ULTRA PEN NEEDLE 32G X 4 MM
- UNIFINE ULTRA PEN NEEDLE 32G X 6 MM
- UNIFINE ULTRA PEN NEEDLE 34G X 3.5 MM

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

- | | |
|--|---|
| • VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 0.5 ML | • VERIFINE INSULIN SYRINGE 31G X 5/16" 0.3 ML |
| • VALUE HEALTH INSULIN SYRINGE 29G X 1/2" 1 ML | • VERIFINE INSULIN SYRINGE 31G X 5/16" 0.5 ML |
| • VANISHPOINT INSULIN SYRINGE 29G X 1/2" 1 ML | • VERIFINE INSULIN SYRINGE 31G X 5/16" 1 ML |
| • VANISHPOINT INSULIN SYRINGE 29G X 5/16" 1 ML | • VERIFINE PLUS PEN NEEDLE 31G X 5 MM |
| • VANISHPOINT INSULIN SYRINGE 30G X 1/2" 0.5 ML | • VERIFINE PLUS PEN NEEDLE 31G X 8 MM |
| • VANISHPOINT INSULIN SYRINGE 30G X 3/16" 0.5 ML | • VERIFINE PLUS PEN NEEDLE 32G X 4 MM |
| • VANISHPOINT INSULIN SYRINGE 30G X 3/16" 1 ML | • VP INSULIN SYRINGE 29G X 1/2" 0.3 ML |
| • VANISHPOINT INSULIN SYRINGE 30G X 5/16" 0.5 ML | • WEBCOL ALCOHOL PREP LARGE PAD 70 % |
| • VANISHPOINT INSULIN SYRINGE 30G X 5/16" 1 ML | • WEBCOL ALCOHOL PREP MEDIUM PAD 70 % |
| • VERIFINE INSULIN PEN NEEDLE 29G X 12MM | • WEGMANS UNIFINE PENTIPS PLUS 31G X 5 MM |
| • VERIFINE INSULIN PEN NEEDLE 31G X 5 MM | • WEGMANS UNIFINE PENTIPS PLUS 31G X 6 MM |
| • VERIFINE INSULIN PEN NEEDLE 31G X 8 MM | • WEGMANS UNIFINE PENTIPS PLUS 31G X 8 MM |
| • VERIFINE INSULIN PEN NEEDLE 32G X 4 MM | • WEGMANS UNIFINE PENTIPS PLUS 32G X 4 MM |
| • VERIFINE INSULIN PEN NEEDLE 32G X 6 MM | • ZEVRX INSULIN SYRINGE 30G X 1/2" 0.5 ML |
| • VERIFINE INSULIN SYRINGE 28G X 1/2" 1 ML | • ZEVRX INSULIN SYRINGE 30G X 1/2" 1 ML |
| • VERIFINE INSULIN SYRINGE 29G X 1/2" 0.5 ML | • ZEVRX INSULIN SYRINGE 30G X 5/16" 0.5 ML |
| • VERIFINE INSULIN SYRINGE 29G X 1/2" 1 ML | • ZEVRX INSULIN SYRINGE 30G X 5/16" 1 ML |
| • VERIFINE INSULIN SYRINGE 30G X 1/2" 1 ML | • ZEVRX PEN NEEDLES 31G X 5 MM |
| • VERIFINE INSULIN SYRINGE 30G X 5/16" 0.5 ML | • ZEVRX PEN NEEDLES 31G X 6 MM |
| • VERIFINE INSULIN SYRINGE 30G X 5/16" 1 ML | • ZEVRX PEN NEEDLES 31G X 8 MM |
| | • ZEVRX PEN NEEDLES 32G X 4 MM |
| | • ZEVRX STERILE ALCOHOL PREP PAD PAD 70 % |

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Exclusion Criteria	ONLY COVERED UNDER PART D WHEN USED CONCURRENTLY WITH INSULIN.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	LIFETIME
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

INTERFERON FOR MS-AVONEX

Products Affected

- AVONEX PEN INTRAMUSCULAR AUTO-INJECTOR KIT
- AVONEX PREFILLED INTRAMUSCULAR PREFILLED SYRINGE KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

INTERFERON FOR MS-BETASERON

Products Affected

- BETASERON SUBCUTANEOUS KIT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

INTERFERON GAMMA-1B

Products Affected

- ACTIMMUNE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: CHRONIC GRANULOMATOUS DISEASE (CGD): PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST, INFECTIOUS DISEASE SPECIALIST, OR IMMUNOLOGIST. SEVERE MALIGNANT OSTEOPETROSIS (SMO): PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR HEMATOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	RENEWAL: CGD, SMO: 1) DEMONSTRATED CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) HAS NOT RECEIVED HEMATOPOIETIC CELL TRANSPLANTATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

IPILIMUMAB

Products Affected

- YERVOY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: UNRESECT/MET MEL: 4MO, RCC/CRC/HCC: 3MO, ALL OTHERS: 12MO. INITIAL/RENEWAL: CUTAN MEL: 6MO
Other Criteria	RENEWAL: ADJUVANT CUTANEOUS MELANOMA: NO EVIDENCE OF DISEASE RECURRENCE (DEFINED AS THE APPEARANCE OF ONE OR MORE NEW MELANOMA LESIONS: LOCAL, REGIONAL OR DISTANT METASTASIS).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ISAVUCONAZONIUM

Products Affected

- CRESEMBA ORAL

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INVASIVE ASPERGILLOSIS, INVASIVE MUCORMYCOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST.
Coverage Duration	6 MONTHS
Other Criteria	INVASIVE ASPERGILLOSIS: TRIAL OF OR CONTRAINDICATION TO VORICONAZOLE. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

IVACAFTOR

Products Affected

- KALYDECO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CYSTIC FIBROSIS (CF): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CYSTIC FIBROSIS EXPERT
Coverage Duration	INITIAL: 12 MONTHS. RENEWAL: LIFETIME
Other Criteria	CF: INITIAL: 1) NOT HOMOZYGOUS FOR F508DEL MUTATION IN THE CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) GENE, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

IVOSIDENIB

Products Affected

- TIBSOVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

IXAZOMIB

Products Affected

- NINLARO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LAMOTRIGINE

Products Affected

- SUBVENITE ORAL SUSPENSION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ALL INDICATIONS: CONTRAINDICATION TO OR UNABLE TO SWALLOW LAMOTRIGINE TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LANREOTIDE

Products Affected

- LANREOTIDE ACETATE
- SOMATULINE DEPOT
SUBCUTANEOUS SOLUTION 60
MG/0.2ML, 90 MG/0.3ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	ACROMEGALY: INITIAL: THERAPY IS PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	ACROMEGALY: INITIAL/RENEWAL: 12 MOS. GEP-NETS, CARCINOID SYNDROME: 12 MOS.
Other Criteria	ACROMEGALY: RENEWAL: 1) REDUCTION, NORMALIZATION, OR MAINTENANCE OF IGF-1 LEVELS BASED ON AGE AND GENDER, AND 2) IMPROVEMENT OR SUSTAINED REMISSION OF CLINICAL SYMPTOMS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LAPATINIB

Products Affected

- lapatinib ditosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LAROTRECTINIB

Products Affected

- VITRAKVI ORAL CAPSULE 100 MG, 25 MG
- VITRAKVI ORAL SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	VITRAKVI ORAL SOLUTION: 1) TRIAL OF VITRAKVI CAPSULES, OR 2) UNABLE TO TAKE CAPSULE FORMULATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LAZERTINIB

Products Affected

- LAZCLUZE ORAL TABLET 240 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LEDIPASVIR-SOFOSBUVIR

Products Affected

- HARVONI ORAL PACKET 33.75-150 MG, 45-200 MG
- HARVONI ORAL TABLET
- *ledipasvir-sofosbuvir*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, AND 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING: CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, ROSUVASTATIN, TIPRANAVIR/RITONAVIR, SOFOSBUVIR (AS A SINGLE AGENT), EPCLUSA, ZEPATIER, MAVYRET, OR VOSEVI.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LENALIDOMIDE

Products Affected

- *lenalidomide*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LENVATINIB

Products Affected

- LENVIMA (10 MG DAILY DOSE)
- LENVIMA (12 MG DAILY DOSE)
- LENVIMA (14 MG DAILY DOSE)
- LENVIMA (18 MG DAILY DOSE)
- LENVIMA (20 MG DAILY DOSE)
- LENVIMA (24 MG DAILY DOSE)
- LENVIMA (4 MG DAILY DOSE)
- LENVIMA (8 MG DAILY DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LETERMOVIR

Products Affected

- PREVYMIS ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	HSCT: NOT AT RISK FOR LATE CMV: 4 MOS, AT RISK FOR LATE CMV: 7 MOS. KIDNEY TRANSPLANT: 7 MOS.
Other Criteria	HEMATOPOIETIC STEM CELL TRANSPLANT (HSCT): 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 28 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 100 DAYS POST TRANSPLANT IF NOT AT RISK FOR LATE CYTOMEGALOVIRUS (CMV) INFECTION AND DISEASE, OR BEYOND 200 DAYS POST TRANSPLANT IF AT RISK FOR LATE CMV INFECTION AND DISEASE. KIDNEY TRANSPLANT: 1) THERAPY WILL BE INITIATED BETWEEN DAY 0 AND DAY 7 POST TRANSPLANT, AND 2) WILL NOT RECEIVE THE MEDICATION BEYOND 200 DAYS POST TRANSPLANT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LEUPROLIDE

Products Affected

- leuprolide acetate injection*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	PROSTATE CANCER: 12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LEUPROLIDE DEPOT

Products Affected

- LEUPROLIDE ACETATE (3 MONTH)
- LUTRATE DEPOT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LEUPROLIDE MESYLATE

Products Affected

- CAMCEVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LEUPROLIDE-ELIGARD

Products Affected

- ELIGARD

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LEUPROLIDE-LUPRON DEPOT

Products Affected

- LUPRON DEPOT (1-MONTH)
- LUPRON DEPOT (3-MONTH)
- LUPRON DEPOT (4-MONTH)
- LUPRON DEPOT (6-MONTH)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: ENDOMETRIOSIS: PRESCRIBED BY OR IN CONSULTATION WITH AN OBSTETRICIAN/GYNECOLOGIST.
Coverage Duration	PROSTATE CA: 12 MOS. UTERINE FIBROIDS: 3 MOS. ENDOMETRIOSIS: INITIAL/RENEWAL: 6 MOS.
Other Criteria	INITIAL: ENDOMETRIOSIS: 1) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, 2) TRIAL OF OR CONTRAINDICATION TO NSAID AND PROGESTIN-CONTAINING PREPARATION, AND 3) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME. RENEWAL: ENDOMETRIOSIS: 1) IMPROVEMENT OF PAIN RELATED TO ENDOMETRIOSIS WHILE ON THERAPY, 2) RECEIVING CONCOMITANT ADD-BACK THERAPY (I.E., COMBINATION ESTROGEN-PROGESTIN OR PROGESTIN-ONLY CONTRACEPTIVE PREPARATION), 3) NO CONCURRENT USE WITH ANOTHER GNRH-MODULATING AGENT, AND 4) HAS NOT RECEIVED A TOTAL OF 12 MONTHS OF TREATMENT PER LIFETIME.
Indications	All FDA-approved Indications.
Off Label Uses	

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LEUPROLIDE-LUPRON DEPOT-PED

Products Affected

- LUPRON DEPOT-PED (3-MONTH)
- LUPRON DEPOT-PED (6-MONTH)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CENTRAL PRECOCIOUS PUBERTY (CPP): INITIAL: FEMALES: ELEVATED LEVEL OF LUTEINIZING HORMONE (LH) LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS. MALES: ELEVATED LEVEL OF LH LEVEL GREATER THAN 0.2 TO 0.3 MIU/ML AT DIAGNOSIS.
Age Restrictions	
Prescriber Restrictions	CPP: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	CPP: INITIAL: FEMALES: 1) YOUNGER THAN 8 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR BREAST DEVELOPMENT AND PUBIC HAIR GROWTH. MALES: 1) YOUNGER THAN 9 YEARS OF AGE AT ONSET OF CPP, AND 2) AT TANNER STAGE 2 OR ABOVE FOR GENITAL DEVELOPMENT AND PUBIC HAIR GROWTH. RENEWAL: 1) TANNER STAGING AT INITIAL DIAGNOSIS HAS STABILIZED OR REGRESSED DURING THREE SEPARATE MEDICAL VISITS IN THE PREVIOUS YEAR, AND 2) HAS NOT REACHED ACTUAL AGE WHICH CORRESPONDS TO CURRENT PUBERTAL AGE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

L-GLUTAMINE

Products Affected

- l-glutamine oral packet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	SICKLE CELL DISEASE(SCD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST
Coverage Duration	INITIAL: 12 MONTHS. RENEWAL: LIFETIME.
Other Criteria	SCD: INITIAL: AGES 18 YEARS OR OLDER: 1) AT LEAST 2 SICKLE CELL CRISES IN THE PAST YEAR, 2) SICKLE-CELL ASSOCIATED SYMPTOMS WHICH ARE INTERFERING WITH ACTIVITIES OF DAILY LIVING, OR 3) HISTORY OF OR HAS RECURRENT ACUTE CHEST SYNDROME. AGES 5 TO 17 YEARS: APPROVED WITHOUT ADDITIONAL CRITERIA. RENEWAL: MAINTAINED OR EXPERIENCED A REDUCTION IN ACUTE COMPLICATIONS OF SCD.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LIDOCAINE OINTMENT

Products Affected

- *lidocaine external ointment 5 %*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LIDOCAINE PRILOCAINE

Products Affected

- *lidocaine-prilocaine external cream*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LINVOSELTAMAB-GCPT

Products Affected

- LYNOZYFIC INTRAVENOUS
SOLUTION 200 MG/10ML, 5 MG/2.5ML

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LONCASTUXIMAB TESIRINE-LPYL

Products Affected

- ZYNLONTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LORLATINIB

Products Affected

- LORBRENA ORAL TABLET 100 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LOTILANER

Products Affected

- XDEM VY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	DEMODEX BLEPHARITIS: 18 YEARS OF AGE OR OLDER
Prescriber Restrictions	
Coverage Duration	6 WEEKS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

LUMACAFITOR-IVACAFITOR

Products Affected

- ORKAMBI ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CYSTIC FIBROSIS (CF): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR CF EXPERT.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: LIFETIME.
Other Criteria	CF: INITIAL: NO CONCURRENT USE WITH ANOTHER CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR (CFTR) MODULATOR. RENEWAL: 1) IMPROVEMENT IN CLINICAL STATUS, AND 2) NO CONCURRENT USE WITH ANOTHER CFTR MODULATOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

MARGETUXIMAB-CMKB

Products Affected

- MARGENZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

MARIBAVIR

Products Affected

- LIVTENCITY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

MAVACAMTEN

Products Affected

- CAMZYOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY(HCM): INITIAL: LEFT VENTRICULAR OUTFLOW TRACK (LVOT) GRADIENT OF 50 MMHG OR HIGHER
Age Restrictions	
Prescriber Restrictions	OBSTRUCTIVE HCM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	OBSTRUCTIVE HCM: INITIAL: TRIAL OF, CONTRAINDICATION, OR INTOLERANCE TO A BETA-BLOCKER OR A NON-DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKER. RENEWAL: CONTINUED CLINICAL BENEFIT (E.G., REDUCTION OF SYMPTOMS, NYHA CLASSIFICATION IMPROVEMENT).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

MECASERMIN

Products Affected

- INCRELEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	GROWTH FAILURE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST OR NEPHROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	GROWTH FAILURE: INITIAL: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF WRIST AND HAND. INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER GROWTH HORMONE MEDICATION. RENEWAL: IMPROVEMENT WHILE ON THERAPY (INCREASE IN HEIGHT OR INCREASE IN HEIGHT VELOCITY).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

MECHLORETHAMINE

Products Affected

- VALCHLOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

MEPOLIZUMAB

Products Affected

- NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR
- NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML
- NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ASTHMA: BLOOD EOSINOPHIL LEVEL OF AT LEAST 150 CELLS/MCL WITHIN THE PAST 12 MONTHS.
Age Restrictions	
Prescriber Restrictions	INITIAL: ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN PULMONARY OR ALLERGY MEDICINE. CRSWNP: PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. EOSINOPHILIC COPD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.
Coverage Duration	INITIAL: CRSWNP: 6 MO. OTHERS: 12 MO. RENEWAL: CRSWNP, ASTHMA, COPD, EGPA, HES: 12 MO.
Other Criteria	INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA. CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) EVIDENCE OF NASAL POLYPS BY DIRECT EXAMINATION, ENDOSCOPY, OR SINUS CT SCAN, AND 3) INADEQUATELY CONTROLLED DISEASE. EOSINOPHILIC COPD: USED IN COMBINATION WITH A LAMA/LABA/ICS. RENEWAL: ASTHMA: 1) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, 2) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE, AND 3) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. CRSWNP: 1) CLINICAL BENEFIT COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS (EGPA): 1) REDUCTION IN EGPA SYMPTOMS COMPARED TO BASELINE OR ABILITY TO REDUCE/ELIMINATE CORTICOSTEROID USE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION. EOSINOPHILIC COPD: 1) USED IN COMBINATION WITH A LAMA/LABA/ICS, 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION, AND 3) CLINICAL RESPONSE AS EVIDENCED BY: (A) REDUCTION IN COPD EXACERBATIONS FROM BASELINE, OR (B) REDUCTION IN SEVERITY OR FREQUENCY OF COPD-RELATED SYMPTOMS.
Indications	All FDA-approved Indications.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

METYROSINE

Products Affected

- metirosine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PHEOCHROMOCYTOMA: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST, ENDOCRINE SURGEON, OR HEMATOLOGIST-ONCOLOGIST.
Coverage Duration	PREOPERATIVE PREPARATION FOR SURGERY: 30 DAYS. MALIGNANT PHEOCHROMOCYTOMA: INITIAL/RENEWAL:12 MOS.
Other Criteria	PHEOCHROMOCYTOMA: INITIAL: HAS NON-METASTATIC PHEOCHROMOCYTOMA. PREOPERATIVE PREPARATION FOR SURGERY: USE IN COMBINATION WITH AN ALPHA-ADRENERGIC RECEPTOR BLOCKER. RENEWAL: MALIGNANT PHEOCHROMOCYTOMA: STABLE OR CLINICAL IMPROVEMENT WHILE ON THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

MIDOSTAURIN

Products Affected

- RYDAPT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	ACUTE MYELOID LEUKEMIA: 6 MONTHS. ADVANCED SYSTEMIC MASTOCYTOSIS: 12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

MIFEPRISTONE

Products Affected

- mifepristone oral tablet 300 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CUSHINGS SYNDROME (CS): INITIAL: DIAGNOSIS CONFIRMED BY: 1) 24-HR URINE FREE CORTISOL (AT LEAST 2 TESTS TO CONFIRM), 2) OVERNIGHT 1MG DEXAMETHASONE TEST, OR 3) LATE NIGHT SALIVARY CORTISOL (AT LEAST 2 TESTS TO CONFIRM).
Age Restrictions	
Prescriber Restrictions	CS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	CS: INITIAL: HYPERCORTISOLISM IS NOT A RESULT OF CHRONIC GLUCOCORTICOIDS. RENEWAL: 1) CONTINUES TO HAVE IMPROVEMENT OF GLUCOSE TOLERANCE OR STABLE GLUCOSE TOLERANCE (E.G., REDUCED A1C, IMPROVED FASTING GLUCOSE), 2) CONTINUES TO HAVE TOLERABILITY TO THERAPY, AND 3) CONTINUES TO NOT BE A CANDIDATE FOR SURGICAL TREATMENT OR HAS FAILED SURGERY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

MILTEFOSINE

Products Affected

- IMPAVIDO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

MIRDAMETINIB

Products Affected

- GOMEKLI ORAL CAPSULE 1 MG, 2 MG
- GOMEKLI ORAL TABLET SOLUBLE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

MIRVETUXIMAB SORAVTANSINE-GYNX

Products Affected

- ELAHERE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: AN OPHTHALMIC EXAM, INCLUDING VISUAL ACUITY AND SLIT LAMP EXAM, WILL BE COMPLETED PRIOR TO THE INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

MOMELOTINIB

Products Affected

- OJJAARA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

MOSUNETUZUMAB-AXGB

Products Affected

- LUNSUMIO
- LUNSUMIO VELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: INITIAL: 6 MONTHS. RENEWAL: 7 MONTHS.
Other Criteria	RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA: RENEWAL: 1) HAS ACHIEVED A PARTIAL RESPONSE TO TREATMENT, AND 2) HAS NOT PREVIOUSLY RECEIVED MORE THAN 17 CYCLES OF TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

NARCOLEPSY AGENTS

Products Affected

- *armodafinil*
- *modafinil oral tablet 100 mg, 200 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

NAXITAMAB-GQGK

Products Affected

- DANYELZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

NERANDOMILAST

Products Affected

- JASCAYD

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: IDIOPATHIC PULMONARY FIBROSIS (IPF): A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT. PROGRESSIVE PULMONARY FIBROSIS (PPF): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) INTERSTITIAL LUNG DISEASE WITH A PROGRESSIVE PHENOTYPE (PF-ILD).
Age Restrictions	
Prescriber Restrictions	INITIAL: IPF: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST. PPF: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: IPF: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, CANCER), AND 2) TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: OFEV, PIRFENIDONE. PPF: 1) LUNG FUNCTION AND RESPIRATORY SYMPTOMS OR CHEST IMAGING HAVE WORSENERED/PROGRESSED DESPITE TREATMENT WITH MEDICATIONS USED IN CLINICAL PRACTICE FOR ILD (NOT ATTRIBUTABLE TO COMORBIDITIES SUCH AS INFECTION,

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	HEART FAILURE), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: OFEV (NINTEDANIB). RENEWAL: IPF, PPF: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

NERATINIB

Products Affected

- NERLYNX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	EARLY-STAGE (STAGE I-III) BREAST CANCER: MEDICATION IS BEING REQUESTED WITHIN 2 YEARS OF COMPLETING THE LAST TRASTUZUMAB DOSE. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

NILOTINIB - TASIGNA

Products Affected

- NILOTINIB D-TARTRATE ORAL CAPSULE 150 MG, 200 MG, 50 MG
- *nilotinib hcl oral capsule 150 mg, 200 mg, 50 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND MEDICATION IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

NILOTINIB-DANZITEN

Products Affected

- DANZITEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PREVIOUSLY TREATED PHILADELPHIA CHROMOSOME-POSITIVE CHRONIC MYELOID LEUKEMIA (Ph+ CML): 1) PERFORMED MUTATIONAL ANALYSIS PRIOR TO INITIATION OF THERAPY, AND 2) THERAPY IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

NINTEDANIB

Products Affected

- nintedanib esylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: IDIOPATHIC PULMONARY FIBROSIS (IPF): A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT. SYSTEMIC SCLEROSIS-ASSOCIATED INTERSTITIAL LUNG DISEASE (SSC-ILD): 1) AT LEAST 10% FIBROSIS ON A CHEST HRCT, AND 2) BASELINE FVC AT LEAST 40% OF PREDICTED VALUE. CHRONIC FIBROSING INTERSTITIAL LUNG DISEASE WITH A PROGRESSIVE PHENOTYPE (PF-ILD): AT LEAST 10% FIBROSIS ON A CHEST HRCT.
Age Restrictions	
Prescriber Restrictions	INITIAL: IPF: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST. SSC-ILD, PF-ILD: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST OR RHEUMATOLOGIST.
Coverage Duration	INITIAL: SSC-ILD: 6 MOS. IPF, PF-ILD: 12 MOS. RENEWAL (ALL INDICATIONS): 12 MOS.
Other Criteria	INITIAL: IPF: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS), AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: ESBRIET (PIRFENIDONE). SSC-ILD: DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., HEART FAILURE/FLUID OVERLOAD, DRUG-INDUCED LUNG TOXICITY, RECURRENT ASPIRATION). PF-ILD: LUNG FUNCTION AND RESPIRATORY SYMPTOMS OR CHEST IMAGING HAVE

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	WORSENER/PROGRESSED DESPITE TREATMENT WITH MEDICATIONS USED IN CLINICAL PRACTICE FOR ILD (NOT ATTRIBUTABLE TO COMORBIDITIES SUCH AS INFECTION, HEART FAILURE). RENEWAL: IPF, SSC-ILD, PF-ILD: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

NIRAPARIB

Products Affected

- ZEJULA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER: 1) ZEJULA WILL BE USED AS MONOTHERAPY, AND 2) ZEJULA IS STARTED NO LATER THAN 8 WEEKS AFTER THE MOST RECENT PLATINUM-CONTAINING REGIMEN.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

NIRAPARIB-ABIRATERONE

Products Affected

- AKEEGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC), METASTATIC CASTRATION-SENSITIVE PROSTATE CANCER (MCSPC): 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

NIROGACESTAT

Products Affected

- OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

NIVOLUMAB

Products Affected

- OPDIVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

NIVOLUMAB-HYALURONIDASE-NVHY

Products Affected

- OPDIVO QVANTIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

NIVOLUMAB-RELATLIMAB-RMBW

Products Affected

- OPDUALAG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

NOGAPENDEKIN ALFA

Products Affected

- ANKTIVA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	40 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

OLAPARIB

Products Affected

- LYNPARZA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER: MEDICATION WILL BE USED AS MONOTHERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG. ALL OTHER FDA APPROVED INDICATIONS ARE COVERED WITHOUT ADDITIONAL CRITERIA, EXCEPT THOSE CRITERIA IN THE FDA APPROVED LABEL.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

OLUTASIDENIB

Products Affected

- REZLIDHIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

OMACETAXINE

Products Affected

- SYNRIBO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

OMALIZUMAB

Products Affected

- XOLAIR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ASTHMA: POSITIVE SKIN PRICK OR BLOOD TEST (E.G., ELISA, FEIA) TO A PERENNIAL AEROALLERGEN AND A BASELINE IGE SERUM LEVEL OF AT LEAST 30 IU/ML. FOOD ALLERGY: 1) IGE SERUM LEVEL OF AT LEAST 30 IU/ML, AND 2) POSITIVE SKIN PRICK TEST TO AT LEAST ONE FOOD, OR POSITIVE MEDICALLY MONITORED FOOD CHALLENGE TO AT LEAST ONE FOOD.
Age Restrictions	
Prescriber Restrictions	INITIAL/RENEWAL: CHRONIC SPONTANEOUS URTICARIA (CSU): PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST. INITIAL: CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. FOOD ALLERGY: PRESCRIBED BY OR IN CONSULTATION WITH ALLERGIST OR IMMUNOLOGIST.
Coverage Duration	INITIAL/RENEWAL: ASTHMA 12 MO/12 MO, CSU 6 MO/12 MO, CRSWNP 6 MO/12 MO, FOOD ALLERGY 12 MO/24 MO
Other Criteria	INITIAL: CSU: 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE, 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA ON MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS, AND 3) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: DUPIXENT. CRSWNP: 1) A 56 DAY TRIAL OF ONE TOPICAL NASAL CORTICOSTEROID, 2) TRIAL OF OR

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: NUCALA, DUPIXENT, 3) EVIDENCE OF NASAL POLYPS BY DIRECT EXAMINATION, ENDOSCOPY, OR SINUS CT SCAN, AND 4) INADEQUATELY CONTROLLED DISEASE. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA. FOOD ALLERGY: CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION . INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE. CRSWNP: CLINICAL BENEFIT COMPARED TO BASELINE. ASTHMA: 1) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. FOOD ALLERGY: 1) PERSISTENT IGE-MEDIATED FOOD ALLERGY, AND 2) CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION.
Indications	All FDA-approved Indications.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

OMALIZUMAB-IGEC

Products Affected

- OMLYCLO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: ASTHMA: POSITIVE SKIN PRICK OR BLOOD TEST (E.G., ELISA, FEIA) TO A PERENNIAL AEROALLERGEN AND A BASELINE IGE SERUM LEVEL OF AT LEAST 30 IU/ML. FOOD ALLERGY: 1) IGE SERUM LEVEL OF AT LEAST 30 IU/ML, AND 2) POSITIVE SKIN PRICK TEST TO AT LEAST ONE FOOD, OR POSITIVE MEDICALLY MONITORED FOOD CHALLENGE TO AT LEAST ONE FOOD.
Age Restrictions	
Prescriber Restrictions	INITIAL/RENEWAL: CHRONIC SPONTANEOUS URTICARIA (CSU): PRESCRIBED BY OR IN CONSULTATION WITH AN ALLERGIST, DERMATOLOGIST, OR IMMUNOLOGIST. INITIAL: CHRONIC RHINOSINUSITIS WITH NASAL POLYPS (CRSWNP): PRESCRIBED BY OR IN CONSULTATION WITH AN OTOLARYNGOLOGIST, ALLERGIST OR IMMUNOLOGIST. ASTHMA: PRESCRIBED BY OR IN CONSULTATION WITH A PHYSICIAN SPECIALIZING IN ALLERGY OR PULMONARY MEDICINE. FOOD ALLERGY: PRESCRIBED BY OR IN CONSULTATION WITH ALLERGIST OR IMMUNOLOGIST.
Coverage Duration	INITIAL/RENEWAL: ASTHMA 12 MO/12 MO, CSU 6 MO/12 MO, CRSWNP 6 MO/12 MO, FOOD ALLERGY 12 MO/24 MO
Other Criteria	INITIAL: CSU: 1) TRIAL OF AND MAINTAINED ON, OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE, AND 2) STILL EXPERIENCES HIVES OR ANGIOEDEMA ON MOST DAYS OF THE WEEK FOR AT LEAST 6 WEEKS. CRSWNP: 1) A 56 DAY TRIAL OF ONE CLINICAL STANDARD OF CARE AGENT: A TOPICAL NASAL CORTICOSTEROID, 2) EVIDENCE OF NASAL POLYPS BY DIRECT

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PA Criteria	Criteria Details
	EXAMINATION, ENDOSCOPY, OR SINUS CT SCAN, AND 3) INADEQUATELY CONTROLLED DISEASE. ASTHMA: 1) CONCURRENT THERAPY WITH A MEDIUM, HIGH-DOSE OR MAXIMALLY TOLERATED DOSE OF AN INHALED CORTICOSTEROID (ICS) AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) ONE OF THE FOLLOWING: (A) AT LEAST ONE ASTHMA EXACERBATION REQUIRING SYSTEMIC CORTICOSTEROID BURST LASTING AT LEAST 3 DAYS WITHIN THE PAST 12 MONTHS OR AT LEAST ONE SERIOUS EXACERBATION REQUIRING HOSPITALIZATION OR ER VISIT WITHIN THE PAST 12 MONTHS, OR (B) POOR SYMPTOM CONTROL DESPITE CURRENT THERAPY AS EVIDENCED BY AT LEAST THREE OF THE FOLLOWING WITHIN THE PAST 4 WEEKS: DAYTIME ASTHMA SYMPTOMS MORE THAN TWICE/WEEK, ANY NIGHT WAKING DUE TO ASTHMA, SABA RELIEVER FOR SYMPTOMS MORE THAN TWICE/WEEK, ANY ACTIVITY LIMITATION DUE TO ASTHMA. FOOD ALLERGY: CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: CSU: MAINTAINED ON OR CONTRAINDICATION TO A SECOND GENERATION H1 ANTI-HISTAMINE. CRSWNP: CLINICAL BENEFIT COMPARED TO BASELINE. ASTHMA: 1) CONTINUED USE OF ICS AND AT LEAST ONE OTHER MAINTENANCE MEDICATION, AND 2) CLINICAL RESPONSE AS EVIDENCED BY ONE OF THE FOLLOWING: (A) REDUCTION IN ASTHMA EXACERBATIONS FROM BASELINE, (B) DECREASED UTILIZATION OF RESCUE MEDICATIONS, (C) REDUCTION IN SEVERITY OR FREQUENCY OF ASTHMA-RELATED SYMPTOMS, OR (D) INCREASE IN PERCENT PREDICTED FEV1 FROM PRETREATMENT BASELINE. FOOD ALLERGY: 1) PERSISTENT IGE-MEDIATED FOOD ALLERGY, AND 2) CONCURRENT USE WITH AN ACTIVE PRESCRIPTION FOR EPINEPHRINE AUTO-INJECTOR/INJECTION.
Indications	All FDA-approved Indications.
Off Label Uses	

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

OSIMERTINIB

Products Affected

- TAGRISSO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PACRITINIB

Products Affected

- VONJO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	MYELOFIBROSIS: RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PALBOCICLIB

Products Affected

- IBRANCE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PASIREOTIDE DIASPARTATE

Products Affected

- SIGNIFOR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CUSHINGS DISEASE (CD): INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	CD: RENEWAL: 1) CONTINUED IMPROVEMENT OF CUSHINGS DISEASE, AND 2) MAINTAINED TOLERABILITY TO SIGNIFOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PAZOPANIB

Products Affected

- pazopanib hcl oral tablet 200 mg, 400 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED SOFT TISSUE SARCOMA (STS): NOT USED FOR ADIPOCYTIC STS OR GASTROINTESTINAL STROMAL TUMORS (GIST)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PEGFILGRASTIM - APGF

Products Affected

- NYVEPRIA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PEGFILGRASTIM - CBQV

Products Affected

- UDENYCA ONBODY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	PRESCRIBED BY OR IN CONSULTATION WITH A HEMATOLOGIST OR ONCOLOGIST.
Coverage Duration	12 MONTHS
Other Criteria	NON MYELOID MALIGNANCY: UDENYCA: TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT NYVEPRIA. UDENYCA ONBODY: 1) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT NYVEPRIA, OR 2) BARRIER TO ACCESS (E.G., TRAVEL BARRIERS, UNABLE TO RETURN TO CLINIC FOR INJECTIONS).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PEGINTERFERON ALFA-2A

Products Affected

- PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML
- PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HEPATITIS B: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, INFECTIOUS DISEASE SPECIALIST, OR PHYSICIAN SPECIALIZING IN THE TREATMENT OF HEPATITIS (E.G., HEPATOLOGIST).
Coverage Duration	HEP B/HEP C: 48 WEEKS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PEGVISOMANT

Products Affected

- SOMAVERT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PEMBROLIZUMAB

Products Affected

- KEYTRUDA INTRAVENOUS SOLUTION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNRESECTABLE OR METASTATIC MELANOMA: NO CONCURRENT USE WITH TARGETED THERAPY (I.E., BRAF INHIBITORS, MEK INHIBITORS, AND NTRK INHIBITORS).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PEMBROLIZUMAB-BERAHYALURONIDASE ALFA-PMPH

Products Affected

- KEYTRUDA QLEX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PEMIGATINIB

Products Affected

- PEMAZYRE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CHOLANGIOCARCINOMA, MYELOID/LYMPHOID NEOPLASMS: COMPREHENSIVE OPHTHALMOLOGICAL EXAMINATION, INCLUDING OPTICAL COHERENCE TOMOGRAPHY (OCT), WILL BE COMPLETED PRIOR TO INITIATION OF THERAPY AND AT THE RECOMMENDED SCHEDULED INTERVALS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PENICILLAMINE TABLET

Products Affected

- penicillamine oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: CYSTINURIA: HAS NEPHROLITHIASIS AND ONE OF THE FOLLOWING: 1) STONE ANALYSIS SHOWING PRESENCE OF CYSTINE, 2) PRESENCE OF PATHOGNOMONIC HEXAGONAL CYSTINE CRYSTALS ON URINALYSIS, OR 3) FAMILY HISTORY OF CYSTINURIA AND POSITIVE CYANIDE-NITROPRUSSIDE SCREENING.
Age Restrictions	
Prescriber Restrictions	INITIAL: WILSONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST. CYSTINURIA: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST. RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: 12 MONTHS, RENEWAL: LIFETIME.
Other Criteria	INITIAL: WILSONS DISEASE: 1) LEIPZIG SCORE OF 4 OR GREATER. RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE GREATER THAN OR EQUAL TO 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. RENEWAL: RA: 1) NO HISTORY OR OTHER EVIDENCE OF RENAL INSUFFICIENCY, AND 2) EXPERIENCED OR MAINTAINED IMPROVEMENT IN TENDER JOINT COUNT OR SWOLLEN JOINT COUNT COMPARED TO BASELINE. WILSONS

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	DISEASE, CYSTINURIA: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PEXIDARTINIB

Products Affected

- TURALIO ORAL CAPSULE 125 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PIMAVANSERIN

Products Affected

- NUPLAZID ORAL CAPSULE
- NUPLAZID ORAL TABLET 10 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	PSYCHOSIS IN PARKINSONS DISEASE (PD): INITIAL: 18 YEARS OR OLDER
Prescriber Restrictions	PSYCHOSIS IN PD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, GERIATRICIAN, OR A BEHAVIORAL HEALTH SPECIALIST (E.G., PSYCHIATRIST).
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PSYCHOSIS IN PD: RENEWAL: IMPROVEMENT IN PSYCHOSIS SYMPTOMS FROM BASELINE AND DEMONSTRATES A CONTINUED NEED FOR TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PIRFENIDONE

Products Affected

- *pirfenidone oral capsule*
- *pirfenidone oral tablet 267 mg, 534 mg, 801 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	IDIOPATHIC PULMONARY FIBROSIS (IPF): INITIAL: A USUAL INTERSTITIAL PNEUMONIA (UIP) PATTERN AS EVIDENCED BY HIGH-RESOLUTION COMPUTED TOMOGRAPHY (HRCT) ALONE OR VIA A COMBINATION OF SURGICAL LUNG BIOPSY AND HRCT.
Age Restrictions	
Prescriber Restrictions	IPF: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	IPF: INITIAL: 1) DOES NOT HAVE OTHER KNOWN CAUSES OF INTERSTITIAL LUNG DISEASE (E.G., CONNECTIVE TISSUE DISEASE, DRUG TOXICITY, ASBESTOS OR BERYLLIUM EXPOSURE, HYPERSENSITIVITY PNEUMONITIS, SYSTEMIC SCLEROSIS, RHEUMATOID ARTHRITIS, RADIATION, SARCOIDOSIS, BRONCHIOLITIS OBLITERANS ORGANIZING PNEUMONIA, HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION, VIRAL HEPATITIS, OR CANCER). RENEWAL: CLINICAL MEANINGFUL IMPROVEMENT OR MAINTENANCE IN ANNUAL RATE OF DECLINE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PIRTOBRUTINIB

Products Affected

- JAYPIRCA ORAL TABLET 100 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

POMALIDOMIDE

Products Affected

- *pomalidomide*
- POMALYST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PONATINIB

Products Affected

- ICLUSIG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CHRONIC MYELOID LEUKEMIA (CML): MUTATIONAL ANALYSIS PRIOR TO INITIATION AND ICLUSIG IS APPROPRIATE PER NCCN GUIDELINE TABLE FOR TREATMENT RECOMMENDATIONS BASED ON BCR-ABL1 MUTATION PROFILE.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

POSACONAZOLE TABLET

Products Affected

- posaconazole oral tablet delayed release*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE, PROPHYLAXIS: 6 MONTHS. TREATMENT: 12 WEEKS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PRALSETINIB

Products Affected

- GAVRETO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PYRIMETHAMINE

Products Affected

- pyrimethamine oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	TOXOPLASMOSIS: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN INFECTIOUS DISEASE SPECIALIST.
Coverage Duration	TOXOPLASMOSIS: INITIAL: 8 WEEKS, RENEWAL: 6 MOS.
Other Criteria	TOXOPLASMOSIS: RENEWAL: ONE OF THE FOLLOWING: (1) PERSISTENT CLINICAL DISEASE (HEADACHE, NEUROLOGICAL SYMPTOMS, OR FEVER) AND PERSISTENT RADIOGRAPHIC DISEASE (ONE OR MORE MASS LESIONS ON BRAIN IMAGING), OR (2) CD4 COUNT LESS THAN 200 CELLS/MM3 AND CURRENTLY TAKING AN ANTI-RETROVIRAL THERAPY IF HIV POSITIVE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

QUININE

Products Affected

- *quinine sulfate oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

QUIZARTINIB

Products Affected

- VANFLYTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

REGORAFENIB

Products Affected

- STIVARGA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RELACORILANT

Products Affected

- LIFYORLI (125 MG DOSE)
- LIFYORLI (150 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	RENEWAL: 1) CLINICAL BENEFIT WHILE ON THERAPY, AND 2) CONTINUATION OF NAB-PACLITAXEL THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RELUGOLIX

Products Affected

- ORGOVYX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

REPOTRECTINIB

Products Affected

- AUGTYRO ORAL CAPSULE 160 MG, 40 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RESMETIROM

Products Affected

- REZDIFFRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	NONALCOHOLIC STEATOHEPATITIS (NASH): INITIAL: DIAGNOSIS CONFIRMED BY BIOPSY OR NONINVASIVE TESTING, OBTAINED IN THE PAST 12 MONTHS, DEMONSTRATING: 1) LIVER FIBROSIS STAGE 2 OR 3, OR 2) NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) ACTIVITY SCORE OF 4 OR MORE.
Age Restrictions	
Prescriber Restrictions	NASH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST, GASTROENTEROLOGIST, OR ENDOCRINOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	NASH: RENEWAL: CONTINUES TO HAVE NONCIRRHOTIC NASH WITH MODERATE TO ADVANCED LIVER FIBROSIS (CONSISTENT WITH STAGES F2 TO F3 FIBROSIS).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RETIFANLIMAB-DLWR

Products Affected

- ZYNYZ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

REVUMENIB

Products Affected

- REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

RIBOCICLIB

Products Affected

- KISQALI (200 MG DOSE)
- KISQALI (400 MG DOSE)
- KISQALI (600 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RIBOCICLIB-LETROZOLE

Products Affected

- KISQALI FEMARA (200 MG DOSE)
- KISQALI FEMARA (400 MG DOSE)
- KISQALI FEMARA (600 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RIFAXIMIN

Products Affected

- XIFAXAN ORAL TABLET 200 MG, 550 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	TRAVELERS DIARRHEA, HEPATIC ENCEPHALOPATHY (HE): 12 MOS. IBS-D: 8 WKS.
Other Criteria	HE: TRIAL OF OR CONTRAINDICATION TO LACTULOSE OR CONCURRENT LACTULOSE THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RILONACEPT

Products Affected

- ARCALYST

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CRYOPYRIN-ASSOCIATED PERIODIC SYNDROMES (CAPS): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE NLRP3 GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR, SERUM AMYLOID A PROTEIN (SAA) OR S100 PROTEINS), AND 2) TWO OF THE FOLLOWING: URTICARIAL-LIKE RASH (NEUTROPHILIC DERMATITIS), COLD-TRIGGERED EPISODES, SENSORINEURAL HEARING LOSS, MUSCULOSKELETAL SYMPTOMS, CHRONIC ASEPTIC MENINGITIS, SKELETAL ABNORMALITIES. DEFICIENCY OF INTERLEUKIN-1 RECEPTOR ANTAGONIST (DIRA): 1) ONE OF THE FOLLOWING: (A) GENETIC TEST FOR GAIN-OF-FUNCTION MUTATIONS IN THE IL1RN GENE, OR (B) HAS INFLAMMATORY MARKERS (I.E., ELEVATED CRP, ESR), AND 2) ONE OF THE FOLLOWING: PUSTULAR PSORIASIS-LIKE RASHES, OSTEOMYELITIS, ABSENCE OF BACTERIAL OSTEOMYELITIS, ONYCHOMADESIS. RECURRENT PERICARDITIS (RP): TWO OF THE FOLLOWING: CHEST PAIN CONSISTENT WITH PERICARDITIS, PERICARDIAL FRICTION RUB, ECG SHOWING DIFFUSE ST-SEGMENT ELEVATION OR PR-SEGMENT DEPRESSION, NEW OR WORSENING PERICARDIAL EFFUSION.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CAPS, DIRA: LIFETIME. RP: 12 MONTHS.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Other Criteria	CAPS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR CAPS. DIRA: 1) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR DIRA, AND 2) TRIAL OF THE PREFERRED AGENT: KINERET. RP: 1) HAD AN EPISODE OF ACUTE PERICARDITIS, 2) SYMPTOM-FREE FOR 4 TO 6 WEEKS, AND 3) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR RP.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RILUZOLE

Products Affected

- TIGLUTIK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	18 YEARS OR OLDER
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	AMYOTROPHIC LATERAL SCLEROSIS (ALS): (1) TRIAL OF RILUZOLE TABLETS, AND (2) PATIENT IS UNABLE TO TAKE TABLET FORMULATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RIMEGEPANT

Products Affected

- NURTEC

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	ACUTE MIGRAINE TREATMENT: INITIAL: TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN). INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR 2) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS. EPISODIC MIGRAINE PREVENTION: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR MIGRAINE PREVENTION. RENEWAL: REDUCTION IN MIGRAINE OR HEADACHE FREQUENCY, MIGRAINE SEVERITY, OR MIGRAINE DURATION WITH THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RIOCIGUAT

Products Affected

- ADEMPAS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PULMONARY ARTERIAL HYPERTENSION (PAH): DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. PERSISTENT/RECURRENT CHRONIC THROMBOEMBOLIC PULMONARY HYPERTENSION (CTEPH) (WHO GROUP 4): WHO FUNCTIONAL CLASS II-IV SYMPTOMS.
Age Restrictions	
Prescriber Restrictions	INITIAL: PAH, CTEPH: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PAH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PHOSPHODIESTERASE (PDE) INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS. CTEPH: 1) NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS, AND 2) NOT A CANDIDATE FOR SURGERY OR HAS INOPERABLE CTEPH OR HAS PERSISTENT OR RECURRENT DISEASE AFTER SURGICAL TREATMENT. RENEWAL: PAH, CTEPH: NO CONCURRENT USE WITH NITRATES, NITRIC OXIDE DONORS, PDE INHIBITORS, OR NON-SPECIFIC PDE INHIBITORS.
Indications	All FDA-approved Indications.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RIPRETINIB

Products Affected

- QINLOCK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RISANKIZUMAB-RZAA

Products Affected

- SKYRIZI
- SKYRIZI PEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PLAQUE PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, FACE, SCALP, OR GENITAL AREA.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSO, PSA: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RITUXIMAB AND HYALURONIDASE HUMAN-SQ

Products Affected

- RITUXAN HYCELA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	FOLLICULAR LYMPHOMA (FL), DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): 1) HAS RECEIVED OR WILL RECEIVE AT LEAST ONE FULL DOSE OF A RITUXIMAB PRODUCT BY INTRAVENOUS INFUSION PRIOR TO INITIATION OF RITUXIMAB AND HYALURONIDASE, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RITUXIMAB-ABBS

Products Affected

- TRUXIMA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. NON-HODGKINS LYMPHOMA (NHL), CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST.
Coverage Duration	RA: INITIAL: 6 MO, RENEWAL: 12 MO. NHL, GPA, MPA, PV: 12 MO. CLL: 6 MO.
Other Criteria	INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. RENEWAL: RA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ROPEGINTERFERON ALFA-2B-NJFT

Products Affected

- BESREMI
- BESREMI PEN

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RUCAPARIB

Products Affected

- RUBRACA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RUXOLITINIB

Products Affected

- JAKAFI
- JAKAFI XR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	MYELOFIBROSIS: INITIAL: 6 MONTHS, RENEWAL: 12 MONTHS. POLYCYTHEMIA VERA, GVHD: 12 MONTHS.
Other Criteria	INITIAL: CHRONIC GRAFT VS HOST DISEASE (CGVHD): NO CONCURRENT USE WITH REZUROCK, NIKTIMVO, OR IMBRUVICA. RENEWAL: MYELOFIBROSIS: CONTINUES TO BENEFIT FROM THE MEDICATION. CGVHD: NO CONCURRENT USE WITH REZUROCK, NIKTIMVO, OR IMBRUVICA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SAPROPTERIN

Products Affected

- javygtor oral tablet*
- sapropterin dihydrochloride oral tablet*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 2 MONTHS, RENEWAL 12 MONTHS.
Other Criteria	HYPERPHENYLALANINEMIA (HPA): INITIAL: NO CONCURRENT USE WITH PALYNZIQ. RENEWAL: 1) CONTINUES TO BENEFIT FROM TREATMENT, AND 2) NO CONCURRENT USE WITH PALYNZIQ.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SECUKINUMAB SQ

Products Affected

- COSENTYX (300 MG DOSE)
- COSENTYX SENSOREADY (300 MG)
- COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML
- COSENTYX UNOREADY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP, OR FACE. NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN (CRP) LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
Age Restrictions	
Prescriber Restrictions	INITIAL: PSO, HIDRADENITIS SUPPURATIVA (HS): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR A DERMATOLOGIST. ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, ENTHESITIS-RELATED ARTHRITIS (ERA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST.
Coverage Duration	INITIAL: HS: 12 MONTHS, ALL OTHER INDICATIONS: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. AS, NR-

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	AXSPA: TRIAL OF OR CONTRAINDICATION TO AN NSAID. ERA: TRIAL OF OR CONTRAINDICATION TO ONE NSAID, SULFASALAZINE, OR METHOTREXATE. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: ALL INDICATIONS: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SELEXIPAG

Products Affected

- UPTRAVI ORAL TABLET 100 MCG, 1000 MCG, 1200 MCG, 1400 MCG, 150 MCG, 1600 MCG, 200 MCG, 400 MCG, 600 MCG, 800 MCG
- UPTRAVI TITRATION

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	PAH: INITIAL: AGES 18 YEARS OR OLDER: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING AGENTS: 1) FORMULARY VERSION OF AN ORAL ENDOTHELIN RECEPTOR ANTAGONIST, 2) FORMULARY VERSION OF AN ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, 3) FORMULARY VERSION OF AN ORAL CGMP STIMULATOR.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SELINEXOR

Products Affected

- XPOVIO (100 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 50
MG
- XPOVIO (40 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 10
MG, 40 MG
- XPOVIO (40 MG TWICE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG
- XPOVIO (60 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 60
MG
- XPOVIO (60 MG TWICE WEEKLY)
- XPOVIO (80 MG ONCE WEEKLY)
ORAL TABLET THERAPY PACK 40
MG, 80 MG
- XPOVIO (80 MG TWICE WEEKLY)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SELPERCATINIB

Products Affected

- RETEVMO ORAL CAPSULE 40 MG, 80 MG
- RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SELUMETINIB

Products Affected

- KOSELUGO ORAL CAPSULE 10 MG, 25 MG
- KOSELUGO ORAL CAPSULE SPRINKLE 5 MG, 7.5 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SEVABERTINIB

Products Affected

- HYRNUO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SILDENAFIL TABLET

Products Affected

- sildenafil citrate oral tablet 20 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: AGES 18 YEARS OR OLDER: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS. AGES 1 TO 17 YEARS: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PAP GREATER THAN 20 MMHG, 2) PCWP OF 15 MMHG OR LESS, AND 3) PVR OF 3 WOOD UNITS OR GREATER.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.
Indications	All Medically-accepted Indications.
Off Label Uses	

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

SIROLIMUS PROTEIN-BOUND

Products Affected

- FYARRO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SODIUM OXYBATE-XYREM

Products Affected

- sodium oxybate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: CATAPLEXY IN NARCOLEPSY, EXCESSIVE DAYTIME SLEEPINESS (EDS) IN NARCOLEPSY: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR SPECIALIST IN SLEEP MEDICINE
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: EDS IN NARCOLEPSY: 1) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT, AND 2) AGES 18 YEARS OR OLDER: TRIAL, FAILURE OF, OR CONTRAINDICATION TO A FORMULARY VERSION OF MODAFINIL, ARMODAFINIL, OR SUNOSI AND ONE GENERIC STIMULANT INDICATED FOR EDS IN NARCOLEPSY. CATAPLEXY IN NARCOLEPSY: NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT. RENEWAL: CATAPLEXY IN NARCOLEPSY, EDS IN NARCOLEPSY: 1) SUSTAINED IMPROVEMENT OF SYMPTOMS COMPARED TO BASELINE, AND 2) NO CONCURRENT USE WITH A SEDATIVE HYPNOTIC AGENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SOFOSBUVIR/VELPATASVIR

Products Affected

- EPCLUSA ORAL PACKET 150-37.5 MG, 200-50 MG
- EPCLUSA ORAL TABLET
- *sofosbuvir-velpatasvir*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, HIV REGIMEN THAT CONTAINS EFAVIRENZ, ROSUVASTATIN AT DOSES ABOVE 10MG, TIPRANA VIR/RITONAVIR, TOPOTECAN, SOVALDI (AS A SINGLE AGENT), HARVONI, ZEPATIER, MAVYRET, OR VOSEVI, AND 3) PATIENTS WITH DECOMPENSATED CIRRHOSIS REQUIRE CONCURRENT RIBAVIRIN UNLESS RIBAVIRIN INELIGIBLE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR

Products Affected

- VOSEVI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	HCV RNA LEVEL WITHIN PAST 6 MONTHS
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE.
Other Criteria	1) CRITERIA WILL BE APPLIED CONSISTENT WITH CURRENT AASLD/IDSA GUIDANCE, 2) NOT CONCURRENTLY TAKING ANY OF THE FOLLOWING MEDICATIONS: AMIODARONE, CARBAMAZEPINE, PHENYTOIN, PHENOBARBITAL, OXCARBAZEPINE, RIFAMPIN, RIFABUTIN, RIFAPENTINE, CYCLOSPORINE, PITAVASTATIN, PRAVASTATIN (DOSES ABOVE 40MG), ROSUVASTATIN, METHOTREXATE, MITOXANTRONE, IMATINIB, IRINOTECAN, LAPATINIB, SULFASALAZINE, TOPOTECAN, OR HIV REGIMEN THAT CONTAINS EFAVIRENZ, ATAZANAVIR, LOPINAVIR, TIPRANAVIR/RITONAVIR, SOVALDI (AS A SINGLE AGENT), EPCLUSA, HARVONI, ZEPATIER, OR MAVYRET, AND 3) DOES NOT HAVE MODERATE OR SEVERE HEPATIC IMPAIRMENT (CHILD-PUGH B OR C).
Indications	All FDA-approved Indications.
Off Label Uses	

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SOMATROPIN - NORDITROPIN

Products Affected

- NORDITROPIN FLEXPRO
SUBCUTANEOUS SOLUTION PEN-
INJECTOR

PA Criteria	Criteria Details
Exclusion Criteria	INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES.
Required Medical Information	INITIAL: PEDIATRIC GROWTH HORMONE DEFICIENCY (GHD), IDIOPATHIC SHORT STATURE (ISS), SMALL FOR GESTATIONAL AGE (SGA), NOONAN SYNDROME: HEIGHT AT LEAST 2 STANDARD DEVIATIONS BELOW THE MEAN HEIGHT FOR CHILDREN OF THE SAME AGE AND GENDER. TURNER SYNDROME (TS): CONFIRMED BY CHROMOSOMAL ANALYSIS (KARYOTYPING). PRADER WILLI SYNDROME (PWS): CONFIRMED GENETIC DIAGNOSIS OF PWS. ADULT GHD: 1) HAS A CONGENITAL, GENETIC, OR ORGANIC DISEASE (E.G., CRANIOPHARYNGIOMA, PITUITARY HYPOPLASIA, ECTOPIC POSTERIOR PITUITARY, PREVIOUS CRANIAL IRRADIATION), OR 2) GHD CONFIRMED BY ONE OF THE FOLLOWING GROWTH HORMONE (GH) STIMULATION TESTS: (A) INSULIN TOLERANCE TEST (PEAK GH OF 5 NG/ML OR LESS), (B) GLUCAGON-STIMULATION TEST (ONE OF THE FOLLOWING: (I) PEAK RESPONSE OF 3 NG/ML OR LESS AND BMI LESS THAN 25 KG/M2, (II) PEAK RESPONSE OF 3 NG/ML OR LESS AND BMI IS BETWEEN 25 - 30 KG/M2 WITH A PRE-TEST PROBABILITY, (III) PEAK RESPONSE OF 1 NG/ML OR LESS AND BMI IS BETWEEN 25 - 30 KG/M2 WITH LOW TEST PROBABILITY, OR (IV) PEAK RESPONSE OF 1 NG/ML OR LESS AND BMI IS GREATER THAN 30 KG/M2), OR (C) MACIMORELIN TEST (PEAK GH OF 2.8 NG/ML OR LESS).
Age Restrictions	SGA: 2 YEARS OF AGE OR OLDER.
Prescriber Restrictions	INITIAL/RENEWAL: ALL INDICATIONS: PRESCRIBED BY OR IN CONSULTATION WITH AN ENDOCRINOLOGIST.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PEDIATRIC GHD, ISS, SGA, TS, NOONAN SYNDROME: OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. INITIAL/RENEWAL: ADULT GHD, PEDIATRIC GHD, SGA, TS, PWS, NOONAN SYNDROME: NO CONCURRENT USE WITH INCRELEX. RENEWAL: ISS: 1) IMPROVEMENT WHILE ON THERAPY (INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND. PEDIATRIC GHD, SGA, TS, NOONAN SYNDROME: 1) IMPROVEMENT WHILE ON THERAPY (INCREASED HEIGHT OR INCREASED GROWTH VELOCITY), AND 2) OPEN EPIPHYSES AS CONFIRMED BY RADIOGRAPH OF THE WRIST AND HAND OR HAS NOT COMPLETED PREPUBERTAL GROWTH. PWS: IMPROVEMENT IN BODY COMPOSITION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SOMATROPIN - SEROSTIM

Products Affected

- SEROSTIM SUBCUTANEOUS
SOLUTION RECONSTITUTED 4 MG, 5
MG, 6 MG

PA Criteria	Criteria Details
Exclusion Criteria	INITIAL/RENEWAL: ATHLETIC ENHANCEMENT, ANTI-AGING PURPOSES
Required Medical Information	INITIAL: HIV/WASTING: ONE OF THE FOLLOWING FOR WEIGHT LOSS: 1) 10% UNINTENTIONAL WEIGHT LOSS OVER 12 MONTHS OR 5% WEIGHT LOSS OVER 6 MONTHS, 2) 5% BODY CELL MASS (BCM) LOSS WITHIN 6 MONTHS, 3) BCM LESS THAN 35% (MEN) OF TOTAL BODY WEIGHT AND BODY MASS INDEX (BMI) LESS THAN 27 KG PER METER SQUARED, 4) BCM LESS THAN 23% (WOMEN) OF TOTAL BODY WEIGHT AND BMI LESS THAN 27 KG PER METER SQUARED, OR 5) BMI LESS THAN 20 KG PER METER SQUARED.
Age Restrictions	
Prescriber Restrictions	HIV/WASTING: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST, NUTRITIONAL SUPPORT SPECIALIST, OR INFECTIOUS DISEASE SPECIALIST.
Coverage Duration	INITIAL/RENEWAL: 9 MONTHS.
Other Criteria	HIV/WASTING: RENEWAL: 1) CLINICAL BENEFIT IN MUSCLE MASS AND WEIGHT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SONIDEGIB

Products Affected

- ODOMZO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	LOCALLY ADVANCED BASAL CELL CARCINOMA (BCC): BASELINE SERUM CREATINE KINASE (CK) AND SERUM CREATININE LEVELS
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SORAFENIB

Products Affected

- *sorafenib tosylate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SOTATERCEPT-CSRK

Products Affected

- WINREVAIR

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PAH: INITIAL: 1) ON BACKGROUND PAH THERAPY (FOR AT LEAST 3 MONTHS) WITH AT LEAST TWO OF THE FOLLOWING AGENTS FROM DIFFERENT DRUG CLASSES: A) ORAL ENDOTHELIN RECEPTOR ANTAGONIST, B) ORAL PHOSPHODIESTERASE TYPE-5 INHIBITOR FOR PAH, C) ORAL CGMP STIMULATOR, D) IV/SQ PROSTACYCLIN, OR 2) ON ONE AGENT FROM ONE OF THE ABOVE DRUG CLASSES, AND HAS A CONTRAINDICATION OR INTOLERANCE TO ALL OF THE OTHER DRUG CLASSES.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C

Formulary ID: 26387

Effective: 10/01/2026

Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SOTORASIB

Products Affected

- LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

STIRIPENTOL

Products Affected

- DIACOMIT ORAL CAPSULE 250 MG, 500 MG
- DIACOMIT ORAL PACKET 250 MG, 500 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	DRAVET SYNDROME: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SUNITINIB

Products Affected

- sunitinib malate*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	GASTROINTESTINAL STROMAL TUMORS (GIST): TRIAL OF OR CONTRAINDICATION TO IMATINIB.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TADALAFIL - ADCIRCA, ALYQ

Products Affected

- *alyq*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	PULMONARY ARTERIAL HYPERTENSION (PAH): INITIAL: DIAGNOSIS CONFIRMED BY RIGHT HEART CATHETERIZATION WITH THE FOLLOWING PARAMETERS: 1) MEAN PULMONARY ARTERY PRESSURE (PAP) GREATER THAN 20 MMHG, 2) PULMONARY CAPILLARY WEDGE PRESSURE (PCWP) OF 15 MMHG OR LESS, AND 3) PULMONARY VASCULAR RESISTANCE (PVR) GREATER THAN 2 WOOD UNITS.
Age Restrictions	
Prescriber Restrictions	PAH: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST OR PULMONOLOGIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS.
Other Criteria	PAH: INITIAL/RENEWAL: 1) NOT CONCURRENTLY OR INTERMITTENTLY TAKING ORAL ERECTILE DYSFUNCTION AGENTS (E.G. CIALIS, VIAGRA) OR ANY ORGANIC NITRATES IN ANY FORM, AND 2) NO CONCURRENT USE WITH GUANYLATE CYCLASE STIMULATORS.
Indications	All Medically-accepted Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TADALAFIL-CIALIS

Products Affected

- tadalafil oral tablet 2.5 mg, 5 mg*

PA Criteria	Criteria Details
Exclusion Criteria	ERECTILE DYSFUNCTION WITHOUT DIAGNOSIS OF BENIGN PROSTATIC HYPERPLASIA (BPH).
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	BPH: 1) TRIAL OF ONE ALPHA BLOCKER (E.G., DOXAZOSIN, TERAZOSIN, TAMSULOSIN, ALFUZOSIN), AND 2) TRIAL OF ONE 5-ALPHA-REDUCTASE INHIBITOR (E.G., FINASTERIDE, DUTASTERIDE). APPLIES TO 2.5MG AND 5MG STRENGTHS ONLY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TAFAMIDIS

Products Affected

- VYNDAMAX

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	CARDIOMYOPATHY ASSOCIATED WITH WILD TYPE OR HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (ATTR-CM): INITIAL: 1) NEW YORK HEART ASSOCIATION (NYHA) CLASS I, II, OR III HEART FAILURE, AND 2) DIAGNOSIS CONFIRMED BY (A) BONE SCAN (SCINTIGRAPHY) STRONGLY POSITIVE FOR MYOCARDIAL UPTAKE OF TC-99M-PYP, OR (B) BIOPSY OF TISSUE OF AFFECTED ORGAN(S) (CARDIAC AND POSSIBLY NON-CARDIAC SITES) TO CONFIRM AMYLOID PRESENCE AND CHEMICAL TYPING TO CONFIRM PRESENCE OF TRANSTHYRETIN (TTR) PROTEIN.
Age Restrictions	
Prescriber Restrictions	ATTR-CM: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A CARDIOLOGIST, ATTR SPECIALIST, OR MEDICAL GENETICIST.
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	ATTR-CM: INITIAL/RENEWAL: NO CONCURRENT USE WITH OTHER ATTR-CM TTR STABILIZERS (E.G., ACORAMIDIS)
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TALAZOPARIB

Products Affected

- TALZENNA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADVANCED OR METASTATIC BREAST CANCER: 1) HAS BEEN TREATED WITH CHEMOTHERAPY IN THE NEOADJUVANT, ADJUVANT, OR METASTATIC SETTING, AND 2) IF HORMONE RECEPTOR (HR)-POSITIVE BREAST CANCER, RECEIVED PRIOR TREATMENT WITH ENDOCRINE THERAPY OR IS CONSIDERED INAPPROPRIATE FOR ENDOCRINE THERAPY. METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: 1) RECEIVED A BILATERAL ORCHIECTOMY, 2) CASTRATE LEVEL OF TESTOSTERONE (I.E., LESS THAN 50 NG/DL), OR 3) CONCURRENT USE WITH A GONADOTROPIN RELEASING HORMONE (GNRH) ANALOG.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TALETRECTINIB

Products Affected

- IBTROZI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TALQUETAMAB-TGVS

Products Affected

- TALVEY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

TARLATAMAB-DLLE

Products Affected

- IMDELLTRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TEBENTAFUSP-TEBN

Products Affected

- KIMMTRAK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TECLISTAMAB-CQYV

Products Affected

- TECVAYLI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

TELISOTUZUMAB VEDOTIN-TLLV

Products Affected

- EMRELIS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TELOTRISTAT

Products Affected

- XERMELO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	CARCINOID SYNDROME DIARRHEA: PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGIST OR GASTROENTEROLOGIST
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TEPOTINIB

Products Affected

- TEPMETKO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TERIPARATIDE

Products Affected

- teriparatide subcutaneous solution pen-injector 560 mcg/2.24ml*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	24 MONTHS
Other Criteria	OSTEOPOROSIS: HAS NOT RECEIVED A TOTAL OF 24 MONTHS CUMULATIVE TREATMENT WITH ANY PARATHYROID HORMONE THERAPY, UNLESS REMAINS AT OR HAS RETURNED TO HAVING A HIGH RISK FOR FRACTURE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TESTOSTERONE

Products Affected

- testosterone gel 1.62 % transdermal
- testosterone transdermal gel 12.5 mg/act (1%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TESTOSTERONE CYPIONATE - DEPO

Products Affected

- *testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: 12 MONTHS
Other Criteria	MALE HYPOGONADISM: INITIAL: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TESTOSTERONE ENANTHATE

Products Affected

- testosterone enanthate intramuscular solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	MALE HYPOGONADISM: INITIAL: CONFIRMED BY: 1) AT LEAST TWO TOTAL SERUM TESTOSTERONE LEVELS OF LESS THAN 300 NG/DL TAKEN ON SEPARATE OCCASIONS, OR 2) FREE SERUM TESTOSTERONE LEVEL OF LESS THAN 5 NG/DL.
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL: MALE DELAYED PUBERTY: 6MO, MALE HYPOGONADISM: 12 MO. OTHER INDICATIONS: 12 MO.
Other Criteria	INITIAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PROSTATE SPECIFIC ANTIGEN (PSA) HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING. RENEWAL: MALE HYPOGONADISM: 1) 40 YEARS OR OLDER: PSA HAS BEEN EVALUATED FOR PROSTATE CANCER SCREENING, AND 2) IMPROVED SYMPTOMS COMPARED TO BASELINE AND TOLERANCE TO TREATMENT. MALE DELAYED PUBERTY: HAS NOT RECEIVED MORE THAN TWO 6-MONTH COURSES OF TESTOSTERONE REPLACEMENT THERAPY
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TETRABENAZINE

Products Affected

- tetrabenazine*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

THALIDOMIDE

Products Affected

- THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TISLELIZUMAB-JSGR

Products Affected

- TEVIMBRA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TISOTUMAB VEDOTIN-TFTV

Products Affected

- TIVDAK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TIVOZANIB

Products Affected

- FOTIVDA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TOCILIZUMAB-AAZG IV

Products Affected

- TYENNE

PA Criteria	Criteria Details
Exclusion Criteria	CORONAVIRUS DISEASE 2019 (COVID-19) IN HOSPITALIZED PATIENTS
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
Coverage Duration	INITIAL: RA, PJIA, SJIA, GCA: 6 MONTHS. CRS: 1 MONTH. RENEWAL: RA, PJIA, SJIA, GCA: 12 MONTHS.
Other Criteria	INITIAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. GIANT CELL ARTERITIS (GCA): 1) HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICOID, AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: RINVOQ. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ IR, ORENCIA, RINVOQ. RENEWAL: RA, PJIA, SJIA: 1) CONTINUES TO BENEFIT FROM THE MEDICATION, AND 2) NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	TARGETED SMALL MOLECULES FOR THE SAME INDICATION. GCA: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES FOR THE SAME INDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TOCILIZUMAB-AAZG SQ

Products Affected

- TYENNE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS (SJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST, DERMATOLOGIST, OR IMMUNOLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ, RINVOQ, ORENCIA. GIANT CELL ARTERITIS (GCA): 1) HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICOID, AND 2) TRIAL OF OR CONTRAINDICATION TO THE PREFERRED AGENT: RINVOQ. PJIA: TRIAL OF OR CONTRAINDICATION TO TWO OF THE FOLLOWING PREFERRED AGENTS: HUMIRA/CYLTEZO/YUFLYMA/HADLIMA, XELJANZ IR, ORENCIA, RINVOQ. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PJIA, SJIA: CONTINUES TO BENEFIT FROM THE MEDICATION.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TOFACITINIB

Products Affected

- *tofacitinib citrate er*
- *tofacitinib citrate oral*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), POLYARTICULAR COURSE JUVENILE IDIOPATHIC ARTHRITIS (PCJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AS: TRIAL OF OR CONTRAINDICATION TO AN NSAID. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PSA, AS, PCJIA: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TOLVAPTAN

Products Affected

- JYNARQUE ORAL TABLET
- *tolvaptan oral tablet therapy pack*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD): INITIAL: CONFIRMED POLYCYSTIC KIDNEY DISEASE VIA CT, MRI, OR ULTRASOUND.
Age Restrictions	
Prescriber Restrictions	ADPKD: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A NEPHROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	ADPKD: INITIAL: DOES NOT HAVE ESRD (I.E., RECEIVING DIALYSIS). RENEWAL: HAS NOT PROGRESSED TO ESRD/DIALYSIS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TOPICAL TRETINOIN

Products Affected

- ALTRENO
- *tretinoin external gel 0.01 %, 0.025 %*
- *tretinoin external cream*

PA Criteria	Criteria Details
Exclusion Criteria	COSMETIC INDICATIONS SUCH AS WRINKLES, PHOTOAGING, MELASMA.
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ACNE VULGARIS: BRAND TOPICAL TRETINOIN REQUIRES TRIAL OF OR CONTRAINDICATION TO A GENERIC TOPICAL TRETINOIN PRODUCT.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TORIPALIMAB-TPZI

Products Affected

- LOQTORZI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	NASOPHARYNGEAL CARCINOMA (NPC): FIRST LINE TREATMENT: 24 MOS, PREVIOUSLY TREATED: LIFETIME.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TOVORAFENIB

Products Affected

- OJEMDA ORAL SUSPENSION • OJEMDA ORAL TABLET
- RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TRAMADOL

Products Affected

- tramadol hcl oral solution*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	6 MONTHS
Other Criteria	PAIN: 1) TRIAL OF OR CONTRAINDICATION TO GENERIC TRAMADOL IMMEDIATE RELEASE TABLET OR GENERIC TRAMADOL/ACETAMINOPHEN COMBINATION PRODUCT, AND 2) UNABLE TO TAKE ORAL SOLID FORMULATIONS OF TRAMADOL OR TRAMADOL/ACETAMINOPHEN COMBINATION PRODUCT (E.G., DIFFICULTY SWALLOWING).
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TRAMETINIB SOLUTION

Products Affected

- MEKINIST ORAL SOLUTION
RECONSTITUTED

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	UNRESECTABLE OR METASTATIC MELANOMA, MELANOMA, METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC), LOCALLY ADVANCED OR METASTATIC ANAPLASTIC THYROID CANCER (ATC), UNRESECTABLE OR METASTATIC SOLID TUMOR, LOW-GRADE GLIOMA (LGG): UNABLE TO SWALLOW MEKINIST TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TRAMETINIB TABLET

Products Affected

- MEKINIST ORAL TABLET 0.5 MG, 2 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TRASTUZUMAB-DKST

Products Affected

- OGIVRI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TRASTUZUMAB-HYALURONIDASE-OYSK

Products Affected

- HERCEPTIN HYLECTA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	ADJUVANT BREAST CANCER, METASTATIC BREAST CANCER: TRIAL OF OR CONTRAINDICATION TO ONE OF THE FOLLOWING PREFERRED AGENTS: HERZUMA, OGIVRI, ONTRUZANT, TRAZIMERA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TRAZODONE

Products Affected

- RALDESY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MAJOR DEPRESSIVE DISORDER (MDD); CONTRAINDICATION TO OR UNABLE TO SWALLOW TRAZODONE TABLETS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

TREMELIMUMAB-ACTL

Products Affected

- IMJUDO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	UHCC: 30 DAYS. METASTATIC NON-SMALL CELL LUNG CANCER (NSCLC): 5 MONTHS.
Other Criteria	UNRESECTABLE HEPATOCELLULAR CARCINOMA (UHCC): HAS NOT RECEIVED PRIOR TREATMENT WITH IMJUDO. NSCLC: HAS NOT RECEIVED A TOTAL OF 5 DOSES OF IMJUDO.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TRIENTINE CAPSULE

Products Affected

- trientine hcl oral capsule 250 mg*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	WILSONS DISEASE: INITIAL: LEIPZIG SCORE OF 4 OR GREATER.
Age Restrictions	
Prescriber Restrictions	WILSONS DISEASE: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH A HEPATOLOGIST OR GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 12 MONTHS, RENEWAL: LIFETIME.
Other Criteria	WILSONS DISEASE: INITIAL: TRIAL OF OR CONTRAINDICATION TO FORMULARY VERSION OF PENICILLAMINE TABLET. RENEWAL: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TRIFLURIDINE/TIPIRACIL

Products Affected

- LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TRIPTORELIN-TRELSTAR

Products Affected

- TRELSTAR MIXJECT

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS.
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TUCATINIB

Products Affected

- TUKYSA ORAL TABLET 150 MG, 50 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

UBROGEPANT

Products Affected

- UBRELVY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	ACUTE MIGRAINE TREATMENT: INITIAL: 1) TRIAL OF OR CONTRAINDICATION TO ONE TRIPTAN (E.G., SUMATRIPTAN, RIZATRIPTAN), AND 2) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT. RENEWAL: 1) NO CONCURRENT USE WITH OTHER CGRP INHIBITORS FOR ACUTE MIGRAINE TREATMENT, AND 2) ONE OF THE FOLLOWING: (A) IMPROVEMENT FROM BASELINE IN A VALIDATED ACUTE TREATMENT PATIENT-REPORTED OUTCOME QUESTIONNAIRE, OR (B) THERAPY WORKS CONSISTENTLY IN MAJORITY OF MIGRAINE ATTACKS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

UPADACITINIB

Products Affected

- RINVOQ
- RINVOQ LQ

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: NON-RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS (NR-AXSPA): 1) C-REACTIVE PROTEIN LEVELS ABOVE THE UPPER LIMIT OF NORMAL, OR 2) SACROILIITIS ON MAGNETIC RESONANCE IMAGING (MRI).
Age Restrictions	
Prescriber Restrictions	INITIAL: RHEUMATOID ARTHRITIS (RA), ANKYLOSING SPONDYLITIS (AS), NR-AXSPA, POLYARTICULAR JUVENILE IDIOPATHIC ARTHRITIS (PJIA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST. PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A RHEUMATOLOGIST OR DERMATOLOGIST. AD: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST, ALLERGIST, OR IMMUNOLOGIST. ULCERATIVE COLITIS (UC), CROHNS DISEASE (CD): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: RA: TRIAL OF OR CONTRAINDICATION TO 3 MONTHS OF TREATMENT WITH ONE CONVENTIONAL SYNTHETIC DMARD (DISEASE-MODIFYING ANTIRHEUMATIC DRUG) - IF A PATIENT TRIED METHOTREXATE, THEN TRIAL AT A DOSE OF AT LEAST 20 MG PER WEEK OR MAXIMALLY TOLERATED DOSE IS REQUIRED. AD: TRIAL OF OR CONTRAINDICATION TO A TOPICAL CORTICOSTEROID, TOPICAL CALCINEURIN INHIBITOR, TOPICAL PDE4 INHIBITOR, TOPICAL AHR AGONIST OR TOPICAL JAK INHIBITOR. AS, NR-AXSPA: TRIAL OF OR

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
	CONTRAINDICATION TO AN NSAID (NON-STEROIDAL ANTI-INFLAMMATORY DRUG). GIANT CELL ARTERITIS (GCA): HAS COMPLETED, STARTED, OR WILL SOON START A TAPERING COURSE OF GLUCOCORTICOIDS. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: RA, PSA, AS, NR-AXSPA, PJIA: CONTINUES TO BENEFIT FROM THE MEDICATION. AD: IMPROVEMENT WHILE ON THERAPY.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

USTEKINUMAB-AAUZ SQ

Products Affected

- ustekinumab-aauz*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

USTEKINUMAB-AEKN IV

Products Affected

- SELARSDI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

USTEKINUMAB-AEKN SQ

Products Affected

- SELARSDI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

USTEKINUMAB-KFCE IV

Products Affected

- YESINTEK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

USTEKINUMAB-KFCE SQ

Products Affected

- YESINTEK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	INITIAL: PLAQUE PSORIASIS (PSO): PSORIASIS COVERING 3 PERCENT OR MORE OF BODY SURFACE AREA OR PSORIATIC LESIONS AFFECTING THE HANDS, FEET, GENITAL AREA, SCALP OR FACE.
Age Restrictions	
Prescriber Restrictions	INITIAL: PSORIATIC ARTHRITIS (PSA): PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST OR RHEUMATOLOGIST. PSO: PRESCRIBED BY OR IN CONSULTATION WITH A DERMATOLOGIST. CROHNS DISEASE (CD), ULCERATIVE COLITIS (UC): PRESCRIBED BY OR IN CONSULTATION WITH A GASTROENTEROLOGIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	INITIAL: PSO: 1) AT LEAST A 3 MONTH TRIAL OF ONE ORAL IMMUNOSUPPRESSANT (CYCLOSPORINE, METHOTREXATE, TACROLIMUS) OR PUVA (PHOTOTHERAPY), 2) CONTRAINDICATION OR INTOLERANCE TO BOTH IMMUNOSUPPRESSANT AND PUVA, OR 3) PATIENT IS SWITCHING FROM A DIFFERENT BIOLOGIC, PDE-4 INHIBITOR, OR JAK INHIBITOR FOR THE SAME INDICATION. INITIAL/RENEWAL: ALL INDICATIONS: NO CONCURRENT USE WITH ANOTHER SYSTEMIC BIOLOGIC OR TARGETED SMALL MOLECULES (E.G., JAK INHIBITOR, PDE-4 INHIBITOR) FOR THE SAME INDICATION. RENEWAL: PSA, PSO: CONTINUES TO BENEFIT FROM THE MEDICATION.
Indications	All FDA-approved Indications.

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

VALBENAZINE

Products Affected

- INGREZZA ORAL CAPSULE
- INGREZZA ORAL CAPSULE SPRINKLE
- INGREZZA ORAL CAPSULE THERAPY PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	TARDIVE DYSKINESIA (TD): PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST, PSYCHIATRIST, OR MOVEMENT DISORDER SPECIALIST. CHOREA ASSOCIATED WITH HUNTINGTONS DISEASE: PRESCRIBED BY OR IN CONSULTATION WITH A NEUROLOGIST OR MOVEMENT DISORDER SPECIALIST.
Coverage Duration	12 MONTHS
Other Criteria	TD: HISTORY OF USING AGENTS THAT CAUSE TARDIVE DYSKINESIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

VANDETANIB

Products Affected

- CAPRELSA ORAL TABLET 100 MG, 300 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	CURRENTLY STABLE ON CAPRELSA REQUIRES NO EXTRA CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

VEMURAFENIB

Products Affected

- ZELBORAF

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MELANOMA: ZELBORAF WILL BE USED ALONE OR IN COMBINATION WITH COTELLIC
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

VENETOCLAX

Products Affected

- VENCLEXTA ORAL TABLET 10 MG, 100 MG, 50 MG
- VENCLEXTA STARTING PACK

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

VEPDEGESTRANT

Products Affected

- VEPPANU

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	ADVANCED OR METASTATIC BREAST CANCER: INITIAL: PRESCRIBED BY OR IN CONSULTATION WITH AN ONCOLOGY SPECIALIST.
Coverage Duration	INITIAL: 6 MONTHS. RENEWAL: 12 MONTHS.
Other Criteria	ADVANCED OR METASTATIC BREAST CANCER: INITIAL/RENEWAL: NO CONCURRENT USE WITH ANOTHER SELECTIVE ESTROGEN RECEPTOR DEGRADER (SERD). RENEWAL: DEMONSTRATED CLINICAL BENEFIT WHILE ON THERAPY AS SHOWN BY A PARTIAL OR COMPLETE RESPONSE OR STABLE DISEASE.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

VERICIGUAT

Products Affected

- VERQUVO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL/RENEWAL:12 MONTHS.
Other Criteria	HEART FAILURE (HF): INITIAL: 1) TRIAL OF, CONTRAINDICATION, OR INTOLERANCE TO ONE PREFERRED SGLT-2 INHIBITOR, AND 2) TRIAL OF, CONTRAINDICATION, OR INTOLERANCE TO ONE AGENT FROM ANY OF THE FOLLOWING STANDARD OF CARE CLASSES: (A) ACE INHIBITOR, ARB, OR ARNI, (B) BETA BLOCKER (BISOPROLOL, CARVEDILOL, METOPROLOL SUCCINATE), OR (C) ALDOSTERONE ANTAGONIST (SPIRONOLACTONE, EPLERENONE). INITIAL/RENEWAL: NO CONCURRENT USE WITH RIOICIGUAT OR PDE-5 INHIBITORS.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

PA Criteria	Criteria Details
Prerequisite Therapy Required	Yes

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

VIMSELTINIB

Products Affected

- ROMVIMZA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

VISMODEGIB

Products Affected

- ERIVEDGE

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

VONOPRAZAN

Products Affected

- VOQUEZNA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	INITIAL: H PYLORI: 30 DAYS. EE: 8 WEEKS. NERD: 4 WEEKS. RENEWAL: EE: 24 WEEKS.
Other Criteria	INITIAL: EROSIVE ESOPHAGITIS (EE): TRIAL OF OR CONTRAINDICATION TO TWO PROTON PUMP INHIBITORS AT MAXIMUM DOSE FOR 8 WEEKS EACH. NON-EROSIVE GASTROESOPHAGEAL REFLUX DISEASE (NERD): 1) NO PREVIOUS TREATMENT FAILURE WITH VOQUEZNA IN THE LAST 12 MONTHS, AND 2) TRIAL OF OR CONTRAINDICATION TO ONE PROTON PUMP INHIBITOR AT MAXIMUM DOSE FOR 8 WEEKS. RENEWAL: EE: MAINTAINED A CLINICAL RESPONSE ON VOQUEZNA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

VORASIDENIB

Products Affected

- VORANIGO

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

VORICONAZOLE SUSPENSION

Products Affected

- voriconazole oral suspension reconstituted*

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	CANDIDA INFECTIONS: 3 MOS. CONTINUATION OF THERAPY, ALL OTHER INDICATIONS: 6 MOS.
Other Criteria	CANDIDA INFECTIONS: CONTRAINDICATION TO OR UNABLE TO SWALLOW FLUCONAZOLE TABLETS. ALL INDICATIONS EXCEPT ESOPHAGEAL CANDIDIASIS: UNABLE TO SWALLOW TABLETS. CONTINUATION OF THERAPY AFTER HOSPITAL DISCHARGE REQUIRES NO EXTRA CRITERIA.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
Formulary ID: 26387
Effective: 10/01/2026
Last Updated: 09/30/2026

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

ZANIDATAMAB-HR11

Products Affected

- ZIIHERA

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ZANUBRUTINIB

Products Affected

- BRUKINSA ORAL CAPSULE
- BRUKINSA ORAL TABLET

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	MANTLE CELL LYMPHOMA: INTOLERANCE TO CALQUENCE. CHRONIC LYMPHOCYTIC LEUKEMIA, SMALL LYMPHOCYTIC LYMPHOMA: INTOLERANCE TO CALQUENCE OR IMBRUVICA. WALDENSTROMS MACROGLOBULINEMIA: NO STEP REQUIRED.
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	Yes

H1587_001PA26_C
 Formulary ID: 26387
 Effective: 10/01/2026
 Last Updated: 09/30/2026

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ZENOCUTUZUMAB-ZBCO

Products Affected

- BIZENGRI (750 MG DOSE)

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ZIFTOMENIB

Products Affected

- KOMZIFTI

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

**AIP Dual Advantage 2026 Formulary
Prior Authorization Criteria**

ZOLBETUXIMAB-CLZB

Products Affected

- VYLOY

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ZONGERTINIB

Products Affected

- HERNEXEOS

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	12 MONTHS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ZURANOLONE

Products Affected

- ZURZUVAE ORAL CAPSULE 20 MG, 25 MG, 30 MG

PA Criteria	Criteria Details
Exclusion Criteria	
Required Medical Information	
Age Restrictions	
Prescriber Restrictions	
Coverage Duration	14 DAYS
Other Criteria	
Indications	All FDA-approved Indications.
Off Label Uses	
Part B Prerequisite	No
Prerequisite Therapy Required	No

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

INDEX

1

1ST TIER UNIFINE PENTIPS 29G X
12MM 171, 194
1ST TIER UNIFINE PENTIPS 31G X 5
MM 171, 194
1ST TIER UNIFINE PENTIPS 31G X 6
MM 171, 194
1ST TIER UNIFINE PENTIPS 31G X 8
MM 171, 194
1ST TIER UNIFINE PENTIPS 32G X 4
MM 171, 194
1ST TIER UNIFINE PENTIPS 32G X 6
MM 171, 194
1ST TIER UNIFINE PENTIPS 33G X 4
MM 171, 194
1ST TIER UNIFINE PENTIPS PLUS 29G
X 12MM..... 171, 194
1ST TIER UNIFINE PENTIPS PLUS 31G
X 5 MM..... 171, 194
1ST TIER UNIFINE PENTIPS PLUS 31G
X 6 MM..... 171, 194
1ST TIER UNIFINE PENTIPS PLUS 31G
X 8 MM..... 171, 194
1ST TIER UNIFINE PENTIPS PLUS 32G
X 4 MM..... 171, 194
1ST TIER UNIFINE PENTIPS PLUS 33G
X 4 MM..... 171, 194

A

abigale 152
abiraterone acetate 7
ABIRATERONE ACETATE
MICRONIZED 8
abirtega..... 7
ABOUTTIME PEN NEEDLE 30G X 8 MM
..... 171, 194
ABOUTTIME PEN NEEDLE 31G X 5 MM
..... 171, 194
ABOUTTIME PEN NEEDLE 31G X 8 MM
..... 171, 194
ABOUTTIME PEN NEEDLE 32G X 4 MM
..... 171, 194
ACTIMMUNE..... 197

adalimumab-aaty (1 pen) auto-injector kit 40
mg/0.4ml subcutaneous..... 14, 15
adalimumab-aaty (1 pen) subcutaneous auto-
injector kit 80 mg/0.8ml..... 14, 15
adalimumab-aaty (2 pen) 14, 15
adalimumab-aaty (2 syringe) 14, 15
adalimumab-aaty cd/uc/hs start..... 14, 15
ADEMPAS 308, 309
ADVOCATE ALCOHOL PREP PADS
PAD 70 % 171, 194
ADVOCATE INSULIN PEN NEEDLE 32G
X 4 MM..... 171, 194
ADVOCATE INSULIN PEN NEEDLES
29G X 12.7MM..... 171, 194
ADVOCATE INSULIN PEN NEEDLES
31G X 5 MM..... 171, 194
ADVOCATE INSULIN PEN NEEDLES
31G X 8 MM..... 171, 194
ADVOCATE INSULIN PEN NEEDLES
33G X 4 MM..... 171, 194
ADVOCATE INSULIN SYRINGE 29G X
1/2 171, 194
ADVOCATE INSULIN SYRINGE 30G X
5/16 171, 194
ADVOCATE INSULIN SYRINGE 31G X
5/16 171, 194
AIMOVIG..... 114
AKEEGA 253
ALCOHOL PADS PAD 70 %..... 171, 194
ALCOHOL PREP PAD..... 171, 194
ALCOHOL PREP PAD 70 %..... 171, 194
ALCOHOL PREP PADS PAD 70 % 171,
194
ALCOHOL SWABS PAD..... 171, 194
ALCOHOL SWABS PAD 70 % 171, 194
ALECENSA..... 21
ALTRENO..... 373
ALUNBRIG ORAL TABLET 180 MG, 30
MG, 90 MG..... 55
ALUNBRIG ORAL TABLET THERAPY
PACK..... 55
ALVAIZ..... 101

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

alyq.....	345	AUM MINI INSULIN PEN NEEDLE 33G	
ANKTIVA	258	X 6 MM.....	172, 194
AQ INSULIN SYRINGE 29G X 1/2.....	171, 194	AUM PEN NEEDLE 32G X 4 MM	172, 194
AQ INSULIN SYRINGE 30G X 5/16...	171, 194	AUM PEN NEEDLE 32G X 5 MM	172, 194
AQ INSULIN SYRINGE 31G X 5/16...	171, 194	AUM PEN NEEDLE 32G X 6 MM	172, 194
AQINJECT PEN NEEDLE 31G X 5 MM		AUM PEN NEEDLE 33G X 4 MM	172, 194
.....	171, 194	AUM PEN NEEDLE 33G X 5 MM	172, 194
AQINJECT PEN NEEDLE 32G X 4 MM		AUM PEN NEEDLE 33G X 6 MM	172, 194
.....	172, 194	AUM READYGARD DUO PEN NEEDLE	
ARCALYST	303, 304	32G X 4 MM.....	172, 194
ARIKAYCE.....	23	AUM SAFETY PEN NEEDLE 31G X 4	
armodafinil.....	243	MM	172, 194
ASSURE ID DUO PRO PEN NEEDLES		AUM SAFETY PEN NEEDLE 31G X 5	
31G X 5 MM.....	172, 194	MM	172, 194
ASSURE ID INSULIN SAFETY SYR 29G		AURORA PEN NEEDLES 29G X 12MM	
X 1/2.....	172, 194		172, 194
ASSURE ID PRO PEN NEEDLES 30G X 5		AURORA PEN NEEDLES 31G X 6 MM	
MM	172, 194		172, 194
ASSURE ID SAFETY PEN NEEDLES 30G		AURORA PEN NEEDLES 31G X 8 MM	
X 8 MM.....	172, 194		172, 194
ATTRUBY.....	10	AUSTEDO ORAL TABLET 12 MG, 6 MG,	
AUGTYRO ORAL CAPSULE 160 MG, 40		9 MG	82
MG	296	AUSTEDO XR ORAL TABLET	
AUM ALCOHOL PREP PADS PAD 70 %		EXTENDED RELEASE 24 HOUR 12	
.....	172, 194	MG, 18 MG, 24 MG, 30 MG, 36 MG, 42	
AUM INSULIN SAFETY PEN NEEDLE		MG, 48 MG, 6 MG	82
31G X 4 MM.....	172, 194	AUSTEDO XR PATIENT TITRATION .	82
AUM INSULIN SAFETY PEN NEEDLE		AUTOKEEPER SAFETY PEN NEEDLE	
31G X 5 MM.....	172, 194	30G X 5 MM.....	172, 194
AUM MINI INSULIN PEN NEEDLE 32G		AUTOKEEPER SAFETY PEN NEEDLE	
X 4 MM.....	172, 194	30G X 8 MM.....	172, 194
AUM MINI INSULIN PEN NEEDLE 32G		AVMAPKI FAKZYNJA CO-PACK.....	37
X 5 MM.....	172, 194	AVONEX PEN INTRAMUSCULAR	
AUM MINI INSULIN PEN NEEDLE 32G		AUTO-INJECTOR KIT.....	195
X 6 MM.....	172, 194	AVONEX PREFILLED	
AUM MINI INSULIN PEN NEEDLE 32G		INTRAMUSCULAR PREFILLED	
X 8 MM.....	172, 194	SYRINGE KIT.....	195
AUM MINI INSULIN PEN NEEDLE 33G		AYVAKIT	36
X 4 MM.....	172, 194	B	
AUM MINI INSULIN PEN NEEDLE 33G		BALVERSA ORAL TABLET 3 MG, 4	
X 5 MM.....	172, 194	MG, 5 MG.....	113
		BD AUTOSHIELD DUO 30G X 5 MM	172, 194

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

BD ECLIPSE SYRINGE 30G X 1/2..... 172, 194	BD SAFETYGLIDE INSULIN SYRINGE 30G X 5/16..... 173, 194
BD INS SYR ULTRAFINE 1/2UNIT 31G X 5/16..... 172, 194	BD SAFETYGLIDE INSULIN SYRINGE 31G X 15/64..... 173, 194
BD INSULIN SYR ULTRAFINE II 31G X 5/16 172, 194	BD SAFETYGLIDE INSULIN SYRINGE 31G X 5/16..... 173, 194
BD INSULIN SYRINGE 27.5G X 5/8.. 172, 194	BD SAFETYGLIDE SYRINGE/NEEDLE 27G X 5/8..... 173, 194
BD INSULIN SYRINGE 27G X 1/2..... 172, 194	BD SWAB SINGLE USE REGULAR PAD 173, 194
BD INSULIN SYRINGE 29G X 1/2..... 172, 194	BD VEO INSULIN SYR U/F 1/2UNIT 31G X 15/64..... 173, 194
BD INSULIN SYRINGE HALF-UNIT 31G X 5/16..... 172, 194	BD VEO INSULIN SYR ULTRAFINE 31G X 15/64..... 173, 194
BD INSULIN SYRINGE MICROFINE 27G X 5/8..... 172, 194	BD VEO INSULIN SYRINGE U/F 31G X 15/64 173, 194
BD INSULIN SYRINGE MICROFINE 28G X 1/2..... 172, 194	BENDAMUSTINE HCL INTRAVENOUS SOLUTION..... 46
BD INSULIN SYRINGE U/F 30G X 1/2 172, 194	bendamustine hcl intravenous solution reconstituted..... 46
BD INSULIN SYRINGE U-100 1 ML . 172, 194	BENDEKA 46
BD INSULIN SYRINGE ULTRAFINE 29G X 1/2..... 172, 173, 194	BENLYSTA SUBCUTANEOUS..... 43
BD INSULIN SYRINGE ULTRAFINE 30G X 1/2..... 173, 194	BESREMI 316
BD INSULIN SYRINGE ULTRAFINE 31G X 5/16..... 173, 194	BESREMI PEN..... 316
BD PEN NEEDLE MICRO ULTRAFINE 32G X 6 MM..... 173, 194	BETASERON SUBCUTANEOUS KIT 196
BD PEN NEEDLE MINI U/F 31G X 5 MM 173, 194	bexarotene 50
BD PEN NEEDLE MINI ULTRAFINE 31G X 5 MM..... 173, 194	BIZENGRI (750 MG DOSE) 413
BD PEN NEEDLE NANO 2ND GEN 32G X 4 MM..... 173, 194	BORTEZOMIB INJECTION 52
BD PEN NEEDLE NANO ULTRAFINE 32G X 4 MM..... 173, 194	BORUZU 52
BD PEN NEEDLE ORIG ULTRAFINE 29G X 12.7MM..... 173, 194	bosentan oral tablet 53
BD PEN NEEDLE SHORT ULTRAFINE 31G X 8 MM..... 173, 194	BOSULIF ORAL CAPSULE 100 MG, 50 MG 54
BD SAFETYGLIDE INSULIN SYRINGE 29G X 1/2..... 173, 194	BOSULIF ORAL TABLET 100 MG, 500 MG 54
	bosutinib oral tablet 100 mg, 400 mg, 500 mg 54
	BRAFTOVI ORAL CAPSULE 75 MG . 105
	BRUKINSA ORAL CAPSULE 412
	BRUKINSA ORAL TABLET 412
	butalbital-apap-caff-cod oral capsule 50-325-40-30 mg..... 149
	butalbital-apap-caffeine oral capsule 149
	butalbital-apap-caffeine oral tablet 50-325-40 mg 149

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

C

CABOMETYX ORAL TABLET 20 MG, 40 MG, 60 MG..... 58

CALQUENCE ORAL TABLET 9

CAMCEVI 214

CAMZYOS 229

CAPRELSA ORAL TABLET 100 MG, 300 MG 401

CAREFINE PEN NEEDLES 29G X 12MM 173, 194

CAREFINE PEN NEEDLES 30G X 8 MM 173, 194

CAREFINE PEN NEEDLES 31G X 6 MM 173, 194

CAREFINE PEN NEEDLES 31G X 8 MM 173, 194

CAREFINE PEN NEEDLES 32G X 4 MM 173, 194

CAREFINE PEN NEEDLES 32G X 5 MM 173, 194

CAREFINE PEN NEEDLES 32G X 6 MM 173, 194

CAREONE INSULIN SYRINGE 30G X 1/2 173, 194

CAREONE INSULIN SYRINGE 31G X 5/16 173, 194

CAREONE UNIFINE PENTIPS PLUS 29G X 12MM..... 173, 194

CAREONE UNIFINE PENTIPS PLUS 31G X 5 MM..... 174, 194

CAREONE UNIFINE PENTIPS PLUS 31G X 6 MM..... 174, 194

CAREONE UNIFINE PENTIPS PLUS 31G X 8 MM..... 174, 194

CAREONE UNIFINE PENTIPS PLUS 32G X 4 MM..... 174, 194

CAREONE UNIFINE PENTIPS PLUS 33G X 4 MM..... 174, 194

CARETOUCH ALCOHOL PREP PAD 70 % 174, 194

CARETOUCH INSULIN SYRINGE 28G X 5/16 174, 194

CARETOUCH INSULIN SYRINGE 29G X 5/16 174, 194

CARETOUCH INSULIN SYRINGE 30G X 5/16 174, 194

CARETOUCH INSULIN SYRINGE 31G X 5/16 174, 194

CARETOUCH PEN NEEDLES 29G X 12MM 174, 194

CARETOUCH PEN NEEDLES 31G X 5 MM 174, 194

CARETOUCH PEN NEEDLES 31G X 6 MM 174, 194

CARETOUCH PEN NEEDLES 31G X 8 MM 174, 194

CARETOUCH PEN NEEDLES 32G X 4 MM 174, 194

CARETOUCH PEN NEEDLES 32G X 5 MM 174, 194

CARETOUCH PEN NEEDLES 33G X 4 MM 174, 194

carglumic acid oral tablet soluble 62

CAYSTON..... 41

chlordiazepoxide-clidinium 150

CIMZIA (1 SYRINGE) 64, 65

CIMZIA (2 SYRINGE) 64, 65

CIMZIA SUBCUTANEOUS KIT 2 X 200 MG 64, 65

CIMZIA-STARTER 64, 65

CLEVER CHOICE COMFORT EZ 29G X 12MM 174, 194

CLEVER CHOICE COMFORT EZ 33G X 4 MM 174, 194

CLICKFINE PEN NEEDLES 31G X 5 MM 174, 194

CLICKFINE PEN NEEDLES 31G X 6 MM 174, 194

CLICKFINE PEN NEEDLES 31G X 8 MM 174, 194

CLICKFINE PEN NEEDLES 32G X 4 MM 174, 194

COMETRIQ (100 MG DAILY DOSE) ORAL KIT 80 & 20 MG 57

COMETRIQ (140 MG DAILY DOSE) ORAL KIT 3 X 20 MG & 80 MG 57

COMETRIQ (60 MG DAILY DOSE)..... 57

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

COMFORT ASSIST INSULIN SYRINGE 29G X 1/2.....	174, 194	COMFORT EZ PRO PEN NEEDLES 31G X 4 MM.....	175, 194
COMFORT ASSIST INSULIN SYRINGE 31G X 5/16.....	174, 194	COMFORT EZ PRO PEN NEEDLES 31G X 5 MM.....	175, 194
COMFORT EZ INSULIN SYRINGE 27G X 1/2.....	174, 194	COMFORT EZ SHORT PEN NEEDLES 31G X 8 MM.....	175, 194
COMFORT EZ INSULIN SYRINGE 28G X 1/2.....	174, 194	COMFORT TOUCH INSULIN PEN NEED 31G X 4 MM.....	175, 194
COMFORT EZ INSULIN SYRINGE 29G X 1/2.....	174, 194	COMFORT TOUCH INSULIN PEN NEED 31G X 5 MM.....	175, 194
COMFORT EZ INSULIN SYRINGE 30G X 1/2.....	174, 194	COMFORT TOUCH INSULIN PEN NEED 31G X 6 MM.....	175, 194
COMFORT EZ INSULIN SYRINGE 30G X 5/16.....	174, 194	COMFORT TOUCH INSULIN PEN NEED 31G X 8 MM.....	175, 194
COMFORT EZ INSULIN SYRINGE 31G X 15/64.....	174, 194	COMFORT TOUCH INSULIN PEN NEED 32G X 4 MM.....	175, 194
COMFORT EZ INSULIN SYRINGE 31G X 5/16.....	174, 175, 194	COMFORT TOUCH INSULIN PEN NEED 32G X 5 MM.....	175, 194
COMFORT EZ MICRO PEN NEEDLES 32G X 4 MM.....	175, 194	COMFORT TOUCH INSULIN PEN NEED 32G X 6 MM.....	175, 194
COMFORT EZ PEN NEEDLES 31G X 5 MM	175, 194	COMFORT TOUCH INSULIN PEN NEED 32G X 8 MM.....	175, 194
COMFORT EZ PEN NEEDLES 31G X 6 MM	175, 194	COMFORT TOUCH INSULIN PEN NEED 33G X 4 MM.....	175, 194
COMFORT EZ PEN NEEDLES 31G X 8 MM	175, 194	COMFORT TOUCH INSULIN PEN NEED 33G X 5 MM.....	175, 194
COMFORT EZ PEN NEEDLES 32G X 4 MM	175, 194	COMFORT TOUCH INSULIN PEN NEED 33G X 6 MM.....	175, 194
COMFORT EZ PEN NEEDLES 32G X 5 MM	175, 194	COPIKTRA.....	95
COMFORT EZ PEN NEEDLES 32G X 6 MM	175, 194	COSENTYX (300 MG DOSE).....	320, 321
COMFORT EZ PEN NEEDLES 32G X 8 MM	175, 194	COSENTYX SENSOREADY (300 MG)	320, 321
COMFORT EZ PEN NEEDLES 33G X 4 MM	175, 194	COSENTYX SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 75 MG/0.5ML	320, 321
COMFORT EZ PEN NEEDLES 33G X 5 MM	175, 194	COSENTYX UNOREADY	320, 321
COMFORT EZ PEN NEEDLES 33G X 6 MM	175, 194	COTELLIC	68
COMFORT EZ PEN NEEDLES 33G X 8 MM	175, 194	CRESEMBA ORAL	199
COMFORT EZ PRO PEN NEEDLES 30G X 8 MM.....	175, 194	CURITY ALCOHOL PREPS PAD 70 %	175, 194
		CURITY ALL PURPOSE SPONGES PAD 2.....	175, 194
		CURITY GAUZE PAD 2	175, 194

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

CURITY GAUZE SPONGE PAD 2.....	175, 194
CURITY SPONGES PAD 2.....	175, 194
CVS ALCOHOL PREP PADS PAD 70 %	175, 194
CVS GAUZE PAD 2	175, 194
CVS GAUZE STERILE PAD 2	175, 194
cvs isopropyl alcohol wipes	175, 194
CVS PREP PAD 70 %.....	175, 194
CYLTEZO (2 PEN)	16, 17
CYLTEZO (2 SYRINGE)	16, 17
CYLTEZO-CD/UC/HS STARTER....	16, 17
CYLTEZO-PSORIASIS/UV STARTER	16, 17
cyproheptadine hcl oral syrup 2 mg/5ml	148
cyproheptadine hcl oral tablet.....	148
D	
dalfampridine er	74
DANYELZA.....	244
DANZITEN	249
dasatinib oral tablet 100 mg, 140 mg, 20 mg, 50 mg, 70 mg, 80 mg	76
DATROWAY	77
DAURISMO ORAL TABLET 100 MG, 25 MG	138
deferasirox granules	79, 80
deferasirox oral tablet	79, 80
DERMACEA GAUZE SPONGE PAD 2	175, 194
DERMACEA IV DRAIN SPONGES PAD 2.....	175, 194
DERMACEA NON-WOVEN SPONGES PAD 2.....	175, 194
DERMACEA TYPE VII GAUZE PAD 2	175, 194
dextromethorphan-quinidine.....	83
DIACOMIT ORAL CAPSULE 250 MG, 500 MG	343
DIACOMIT ORAL PACKET 250 MG, 500 MG	343
DIATHRIVE PEN NEEDLE 31G X 5 MM	175, 194
DIATHRIVE PEN NEEDLE 31G X 6 MM	175, 194
DIATHRIVE PEN NEEDLE 31G X 8 MM	175, 194
DIATHRIVE PEN NEEDLE 32G X 4 MM	175, 194
diclofenac epolamine external	85
diclofenac sodium external solution 2 %..	84
dimethyl fumarate oral capsule delayed release 120 mg, 240 mg	86
dimethyl fumarate starter pack oral capsule delayed release therapy pack	86
diphenoxylate-atropine oral tablet 2.5-0.025 mg	159
dipyridamole oral.....	151
dronabinol oral capsule	90
DROPLET INSULIN SYRINGE 29G X 1/2	175, 176, 194
DROPLET INSULIN SYRINGE 30G X 1/2	176, 194
DROPLET INSULIN SYRINGE 30G X 15/64	176, 194
DROPLET INSULIN SYRINGE 30G X 5/16	176, 194
DROPLET INSULIN SYRINGE 31G X 15/64	176, 194
DROPLET INSULIN SYRINGE 31G X 5/16	176, 194
DROPLET MICRON 34G X 3.5 MM...	176, 194
DROPLET PEN NEEDLES 29G X 10MM	176, 194
DROPLET PEN NEEDLES 29G X 12MM	176, 194
DROPLET PEN NEEDLES 30G X 8 MM	176, 194
DROPLET PEN NEEDLES 31G X 5 MM	176, 194
DROPLET PEN NEEDLES 31G X 6 MM	176, 194
DROPLET PEN NEEDLES 31G X 8 MM	176, 194
DROPLET PEN NEEDLES 32G X 4 MM	176, 194
DROPLET PEN NEEDLES 32G X 5 MM	176, 194

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

DROPLET PEN NEEDLES 32G X 6 MM 176, 194	EASY COMFORT INSULIN SYRINGE 30G X 1/2..... 177, 194
DROPLET PEN NEEDLES 32G X 8 MM 176, 194	EASY COMFORT INSULIN SYRINGE 30G X 5/16..... 177, 194
DROPSAFE ALCOHOL PREP PAD 70 % 176, 194	EASY COMFORT INSULIN SYRINGE 31G X 1/2..... 177, 194
DROPSAFE AUTOPROTECT DUO 31G X 4 MM 176, 194	EASY COMFORT INSULIN SYRINGE 31G X 5/16..... 177, 194
DROPSAFE AUTOPROTECT DUO 31G X 5 MM 176, 194	EASY COMFORT INSULIN SYRINGE 32G X 5/16..... 177, 194
DROPSAFE AUTOPROTECT DUO 31G X 8 MM 176, 194	EASY COMFORT PEN NEEDLES 29G X 4MM 177, 194
DROPSAFE SAFETY PEN NEEDLES 31G X 5 MM..... 176, 194	EASY COMFORT PEN NEEDLES 29G X 5MM 177, 194
DROPSAFE SAFETY PEN NEEDLES 31G X 6 MM..... 176, 194	EASY COMFORT PEN NEEDLES 31G X 5 MM 177, 194
DROPSAFE SAFETY PEN NEEDLES 31G X 8 MM..... 176, 194	EASY COMFORT PEN NEEDLES 31G X 6 MM 177, 194
DROPSAFE SAFETY SYRINGE/NEEDLE 29G X 1/2..... 176, 194	EASY COMFORT PEN NEEDLES 31G X 8 MM 177, 194
DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 15/64..... 176, 194	EASY COMFORT PEN NEEDLES 32G X 4 MM 177, 194
DROPSAFE SAFETY SYRINGE/NEEDLE 31G X 5/16..... 176, 194	EASY COMFORT PEN NEEDLES 33G X 4 MM 177, 194
droxidopa 91	EASY COMFORT PEN NEEDLES 33G X 5 MM 177, 194
DRUG MART UNIFINE PENTIPS 29G X 12MM 176, 194	EASY COMFORT PEN NEEDLES 33G X 6 MM 177, 194
DRUG MART UNIFINE PENTIPS 31G X 6 MM 176, 194	EASY GLIDE PEN NEEDLES 33G X 4 MM 177, 194
DRUG MART UNIFINE PENTIPS 31G X 8 MM 176, 194	EASY TOUCH ALCOHOL PREP MEDIUM PAD 70 %..... 177, 194
DRUG MART UNIFINE PENTIPS PLUS 32G X 4 MM..... 176, 194	EASY TOUCH FLIPLOCK INSULIN SY 29G X 1/2..... 177, 194
DUPIXENT SUBCUTANEOUS SOLUTION AUTO-INJECTOR ... 92, 93, 94	EASY TOUCH FLIPLOCK INSULIN SY 30G X 1/2..... 177, 194
DUPIXENT SUBCUTANEOUS SOLUTION PREFILLED SYRINGE . 92, 93, 94	EASY TOUCH FLIPLOCK INSULIN SY 30G X 5/16..... 177, 194
E	EASY TOUCH FLIPLOCK INSULIN SY 31G X 5/16..... 177, 194
EASY COMFORT ALCOHOL PADS PAD 176, 194	EASY TOUCH FLIPLOCK SAFETY SYR 27G X 1/2..... 177, 194
EASY COMFORT INSULIN SYRINGE 29G X 5/16..... 176, 194	EASY TOUCH INSULIN BARRELS U- 100 I ML..... 177, 194

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

EASY TOUCH INSULIN SAFETY SYR 29G X 1/2.....	177, 194	EASY TOUCH SAFETY PEN NEEDLES 30G X 8 MM.....	178, 194
EASY TOUCH INSULIN SAFETY SYR 30G X 1/2.....	177, 194	EASY TOUCH SHEATHLOCK SYRINGE 29G X 1/2.....	178, 194
EASY TOUCH INSULIN SAFETY SYR 30G X 5/16.....	177, 194	EASY TOUCH SHEATHLOCK SYRINGE 30G X 1/2.....	178, 194
EASY TOUCH INSULIN SYRINGE 27G X 1/2.....	177, 194	EASY TOUCH SHEATHLOCK SYRINGE 30G X 5/16.....	178, 194
EASY TOUCH INSULIN SYRINGE 27G X 5/8.....	177, 194	EASY TOUCH SHEATHLOCK SYRINGE 31G X 5/16.....	178, 194
EASY TOUCH INSULIN SYRINGE 28G X 1/2.....	177, 194	ELAHERE	240
EASY TOUCH INSULIN SYRINGE 29G X 1/2.....	177, 194	ELIGARD	215
EASY TOUCH INSULIN SYRINGE 30G X 1/2.....	177, 194	ELREXFIO SUBCUTANEOUS SOLUTION 44 MG/1.1ML, 76 MG/1.9ML	100
EASY TOUCH INSULIN SYRINGE 30G X 5/16.....	177, 194	eltrombopag olamine oral packet 12.5 mg, 25 mg	102, 103
EASY TOUCH INSULIN SYRINGE 30G X 5/16.....	177, 194	eltrombopag olamine oral tablet 12.5 mg, 25 mg, 50 mg, 75 mg	102, 103
EASY TOUCH INSULIN SYRINGE 31G X 5/16.....	178, 194	EMBECTA AUTOSHIELD DUO 30G X 5 MM	178, 194
EASY TOUCH PEN NEEDLES 29G X 12MM	178, 194	EMBECTA INS SYR U/F 1/2 UNIT 31G X 15/64	178, 194
EASY TOUCH PEN NEEDLES 30G X 5 MM	178, 194	EMBECTA INS SYR U/F 1/2 UNIT 31G X 5/16	178, 194
EASY TOUCH PEN NEEDLES 30G X 6 MM	178, 194	EMBECTA INSULIN SYR ULTRAFINE 30G X 1/2.....	178, 194
EASY TOUCH PEN NEEDLES 30G X 8 MM	178, 194	EMBECTA INSULIN SYR ULTRAFINE 31G X 15/64.....	178, 194
EASY TOUCH PEN NEEDLES 31G X 5 MM	178, 194	EMBECTA INSULIN SYR ULTRAFINE 31G X 5/16.....	178, 194
EASY TOUCH PEN NEEDLES 31G X 6 MM	178, 194	EMBECTA INSULIN SYRINGE 28G X 1/2	178, 194
EASY TOUCH PEN NEEDLES 31G X 8 MM	178, 194	EMBECTA INSULIN SYRINGE U-100 27G X 5/8.....	178, 194
EASY TOUCH PEN NEEDLES 32G X 4 MM	178, 194	EMBECTA INSULIN SYRINGE U-500	178, 194
EASY TOUCH PEN NEEDLES 32G X 5 MM	178, 194	EMBECTA PEN NEEDLE NANO 2 GEN 32G X 4 MM.....	178, 194
EASY TOUCH PEN NEEDLES 32G X 6 MM	178, 194	EMBECTA PEN NEEDLE NANO 32G X 4 MM	178, 194
EASY TOUCH SAFETY PEN NEEDLES 29G X 5MM.....	178, 194	EMBECTA PEN NEEDLE ULTRAFINE 29G X 12.7MM.....	178, 194
EASY TOUCH SAFETY PEN NEEDLES 29G X 8MM.....	178, 194		

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

EMBECTA PEN NEEDLE ULTRAFINE 31G X 5 MM.....	178, 194
EMBECTA PEN NEEDLE ULTRAFINE 31G X 8 MM.....	178, 194
EMBECTA PEN NEEDLE ULTRAFINE 32G X 6 MM.....	178, 194
EMBRACE PEN NEEDLES 29G X 12MM	178, 194
EMBRACE PEN NEEDLES 30G X 5 MM	178, 194
EMBRACE PEN NEEDLES 30G X 8 MM	179, 194
EMBRACE PEN NEEDLES 31G X 5 MM	179, 194
EMBRACE PEN NEEDLES 31G X 6 MM	179, 194
EMBRACE PEN NEEDLES 31G X 8 MM	179, 194
EMBRACE PEN NEEDLES 32G X 4 MM	179, 194
EMGALITY.....	133
EMGALITY (300 MG DOSE).....	133
EMRELIS	354
ENBREL MINI.....	117, 118
ENBREL SUBCUTANEOUS SOLUTION 25 MG/0.5ML.....	117, 118
ENBREL SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	117, 118
ENBREL SURECLICK SUBCUTANEOUS SOLUTION AUTO-INJECTOR	117, 118
ENSACOVE ORAL CAPSULE 100 MG, 25 MG	106
EPCLUSA ORAL PACKET 150-37.5 MG, 200-50 MG.....	332
EPCLUSA ORAL TABLET.....	332
EPIDIOLEX.....	59
EPKINLY	110
EQL ALCOHOL SWABS PAD 70 %... 179, 194	
EQL GAUZE PAD 2	179, 194
EQL INSULIN SYRINGE 29G X 1/2... 179, 194	
EQL INSULIN SYRINGE 30G X 5/16. 179, 194	
EQL INSULIN SYRINGE 31G X 5/16. 179, 194	
ERBITUX	66
ERIVEDGE.....	407
ERLEADA ORAL TABLET 240 MG, 60 MG	28
erlotinib hcl oral tablet 100 mg, 150 mg, 25 mg	115
estradiol-norethindrone acet.....	152
everolimus oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg	119
everolimus oral tablet soluble	120
EXEL COMFORT POINT PEN NEEDLE 29G X 12MM.....	179, 194
EXXUA.....	136
EXXUA TITRATION PACK.....	136
F	
FASENRA	47, 48
FASENRA PEN.....	47, 48
fentanyl citrate buccal lozenge on a handle	124
FIFTY50 ALCOHOL PREP PAD 70 % 179, 194	
FIFTY50 PEN NEEDLES 31G X 5 MM	179, 194
FIFTY50 PEN NEEDLES 31G X 8 MM	179, 194
FIFTY50 PEN NEEDLES 32G X 4 MM	179, 194
FIFTY50 PEN NEEDLES 32G X 6 MM	179, 194
FIFTY50 SUPERIOR COMFORT SYR 31G X 5/16.....	179, 194
fingolimod hcl	129
FINTEPLA.....	123
FOTIVDA	365
FRUZAQLA ORAL CAPSULE 1 MG, 5 MG	131
FYARRO	329
G	
GAUZE PADS PAD 2.....	179, 194
GAUZE TYPE VII MEDI-PAK PAD 2 179, 194	
GAVRETO	289

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

gefitinib	135	GNP ALCOHOL SWABS PAD 70 % ..	180, 194
GILOTRIF	20	GNP CLICKFINE PEN NEEDLES 31G X 6 MM	180, 194
glatiramer acetate subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml	139	GNP CLICKFINE PEN NEEDLES 31G X 8 MM	180, 194
glatopa subcutaneous solution prefilled syringe 20 mg/ml, 40 mg/ml.....	139	GNP INSULIN SYRINGE 28G X 1/2 ..	180, 194
GLOBAL ALCOHOL PREP EASE	179, 194	GNP INSULIN SYRINGE 29G X 1/2 ..	180, 194
GLOBAL EASE INJECT PEN NEEDLES 29G X 12MM.....	179, 194	GNP INSULIN SYRINGE 30G X 5/16	180, 194
GLOBAL EASE INJECT PEN NEEDLES 31G X 5 MM.....	179, 194	GNP INSULIN SYRINGE 31G X 5/16	180, 194
GLOBAL EASE INJECT PEN NEEDLES 31G X 8 MM.....	179, 194	GNP INSULIN SYRINGES 28GX1/2 ..	180, 194
GLOBAL EASE INJECT PEN NEEDLES 32G X 4 MM.....	179, 194	GNP INSULIN SYRINGES 29GX1/2 ..	180, 194
GLOBAL EASY GLIDE INSULIN SYR 31G X 15/64.....	179, 194	GNP INSULIN SYRINGES 30G X 5/16	180, 194
GLOBAL EASY GLIDE INSULIN SYR 31G X 5/16.....	179, 194	GNP INSULIN SYRINGES 30GX5/16	180, 194
GLOBAL EASY GLIDE PEN NEEDLES 32G X 4 MM.....	179, 194	GNP INSULIN SYRINGES 31GX5/16	180, 194
GLOBAL INJECT EASE INSULIN SYR 28G X 1/2.....	179, 194	GNP PEN NEEDLES 31G X 5 MM	180, 194
GLOBAL INJECT EASE INSULIN SYR 29G X 1/2.....	179, 194	GNP PEN NEEDLES 31G X 8 MM	180, 194
GLOBAL INJECT EASE INSULIN SYR 30G X 1/2.....	179, 194	GNP PEN NEEDLES 32G X 4 MM	180, 194
GLOBAL INJECT EASE INSULIN SYR 30G X 5/16.....	179, 194	GNP PEN NEEDLES 32G X 6 MM	180, 194
GLOBAL INJECT EASE INSULIN SYR 31G X 5/16.....	179, 180, 194	GNP STERILE GAUZE PAD 2	180, 194
GLOBAL INSULIN SYRINGES 30G X 1/2	180, 194	GNP ULTICARE PEN NEEDLES 31G X 5 MM	180, 194
GLOBAL INSULIN SYRINGES 30G X 5/16	180, 194	GNP ULTICARE PEN NEEDLES 31G X 8 MM	180, 194
GLUCOPRO INSULIN SYRINGE 30G X 1/2	180, 194	GNP ULTICARE PEN NEEDLES 32G X 4 MM	180, 194
GLUCOPRO INSULIN SYRINGE 30G X 5/16	180, 194	GNP ULTICARE PEN NEEDLES 32G X 6 MM	180, 194
GLUCOPRO INSULIN SYRINGE 31G X 5/16	180, 194	GNP ULTIGUARD SAFEPAK NEEDLE 31G X 5 MM.....	180, 194
glyburide micronized	154		
glyburide oral.....	154		
glyburide-metformin	154		

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

GNP ULTIGUARD SAFEPAK NEEDLE
31G X 8 MM..... 180, 194

GNP ULTIGUARD SAFEPAK NEEDLE
32G X 4 MM..... 180, 194

GNP ULTIGUARD SAFEPAK NEEDLE
32G X 6 MM..... 180, 194

GNP ULTRA COM INSULIN SYRINGE
28G X 1/2..... 180, 194

GOMEKLI ORAL CAPSULE 1 MG, 2 MG
..... 239

GOMEKLI ORAL TABLET SOLUBLE239

GOODSENSE ALCOHOL SWABS PAD
70 % 180, 194

GOODSENSE CLICKFINE PEN NEEDLE
31G X 5 MM..... 180, 194

GOODSENSE PEN NEEDLE PENFINE
31G X 5 MM..... 181, 194

GOODSENSE PEN NEEDLE PENFINE
31G X 8 MM..... 181, 194

GOODSENSE PEN NEEDLE PENFINE
32G X 4 MM..... 181, 194

GOODSENSE PEN NEEDLE PENFINE
32G X 6 MM..... 181, 194

H

HADLIMA..... 18, 19

HADLIMA PUSHTOUCH..... 18, 19

HAEGARDA SUBCUTANEOUS
SOLUTION RECONSTITUTED 2000
UNIT, 3000 UNIT 56

HARVONI ORAL PACKET 33.75-150
MG, 45-200 MG 208

HARVONI ORAL TABLET 208

HEALTHWISE INSULIN SYR/NEEDLE
30G X 5/16..... 181, 194

HEALTHWISE INSULIN SYR/NEEDLE
31G X 5/16..... 181, 194

HEALTHWISE MICRON PEN NEEDLES
32G X 4 MM..... 181, 194

HEALTHWISE SHORT PEN NEEDLES
31G X 5 MM..... 181, 194

HEALTHWISE SHORT PEN NEEDLES
31G X 8 MM..... 181, 194

H-E-B INCONTROL ALCOHOL PAD 181,
194

H-E-B INCONTROL PEN NEEDLES 29G
X 12MM..... 181, 194

H-E-B INCONTROL PEN NEEDLES 31G
X 5 MM..... 181, 194

H-E-B INCONTROL PEN NEEDLES 31G
X 6 MM..... 181, 194

H-E-B INCONTROL PEN NEEDLES 31G
X 8 MM..... 181, 194

H-E-B INCONTROL PEN NEEDLES 32G
X 4 MM..... 181, 194

H-E-B INCONTROL UNIFINE PENTIP
31G X 5 MM..... 181, 194

H-E-B INCONTROL UNIFINE PENTIP
31G X 6 MM..... 181, 194

H-E-B INCONTROL UNIFINE PENTIP
31G X 8 MM..... 181, 194

H-E-B INCONTROL UNIFINE PENTIP
32G X 4 MM..... 181, 194

H-E-B INCONTROL UNIFINE PENTIP
33G X 4 MM..... 181, 194

HERCEPTIN HYLECTA..... 380

HERNEXEOS..... 416

HM STERILE PADS PAD 2..... 181, 194

HM ULTICARE INSULIN SYRINGE 30G
X 1/2..... 181, 194

HM ULTICARE INSULIN SYRINGE 31G
X 5/16..... 181, 194

HM ULTICARE MINI PEN NEEDLES
31G X 5 MM..... 181, 194

HM ULTICARE SHORT PEN NEEDLES
31G X 8 MM..... 181, 194

HUMIRA (2 PEN) SUBCUTANEOUS
AUTO-INJECTOR KIT..... 12, 13

HUMIRA (2 SYRINGE)
SUBCUTANEOUS PREFILLED
SYRINGE KIT 10 MG/0.1ML, 20
MG/0.2ML, 40 MG/0.4ML, 40
MG/0.8ML 12, 13

HUMIRA-CD/UC/HS STARTER
SUBCUTANEOUS AUTO-INJECTOR
KIT 12, 13

HUMIRA-PED<40KG CROHNS
STARTER..... 12, 13

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

HUMIRA-PED $\geq$ 40KG CROHNS START 12, 13
 HUMIRA-PED $\geq$ 40KG UC STARTER
 SUBCUTANEOUS AUTO-INJECTOR
 KIT 12, 13
 HUMIRA-PSORIASIS/UEVIT STARTER
 SUBCUTANEOUS AUTO-INJECTOR
 KIT 12, 13
 HYRNUO 326
I
 IBRANCE 269
 IBTROZI 349
 icanibant acetate 164
 ICLUSIG 287
 IDHIFA 104
 imatinib mesylate oral tablet 100 mg, 400
 mg 166
 IMBRUVICA ORAL CAPSULE 140 MG,
 70 MG 163
 IMBRUVICA ORAL SUSPENSION..... 163
 IMBRUVICA ORAL TABLET 140 MG,
 280 MG, 420 MG..... 163
 IMDELLTRA 351
 IMJUDO 382
 IMKELDI 167
 IMPAVIDO 238
 INCONTROL ULTICARE PEN NEEDLES
 31G X 6 MM..... 181, 194
 INCONTROL ULTICARE PEN NEEDLES
 31G X 8 MM..... 181, 194
 INCONTROL ULTICARE PEN NEEDLES
 32G X 4 MM..... 181, 194
 INCRELEX 230
 indomethacin oral capsule 25 mg, 50 mg 160
 INGREZZA ORAL CAPSULE 400
 INGREZZA ORAL CAPSULE SPRINKLE
 400
 INGREZZA ORAL CAPSULE THERAPY
 PACK 400
 INLURIYO 169
 INLYTA ORAL TABLET 1 MG, 5 MG.. 39
 INQOVI 78
 INREBIC 122
 INSULIN SYRINGE 28G X 1/2 181, 194

INSULIN SYRINGE 29G X 1/2 181, 194
 INSULIN SYRINGE 30G X 5/16 .. 181, 194
 INSULIN SYRINGE 31G X 5/16 .. 181, 194
 INSULIN SYRINGE-NEEDLE U-100 27G
 X 1/2..... 181, 194
 INSULIN SYRINGE-NEEDLE U-100 28G
 X 1/2..... 181, 182, 194
 INSULIN SYRINGE-NEEDLE U-100 29G
 X 1/2..... 182, 194
 INSULIN SYRINGE-NEEDLE U-100 30G
 X 1/2..... 182, 194
 INSULIN SYRINGE-NEEDLE U-100 30G
 X 5/16..... 182, 194
 INSULIN SYRINGE-NEEDLE U-100 31G
 X 1/4..... 182, 194
 INSULIN SYRINGE-NEEDLE U-100 31G
 X 5/16..... 182, 194
 INSUPEN PEN NEEDLES 29G X 12MM
 182, 194
 INSUPEN PEN NEEDLES 31G X 5 MM
 182, 194
 INSUPEN PEN NEEDLES 31G X 8 MM
 182, 194
 INSUPEN PEN NEEDLES 32G X 4 MM
 182, 194
 INSUPEN PEN NEEDLES 33G X 4 MM
 182, 194
 INSUPEN SENSITIVE 32G X 6 MM .. 182,
 194
 INSUPEN SENSITIVE 32G X 8 MM .. 182,
 194
 INSUPEN ULTRAFIN 30G X 8 MM... 182,
 194
 INSUPEN ULTRAFIN 31G X 6 MM... 182,
 194
 INSUPEN ULTRAFIN 31G X 8 MM... 182,
 194
 INSUPEN32G EXTR3ME 32G X 6 MM
 182, 194
 ITOVEBI ORAL TABLET 3 MG, 9 MG
 170
 IWILFIN 96
J
 J & J GAUZE PAD 2..... 182, 194

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

JAKAFI.....	318	KOSELUGO ORAL CAPSULE	
JAKAFI XR	318	SPRINKLE 5 MG, 7.5 MG.....	325
JASCAYD.....	245, 246	KRAZATI.....	11
javygtor oral tablet.....	319	KROGER INSULIN SYRINGE 29G X 1/2	
JAYPIRCA ORAL TABLET 100 MG, 50			182, 194
MG	285	KROGER INSULIN SYRINGE 30G X 5/16	
JEMPERLI.....	89		182, 194
JYNARQUE ORAL TABLET	372	KROGER INSULIN SYRINGE 31G X 5/16	
K			182, 194
KALYDECO.....	200	KROGER PEN NEEDLES 29G X 12MM	
KENDALL HYDROPHILIC FOAM			183, 194
DRESS PAD 2	182, 194	KROGER PEN NEEDLES 31G X 5 MM	
KENDALL HYDROPHILIC FOAM PLUS			183, 194
PAD 2.....	182, 194	KROGER PEN NEEDLES 31G X 6 MM	
KERENDIA	128		183, 194
KEYTRUDA INTRAVENOUS		KROGER PEN NEEDLES 31G X 8 MM	
SOLUTION.....	276		183, 194
KEYTRUDA QLEX.....	277	KROGER PEN NEEDLES 32G X 4 MM	
KIMMTRAK	352		183, 194
KINERET SUBCUTANEOUS SOLUTION		KROGER PEN NEEDLES 33G X 4 MM	
PREFILLED SYRINGE	26, 27		183, 194
KINRAY INSULIN SYRINGE 29G X 1/2		L	
.....	182, 194	LANREOTIDE ACETATE	204
KINRAY INSULIN SYRINGE 31G X 5/16		lapatinib ditosylate	205
.....	182, 194	LAZCLUZE ORAL TABLET 240 MG, 80	
KISQALI (200 MG DOSE).....	300	MG	207
KISQALI (400 MG DOSE).....	300	LEADER INSULIN SYRINGE 28G X 1/2	
KISQALI (600 MG DOSE).....	300		183, 194
KISQALI FEMARA (200 MG DOSE) ..	301	LEADER INSULIN SYRINGE 29G X 1/2	
KISQALI FEMARA (400 MG DOSE) ..	301		183, 194
KISQALI FEMARA (600 MG DOSE) ..	301	LEADER INSULIN SYRINGE 30G X 5/16	
KMART VALU INSULIN SYRINGE 29G			183, 194
U-100 0.5 ML	182, 194	LEADER INSULIN SYRINGE 31G X 5/16	
KMART VALU INSULIN SYRINGE 29G			183, 194
U-100 1 ML	182, 194	LEADER UNIFINE PENTIPS 31G X 5	
KMART VALU INSULIN SYRINGE 30G		MM	183, 194
U-100 0.3 ML	182, 194	LEADER UNIFINE PENTIPS 32G X 4	
KMART VALU INSULIN SYRINGE 30G		MM	183, 194
U-100 0.5 ML	182, 194	LEADER UNIFINE PENTIPS PLUS 31G	
KMART VALU INSULIN SYRINGE 30G		X 5 MM.....	183, 194
U-100 1 ML	182, 194	LEADER UNIFINE PENTIPS PLUS 31G	
KOMZIFTI	414	X 8 MM.....	183, 194
KOSELUGO ORAL CAPSULE 10 MG, 25		LEADER UNIFINE PENTIPS PLUS 32G	
MG	325	X 4 MM.....	183, 194

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ledipasvir-sofosbuvir.....	208	LUMAKRAS ORAL TABLET 120 MG, 240 MG, 320 MG.....	342
lenalidomide.....	209	LUNSUMIO	242
LENVIMA (10 MG DAILY DOSE)	210	LUNSUMIO VELO.....	242
LENVIMA (12 MG DAILY DOSE)	210	LUPRON DEPOT (1-MONTH)	216, 217
LENVIMA (14 MG DAILY DOSE)	210	LUPRON DEPOT (3-MONTH)	216, 217
LENVIMA (18 MG DAILY DOSE)	210	LUPRON DEPOT (4-MONTH)	216, 217
LENVIMA (20 MG DAILY DOSE)	210	LUPRON DEPOT (6-MONTH)	216, 217
LENVIMA (24 MG DAILY DOSE)	210	LUPRON DEPOT-PED (3-MONTH)	218
LENVIMA (4 MG DAILY DOSE)	210	LUPRON DEPOT-PED (6-MONTH)	218
LENVIMA (8 MG DAILY DOSE)	210	LUTRATE DEPOT	213
LEUPROLIDE ACETATE (3 MONTH).....	213	LYNOZYFIC INTRAVENOUS SOLUTION 200 MG/10ML, 5 MG/2.5ML	222
leuprolide acetate injection	212	LYNPARZA ORAL TABLET	259
l-glutamine oral packet	219	LYTGOBI (12 MG DAILY DOSE)	132
lidocaine external ointment 5 %	220	LYTGOBI (16 MG DAILY DOSE)	132
lidocaine-prilocaine external cream	221	LYTGOBI (20 MG DAILY DOSE)	132
LIFYORLI (125 MG DOSE).....	294	M	
LIFYORLI (150 MG DOSE).....	294	MAGELLAN INSULIN SAFETY SYR 29G X 1/2.....	183, 194
LITETOUCH INSULIN SYRINGE 28G X 1/2	183, 194	MAGELLAN INSULIN SAFETY SYR 30G X 5/16.....	183, 194
LITETOUCH INSULIN SYRINGE 29G X 1/2	183, 194	MARATHON MEDICAL PENTIPS 29G X 12MM	183, 194
LITETOUCH INSULIN SYRINGE 30G X 5/16	183, 194	MARATHON MEDICAL PENTIPS 31G X 5 MM	183, 194
LITETOUCH INSULIN SYRINGE 31G X 5/16	183, 194	MARATHON MEDICAL PENTIPS 31G X 8 MM	184, 194
LITETOUCH PEN NEEDLES 29G X 12.7MM	183, 194	MARATHON MEDICAL PENTIPS 32G X 4 MM	184, 194
LITETOUCH PEN NEEDLES 31G X 5 MM	183, 194	MARGENZA	227
LITETOUCH PEN NEEDLES 31G X 6 MM	183, 194	MAVYRET ORAL TABLET.....	140, 141
LITETOUCH PEN NEEDLES 31G X 8 MM	183, 194	MAXICOMFORT II PEN NEEDLE 31G X 6 MM	184, 194
LITETOUCH PEN NEEDLES 32G X 4 MM	183, 194	MAXI-COMFORT INSULIN SYRINGE 28G X 1/2.....	184, 194
LIVTENCITY.....	228	MAXI-COMFORT SAFETY PEN NEEDLE 29G X 5MM.....	184, 194
LONGS INSULIN SYRINGE 31G X 5/16	183, 194	MAXI-COMFORT SAFETY PEN NEEDLE 29G X 8MM.....	184, 194
LONSURF ORAL TABLET 15-6.14 MG, 20-8.19 MG.....	384	MAXICOMFORT SYR 27G X 1/2	184, 194
LOQTORZI.....	374	MEDIC INSULIN SYRINGE 30G X 5/16	184, 194
LORBRENA ORAL TABLET 100 MG, 25 MG	224		

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

MEDICINE SHOPPE PEN NEEDLES 29G X 12MM.....	184, 194
MEDICINE SHOPPE PEN NEEDLES 31G X 8 MM.....	184, 194
MEDPURA ALCOHOL PADS 70 % EXTERNAL	184, 194
megestrol acetate oral suspension 40 mg/ml, 625 mg/5ml	161
megestrol acetate oral tablet.....	161
MEIJER ALCOHOL SWABS PAD 70 %	184, 194
MEIJER PEN NEEDLES 29G X 12MM	184, 194
MEIJER PEN NEEDLES 31G X 6 MM	184, 194
MEIJER PEN NEEDLES 31G X 8 MM	184, 194
MEKINIST ORAL SOLUTION RECONSTITUTED.....	377
MEKINIST ORAL TABLET 0.5 MG, 2 MG	378
MEKTOVI	51
metyrosine.....	235
MICRODOT PEN NEEDLE 31G X 6 MM	184, 194
MICRODOT PEN NEEDLE 32G X 4 MM	184, 194
MICRODOT PEN NEEDLE 33G X 4 MM	184, 194
mifepristone oral tablet 300 mg	237
mimvey	152
MIPLYFFA.....	32
MIRASORB SPONGES 2.....	184, 194
MM INSULIN SYRINGE/NEEDLE 30G X 5/16	184, 194
MM INSULIN SYRINGE/NEEDLE 31G X 5/16	184, 194
MM PEN NEEDLES 31G X 5 MM	184, 194
MM PEN NEEDLES 31G X 6 MM	184, 194
MM PEN NEEDLES 31G X 8 MM	184, 194
MM PEN NEEDLES 32G X 4 MM	184, 194
modafinil oral tablet 100 mg, 200 mg.....	243
MODEYSO	88
MONOJECT INSULIN SYRINGE 25G X 5/8	184, 194
MONOJECT INSULIN SYRINGE 27G X 1/2	184, 194
MONOJECT INSULIN SYRINGE 28G X 1/2	184, 194
MONOJECT INSULIN SYRINGE 29G X 1/2	184, 194
MONOJECT INSULIN SYRINGE 30G X 5/16	184, 194
MONOJECT INSULIN SYRINGE 31G X 5/16	184, 194
MONOJECT INSULIN SYRINGE U-100 1 ML.....	184, 194
MONOJECT ULTRA COMFORT SYRINGE 28G X 1/2	184, 185, 194
MONOJECT ULTRA COMFORT SYRINGE 29G X 1/2	185, 194
MONOJECT ULTRA COMFORT SYRINGE 30G X 5/16	185, 194
MONOJECT ULTRA COMFORT SYRINGE 31G X 5/16	185, 194
MOUNJARO SUBCUTANEOUS SOLUTION AUTO-INJECTOR	144
MS INSULIN SYRINGE 31G X 5/16...	185, 194
N	
NERLYNX	247
NIKTIMVO	38
NILOTINIB D-TARTRATE ORAL CAPSULE 150 MG, 200 MG, 50 MG	248
nilotinib hcl oral capsule 150 mg, 200 mg, 50 mg	248
NINLARO.....	202
nintedanib esylate.....	250, 251
NIVESTYM.....	127
NORDITROPIN FLEXPPO SUBCUTANEOUS SOLUTION PEN-INJECTOR.....	335, 336
NOVOFINE AUTOCOVER PEN NEEDLE 30G X 8 MM.....	185, 194
NOVOFINE PEN NEEDLE 32G X 6 MM	185, 194

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

NOVOFINE PLUS PEN NEEDLE 32G X 4 MM 185, 194

NUBEQA..... 75

NUCALA SUBCUTANEOUS SOLUTION AUTO-INJECTOR 232, 233, 234

NUCALA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 100 MG/ML, 40 MG/0.4ML 232, 233, 234

NUCALA SUBCUTANEOUS SOLUTION RECONSTITUTED 232, 233, 234

NUDEXTA..... 83

NUPLAZID ORAL CAPSULE..... 282

NUPLAZID ORAL TABLET 10 MG.... 282

NURTEC..... 306, 307

NYVEPRIA 272

O

ODOMZO 338

OGIVRI..... 379

OGSIVEO ORAL TABLET 100 MG, 150 MG, 50 MG..... 254

OJEMDA ORAL SUSPENSION RECONSTITUTED..... 375

OJEMDA ORAL TABLET 375

OJJAARA 241

OMLYCLO..... 265, 266

ONAPGO 29

ONUREG 40

OPDIVO 255

OPDIVO QVANTIG 256

OPDUALAG..... 257

ORENCIA CLICKJECT..... 4, 5

ORENCIA INTRAVENOUS 2, 3

ORENCIA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 4, 5

ORGOVYX..... 295

ORKAMBI ORAL TABLET 226

ORSERDU ORAL TABLET 345 MG, 86 MG 97

OSENVELT 81

OTEZLA 30, 31

OTEZLA XR 30, 31

OTEZLA/OTEZLA XR INITIATION PK 30, 31

OZEMPIC 143

OZEMPIC (0.25 OR 0.5 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 2 MG/3ML 143

OZEMPIC (1 MG/DOSE) SUBCUTANEOUS SOLUTION PEN-INJECTOR 4 MG/3ML 143

OZEMPIC (2 MG/DOSE) 143

P

paroxetine hcl..... 162

paroxetine hcl er..... 162

pazopanib hcl oral tablet 200 mg, 400 mg 271

PC UNIFINE PENTIPS 31G X 5 MM.. 185, 194

PC UNIFINE PENTIPS 31G X 6 MM.. 185, 194

PC UNIFINE PENTIPS 31G X 8 MM.. 185, 194

PEGASYS SUBCUTANEOUS SOLUTION 180 MCG/ML 274

PEGASYS SUBCUTANEOUS SOLUTION PREFILLED SYRINGE 274

PEMAZYRE 278

PEN NEEDLE/5-BEVEL TIP 31G X 8 MM 185, 194

PEN NEEDLE/5-BEVEL TIP 32G X 4 MM 185, 194

PEN NEEDLES 29G X 12MM 185, 194

PEN NEEDLES 30G X 5 MM (OTC)... 185, 194

PEN NEEDLES 30G X 5 MM (RX) 185, 194

PEN NEEDLES 30G X 8 MM 185, 194

PEN NEEDLES 31G X 5 MM (OTC)... 185, 194

PEN NEEDLES 31G X 5 MM (RX) 185, 194

PEN NEEDLES 31G X 6 MM 185, 194

PEN NEEDLES 31G X 8 MM (OTC)... 185, 194

PEN NEEDLES 31G X 8 MM (RX) 185, 194

PEN NEEDLES 32G X 4 MM (OTC)... 185, 194

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

PEN NEEDLES 32G X 4 MM (RX)	185, 194
PEN NEEDLES 32G X 5 MM	185, 194
PEN NEEDLES 32G X 6 MM	185, 194
PEN NEEDLES 33G X 4 MM	185, 194
PEN NEEDLES 5/16	185, 194
penicillamine oral tablet.....	279, 280
PENTIPS 29G X 12MM (OTC)	185, 194
PENTIPS 29G X 12MM (RX).....	185, 194
PENTIPS 31G X 5 MM (OTC)	185, 194
PENTIPS 31G X 5 MM (RX).....	185, 194
PENTIPS 31G X 6 MM.....	185, 194
PENTIPS 31G X 8 MM (OTC)	185, 194
PENTIPS 31G X 8 MM (RX).....	185, 194
PENTIPS 32G X 4 MM (OTC)	185, 194
PENTIPS 32G X 4 MM (RX).....	185, 194
PENTIPS 32G X 6 MM.....	185, 194
PENTIPS GENERIC PEN NEEDLES 29G X 12MM.....	185, 194
PENTIPS GENERIC PEN NEEDLES 31G X 5 MM.....	185, 194
PENTIPS GENERIC PEN NEEDLES 31G X 6 MM.....	185, 194
PENTIPS GENERIC PEN NEEDLES 31G X 8 MM.....	185, 194
PENTIPS GENERIC PEN NEEDLES 32G X 4 MM.....	185, 194
PENTIPS GENERIC PEN NEEDLES 32G X 6 MM.....	185, 194
PHARMACIST CHOICE ALCOHOL PAD	185, 194
phenobarbital oral elixir 20 mg/5ml	155
phenobarbital oral tablet	155
PIP PEN NEEDLES 31G X 5MM 31G X 5 MM	185, 194
PIP PEN NEEDLES 32G X 4MM 32G X 4 MM	185, 194
PIQRAY (200 MG DAILY DOSE).....	22
PIQRAY (250 MG DAILY DOSE).....	22
PIQRAY (300 MG DAILY DOSE).....	22
pirfenidone oral capsule.....	283, 284
pirfenidone oral tablet 267 mg, 534 mg, 801 mg	283, 284
pomalidomide	286
POMALYST	286
posaconazole oral tablet delayed release	288
PRECISION SURE-DOSE SYRINGE 30G X 5/16.....	185, 194
PREFERRED PLUS INSULIN SYRINGE 28G X 1/2.....	185, 194
PREFERRED PLUS INSULIN SYRINGE 29G X 1/2.....	186, 194
PREFERRED PLUS INSULIN SYRINGE 30G X 5/16.....	186, 194
PREFERRED PLUS UNIFINE PENTIPS 29G X 12MM.....	186, 194
PREMPHASE	153
PREMPRO	153
PREVENT DROPSAFE PEN NEEDLES 31G X 6 MM.....	186, 194
PREVENT DROPSAFE PEN NEEDLES 31G X 8 MM.....	186, 194
PREVENT SAFETY PEN NEEDLES 31G X 6 MM.....	186, 194
PREVENT SAFETY PEN NEEDLES 31G X 8 MM.....	186, 194
PREVYMIS ORAL TABLET	211
PRO COMFORT ALCOHOL PAD 70 %	186, 194
PRO COMFORT INSULIN SYRINGE 30G X 1/2.....	186, 194
PRO COMFORT INSULIN SYRINGE 30G X 5/16.....	186, 194
PRO COMFORT INSULIN SYRINGE 31G X 5/16.....	186, 194
PRO COMFORT PEN NEEDLES 32G X 4 MM	186, 194
PRO COMFORT PEN NEEDLES 32G X 5 MM	186, 194
PRO COMFORT PEN NEEDLES 32G X 6 MM	186, 194
PRO COMFORT PEN NEEDLES 32G X 8 MM	186, 194
PRODIGY INSULIN SYRINGE 28G X 1/2	186, 194
PRODIGY INSULIN SYRINGE 31G X 5/16	186, 194

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

promethazine hcl injection solution 25 mg/ml 156, 157
 promethazine hcl oral tablet..... 156, 157
 promethazine hcl rectal suppository 25 mg 156, 157
 promethegan rectal suppository 12.5 mg, 25 mg 156, 157
 PURE COMFORT ALCOHOL PREP PAD 186, 194
 PURE COMFORT PEN NEEDLE 32G X 4 MM 186, 194
 PURE COMFORT PEN NEEDLE 32G X 5 MM 186, 194
 PURE COMFORT PEN NEEDLE 32G X 6 MM 186, 194
 PURE COMFORT PEN NEEDLE 32G X 8 MM 186, 194
 PURE COMFORT SAFETY PEN NEEDLE 31G X 5 MM..... 186, 194
 PURE COMFORT SAFETY PEN NEEDLE 31G X 6 MM..... 186, 194
 PURE COMFORT SAFETY PEN NEEDLE 32G X 4 MM..... 186, 194
 PX EXTRA SHORT PEN NEEDLES 31G X 6 MM..... 186, 194
 PX INSULIN SYRINGE 30G X 1/2 186, 194
 PX MINI PEN NEEDLES 31G X 5 MM 186, 194
 PX PEN NEEDLE 29G X 12MM .. 186, 194
 PX PEN NEEDLE 31G X 8 MM ... 186, 194
 PX SHORTLENGTH PEN NEEDLES 31G X 8 MM..... 186, 194
 pyrimethamine oral 290

Q

QC ALCOHOL..... 186, 194
 QC ALCOHOL SWABS PAD 70 %..... 186, 194
 QC BORDER ISLAND GAUZE PAD 2 186, 194
 QC PEN NEEDLES 29G X 12MM 186, 194
 QC PEN NEEDLES 31G X 6 MM. 186, 194
 QC PEN NEEDLES 31G X 8 MM. 186, 194

QC UNIFINE PENTIPS 32G X 4 MM . 186, 194
 QINLOCK..... 310
 QUICK TOUCH INSULIN PEN NEEDLE 29G X 12.7MM..... 186, 194
 QUICK TOUCH INSULIN PEN NEEDLE 31G X 4 MM..... 186, 194
 QUICK TOUCH INSULIN PEN NEEDLE 31G X 5 MM..... 186, 194
 QUICK TOUCH INSULIN PEN NEEDLE 31G X 6 MM..... 186, 194
 QUICK TOUCH INSULIN PEN NEEDLE 31G X 8 MM..... 187, 194
 QUICK TOUCH INSULIN PEN NEEDLE 32G X 4 MM..... 187, 194
 QUICK TOUCH INSULIN PEN NEEDLE 32G X 5 MM..... 187, 194
 QUICK TOUCH INSULIN PEN NEEDLE 32G X 6 MM..... 187, 194
 QUICK TOUCH INSULIN PEN NEEDLE 32G X 8 MM..... 187, 194
 QUICK TOUCH INSULIN PEN NEEDLE 33G X 4 MM..... 187, 194
 QUICK TOUCH INSULIN PEN NEEDLE 33G X 5 MM..... 187, 194
 QUICK TOUCH INSULIN PEN NEEDLE 33G X 6 MM..... 187, 194
 QUICK TOUCH INSULIN PEN NEEDLE 33G X 8 MM..... 187, 194
 quinine sulfate oral..... 291
 QULIPTA 34

R

RA ALCOHOL SWABS PAD 70 %..... 187, 194
 RA INSULIN SYRINGE 29G X 1/2..... 187, 194
 RA INSULIN SYRINGE 30G X 5/16... 187, 194
 ra isopropyl alcohol wipes 187, 194
 RA PEN NEEDLES 31G X 5 MM. 187, 194
 RA PEN NEEDLES 31G X 8 MM. 187, 194
 RA STERILE PAD 2 187, 194
 RALDESY 381

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

RAYA SURE PEN NEEDLE 29G X 12MM 187, 194	UNIT/ML, 3000 UNIT/ML, 4000
RAYA SURE PEN NEEDLE 31G X 4 MM 187, 194	UNIT/ML, 40000 UNIT/ML 111, 112
RAYA SURE PEN NEEDLE 31G X 5 MM 187, 194	RETEVMO ORAL CAPSULE 40 MG, 80 MG 324
RAYA SURE PEN NEEDLE 31G X 6 MM 187, 194	RETEVMO ORAL TABLET 120 MG, 160 MG, 40 MG, 80 MG 324
RAYA SURE PEN NEEDLE 31G X 8 MM 187, 194	REVCIVI..... 98
REALITY INSULIN SYRINGE 28G X 1/2 187, 194	REVUFORJ ORAL TABLET 110 MG, 160 MG, 25 MG..... 299
REALITY INSULIN SYRINGE 29G X 1/2 187, 194	REZDIFFRA..... 297
REALITY SWABS PAD..... 187, 194	REZLIDHIA 260
RELION ALCOHOL SWABS PAD..... 187, 194	REZUROCK..... 44
RELION ALCOHOL SWABS PAD 70 % 187, 194	RINVOQ 388, 389
RELI-ON INSULIN SYRINGE 29G 0.3 ML..... 187, 194	RINVOQ LQ..... 388, 389
RELION INSULIN SYRINGE 29G X 1/2 187, 194	RITUXAN HYCELA 313
RELION INSULIN SYRINGE 31G X 15/64 187, 194	ROMVIMZA 406
RELION INSULIN SYRINGE 31G X 5/16 187, 194	ROZLYTREK ORAL CAPSULE 100 MG, 200 MG 107
RELION MINI PEN NEEDLES 31G X 6 MM 187, 194	ROZLYTREK ORAL PACKET 108
RELION PEN NEEDLES 29G X 12MM 187, 194	RUBRACA 317
RELION PEN NEEDLES 31G X 6 MM187, 194	RYBELSUS 143
RELION PEN NEEDLES 31G X 8 MM187, 194	RYBELSUS (FORMULATION R2)..... 143
RELION PEN NEEDLES 32G X 4 MM187, 194	RYBREVANT 25
RELION SHORT PEN NEEDLES 31G X 8 MM 187, 194	RYBREVANT FASPRO 24
RESTORE CONTACT LAYER PAD 2 187, 194	RYDAPT..... 236
RETACRIT INJECTION SOLUTION 10000 UNIT/ML, 10000 UNIT/ML(1ML), 2000 UNIT/ML, 20000	RYTELO..... 168
	S
	SAFETY PEN NEEDLES 30G X 5 MM 187, 194
	SAFETY PEN NEEDLES 30G X 8 MM 187, 194
	sapropterin dihydrochloride oral tablet... 319
	SAPS CARE ALCOHOL PREP PAD 70 % 187, 194
	SAPS HEALTH ALCOHOL PREP PAD 70 % 187, 194
	SAPS HEALTH CARE ALCOHOL PREP PAD 70 % 187, 194
	SB ALCOHOL PREP PAD 70 %... 187, 194
	SB INSULIN SYRINGE 29G X 1/2 187, 188, 194
	SB INSULIN SYRINGE 30G X 5/16 ... 188, 194

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

SB INSULIN SYRINGE 31G X 5/16 ... 188, 194	SURE COMFORT INSULIN SYRINGE 30G X 5/16..... 188, 194
SCEMBLIX ORAL TABLET 100 MG, 20 MG, 40 MG..... 33	SURE COMFORT INSULIN SYRINGE 31G X 1/4..... 188, 194
scopolamine 158	SURE COMFORT INSULIN SYRINGE 31G X 5/16..... 188, 194
SECURESAFE INSULIN SYRINGE 29G X 1/2..... 188, 194	SURE COMFORT PEN NEEDLES 29G X 12.7MM 188, 194
SECURESAFE SAFETY PEN NEEDLES 30G X 8 MM..... 188, 194	SURE COMFORT PEN NEEDLES 30G X 8 MM 188, 194
SECURESAFE SAFETY PEN NEEDLES 31G X 5 MM..... 188, 194	SURE COMFORT PEN NEEDLES 31G X 5 MM 188, 194
SELARSDI 392, 393, 394, 395	SURE COMFORT PEN NEEDLES 31G X 6 MM 188, 194
SEROSTIM SUBCUTANEOUS SOLUTION RECONSTITUTED 4 MG, 5 MG, 6 MG..... 337	SURE COMFORT PEN NEEDLES 31G X 8 MM 188, 194
SIGNIFOR 270	SURE COMFORT PEN NEEDLES 32G X 4 MM (OTC)..... 188, 194
sildenafil citrate oral tablet 20 mg .. 327, 328	SURE COMFORT PEN NEEDLES 32G X 4 MM (RX) 188, 194
SIRTURO 42	SURE COMFORT PEN NEEDLES 32G X 6 MM 188, 194
SKYRIZI..... 311, 312	SURGICAL GAUZE SPONGE PAD 2 188, 194
SKYRIZI PEN 311, 312	SYMPAZAN..... 67
SM STERILE PAD 2..... 188, 194	SYNRIBO 261
sodium oxybate 330, 331	T
sofosbuvir-velpatasvir 332	TABRECTA 61
SOMATULINE DEPOT SUBCUTANEOUS SOLUTION 60 MG/0.2ML, 90 MG/0.3ML 204	tadalafil oral tablet 2.5 mg, 5 mg 346
SOMAVERT..... 275	TAFINLAR ORAL CAPSULE 71
sorafenib tosylate 339	TAFINLAR ORAL TABLET SOLUBLE 72
SPRAVATO (56 MG DOSE)..... 116	TAGRISO 267
SPRAVATO (84 MG DOSE)..... 116	TALVEY..... 350
STERILE GAUZE PAD 2 188, 194	TALZENNA 348
STERILE PAD 2..... 188, 194	TAVNEOS..... 35
STIVARGA 293	TECHLITE INSULIN SYRINGE 30G X 1/2 188, 194
SUBVENITE ORAL SUSPENSION 203	TECHLITE INSULIN SYRINGE 31G X 15/64 188, 194
sunitinib malate..... 344	TECHLITE INSULIN SYRINGE 31G X 5/16 188, 194
SURE COMFORT ALCOHOL PREP PAD 70 % 188, 194	TECHLITE PEN NEEDLES 29G X 12MM 188, 194
SURE COMFORT INSULIN SYRINGE 28G X 1/2..... 188, 194	
SURE COMFORT INSULIN SYRINGE 29G X 1/2..... 188, 194	
SURE COMFORT INSULIN SYRINGE 30G X 1/2..... 188, 194	

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TECHLITE PEN NEEDLES 31G X 5 MM	189, 194
TECHLITE PEN NEEDLES 31G X 8 MM	189, 194
TECHLITE PEN NEEDLES 32G X 4 MM	189, 194
TECHLITE PEN NEEDLES 32G X 6 MM	189, 194
TECHLITE PLUS PEN NEEDLES 32G X 4 MM	189, 194
TECVAYLI	353
TEGADERM FOAM PAD 2	189, 194
TEPMETKO	356
teriparatide subcutaneous solution pen-injector 560 mcg/2.24ml	357
testosterone cypionate intramuscular solution 100 mg/ml, 200 mg/ml, 200 mg/ml (1 ml)	359
testosterone enanthate intramuscular solution	360
testosterone gel 1.62 % transdermal	358
testosterone transdermal gel 12.5 mg/act (1%), 20.25 mg/act (1.62%), 25 mg/2.5gm (1%), 50 mg/5gm (1%)	358
tetrabenazine	361
TEVIMBRA	363
THALOMID ORAL CAPSULE 100 MG, 150 MG, 200 MG, 50 MG	362
TIBSOVO	201
TIGLUTIK	305
TIVDAK	364
TODAYS HEALTH PEN NEEDLES 29G X 12MM	189, 194
TODAYS HEALTH SHORT PEN NEEDLE 31G X 8 MM	189, 194
tofacitinib citrate er	370, 371
tofacitinib citrate oral	370, 371
tolvaptan oral tablet therapy pack	372
TOPCARE CLICKFINE PEN NEEDLES 31G X 6 MM	189, 194
TOPCARE CLICKFINE PEN NEEDLES 31G X 8 MM	189, 194
TOPCARE ULTRA COMFORT INS SYR 29G X 1/2	189, 194
TOPCARE ULTRA COMFORT INS SYR 30G X 5/16	189, 194
TOPCARE ULTRA COMFORT INS SYR 31G X 5/16	189, 194
TOPFINE INSULIN PEN NEEDLE 32G X 4 MM	189, 194
torpenz oral tablet 10 mg, 2.5 mg, 5 mg, 7.5 mg	119
tramadol hcl oral solution	376
TRELSTAR MIXJECT	385
TREMFYA INTRAVENOUS	146, 147
TREMFYA ONE-PRESS SUBCUTANEOUS SOLUTION PEN-INJECTOR	146, 147
TREMFYA PEN SUBCUTANEOUS SOLUTION AUTO-INJECTOR 200 MG/2ML	146, 147
TREMFYA SUBCUTANEOUS SOLUTION PREFILLED SYRINGE	146, 147
TREMFYA-CD/UC INDUCTION	146, 147
tretinoin external cream	373
tretinoin external gel 0.01 %, 0.025 %	373
trientine hcl oral capsule 250 mg	383
TRIKAFTA ORAL TABLET THERAPY PACK	99
TRIKAFTA ORAL THERAPY PACK	99
TRUE COMFORT ALCOHOL PREP PADS PAD 70 %	189, 194
TRUE COMFORT INSULIN SYRINGE 30G X 1/2	189, 194
TRUE COMFORT INSULIN SYRINGE 30G X 5/16	189, 194
TRUE COMFORT INSULIN SYRINGE 31G X 5/16	189, 194
TRUE COMFORT INSULIN SYRINGE 32G X 5/16	189, 194
TRUE COMFORT PEN NEEDLES 31G X 5 MM	189, 194
TRUE COMFORT PEN NEEDLES 31G X 6 MM	189, 194
TRUE COMFORT PEN NEEDLES 32G X 4 MM	189, 194

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

TRUE COMFORT PRO ALCOHOL PREP PAD 70 %..... 189, 194	TRUEPLUS INSULIN SYRINGE 28G X 1/2 190, 194
TRUE COMFORT PRO INSULIN SYR 30G X 1/2..... 189, 194	TRUEPLUS INSULIN SYRINGE 29G X 1/2 190, 194
TRUE COMFORT PRO INSULIN SYR 30G X 5/16..... 189, 194	TRUEPLUS INSULIN SYRINGE 30G X 5/16 190, 194
TRUE COMFORT PRO INSULIN SYR 31G X 5/16..... 189, 194	TRUEPLUS INSULIN SYRINGE 31G X 5/16 190, 194
TRUE COMFORT PRO INSULIN SYR 32G X 5/16..... 189, 194	TRUEPLUS PEN NEEDLES 29G X 12MM 190, 194
TRUE COMFORT PRO PEN NEEDLES 31G X 5 MM..... 189, 194	TRUEPLUS PEN NEEDLES 31G X 5 MM 190, 194
TRUE COMFORT PRO PEN NEEDLES 31G X 6 MM..... 189, 194	TRUEPLUS PEN NEEDLES 31G X 6 MM 190, 194
TRUE COMFORT PRO PEN NEEDLES 31G X 8 MM..... 189, 194	TRUEPLUS PEN NEEDLES 31G X 8 MM 190, 194
TRUE COMFORT PRO PEN NEEDLES 32G X 4 MM..... 189, 194	TRUEPLUS PEN NEEDLES 32G X 4 MM 190, 194
TRUE COMFORT PRO PEN NEEDLES 32G X 5 MM..... 189, 194	TRULICITY SUBCUTANEOUS SOLUTION AUTO-INJECTOR 142
TRUE COMFORT PRO PEN NEEDLES 32G X 6 MM..... 190, 194	TRUQAP ORAL TABLET 200 MG..... 60
TRUE COMFORT PRO PEN NEEDLES 33G X 4 MM..... 190, 194	TRUQAP ORAL TABLET THERAPY PACK 160 MG 60
TRUE COMFORT PRO PEN NEEDLES 33G X 5 MM..... 190, 194	TRUXIMA..... 314, 315
TRUE COMFORT PRO PEN NEEDLES 33G X 6 MM..... 190, 194	TUKYSA ORAL TABLET 150 MG, 50 MG 386
TRUE COMFORT SAFETY PEN NEEDLE 31G X 5 MM 190, 194	TURALIO ORAL CAPSULE 125 MG.. 281
TRUE COMFORT SAFETY PEN NEEDLE 31G X 6 MM 190, 194	TYENNE..... 366, 367, 368, 369
TRUE COMFORT SAFETY PEN NEEDLE 32G X 4 MM 190, 194	TYMLOS 1
TRUEPLUS 5-BEVEL PEN NEEDLES 29G X 12.7MM..... 190, 194	U
TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 5 MM..... 190, 194	UBRELVY..... 387
TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 6 MM..... 190, 194	UDENYCA ONBODY 273
TRUEPLUS 5-BEVEL PEN NEEDLES 31G X 8 MM..... 190, 194	ULTICARE ALCOHOL SWABS PAD 190, 194
TRUEPLUS 5-BEVEL PEN NEEDLES 32G X 4 MM..... 190, 194	ULTICARE ALCOHOL SWABS PAD 70 % 190, 194
	ULTICARE INSULIN SAFETY SYR 29G X 1/2..... 190, 194
	ULTICARE INSULIN SYR 1/2 UNIT 31G X 1/4..... 190, 194
	ULTICARE INSULIN SYRINGE 28G X 1/2 190, 194
	ULTICARE INSULIN SYRINGE 29G X 1/2 190, 194

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

ULTICARE INSULIN SYRINGE 30G X
 1/2 190, 194
 ULTICARE INSULIN SYRINGE 30G X
 5/16 190, 194
 ULTICARE INSULIN SYRINGE 31G X
 1/4 191, 194
 ULTICARE INSULIN SYRINGE 31G X
 5/16 191, 194
 ULTICARE MICRO PEN NEEDLES 31G
 X 6 MM..... 191, 194
 ULTICARE MICRO PEN NEEDLES 31G
 X 8 MM..... 191, 194
 ULTICARE MICRO PEN NEEDLES 32G
 X 4 MM..... 191, 194
 ULTICARE MINI PEN NEEDLES 30G X 5
 MM 191, 194
 ULTICARE MINI PEN NEEDLES 31G X 6
 MM 191, 194
 ULTICARE MINI PEN NEEDLES 32G X 6
 MM 191, 194
 ULTICARE PEN NEEDLES 29G X
 12.7MM (OTC)..... 191, 194
 ULTICARE PEN NEEDLES 29G X
 12.7MM (RX) 191, 194
 ULTICARE PEN NEEDLES 31G X 5 MM
 191, 194
 ULTICARE SHORT PEN NEEDLES 30G
 X 8 MM..... 191, 194
 ULTICARE SHORT PEN NEEDLES 31G
 X 8 MM (OTC)..... 191, 194
 ULTICARE SHORT PEN NEEDLES 31G
 X 8 MM (RX) 191, 194
 ULTIGUARD SAFEPACK PEN NEEDLE
 29G X 12.7MM..... 191, 194
 ULTIGUARD SAFEPACK PEN NEEDLE
 31G X 5 MM..... 191, 194
 ULTIGUARD SAFEPACK PEN NEEDLE
 31G X 6 MM..... 191, 194
 ULTIGUARD SAFEPACK PEN NEEDLE
 31G X 8 MM..... 191, 194
 ULTIGUARD SAFEPACK PEN NEEDLE
 32G X 4 MM..... 191, 194
 ULTIGUARD SAFEPACK PEN NEEDLE
 32G X 6 MM..... 191, 194

ULTIGUARD SAFEPACK SYR/NEEDLE
 30G X 1/2..... 191, 194
 ULTIGUARD SAFEPACK SYR/NEEDLE
 31G X 5/16..... 191, 194
 ULTILET ALCOHOL SWABS PAD ... 191,
 194
 ULTILET PEN NEEDLE 29G X 12.7MM
 191, 194
 ULTILET PEN NEEDLE 31G X 5 MM 191,
 194
 ULTILET PEN NEEDLE 31G X 8 MM 191,
 194
 ULTILET PEN NEEDLE 32G X 4 MM 191,
 194
 ULTRA COMFORT INSULIN SYRINGE
 30G X 5/16..... 191, 194
 ULTRA FLO INSULIN PEN NEEDLES
 29G X 12MM..... 191, 194
 ULTRA FLO INSULIN PEN NEEDLES
 31G X 5 MM..... 191, 194
 ULTRA FLO INSULIN PEN NEEDLES
 31G X 8 MM..... 191, 194
 ULTRA FLO INSULIN PEN NEEDLES
 32G X 4 MM..... 191, 194
 ULTRA FLO INSULIN PEN NEEDLES
 33G X 4 MM..... 191, 194
 ULTRA FLO INSULIN SYR 1/2 UNIT
 30G X 1/2..... 191, 194
 ULTRA FLO INSULIN SYR 1/2 UNIT
 30G X 5/16..... 191, 194
 ULTRA FLO INSULIN SYR 1/2 UNIT
 31G X 5/16..... 191, 194
 ULTRA FLO INSULIN SYRINGE 29G X
 1/2 191, 192, 194
 ULTRA FLO INSULIN SYRINGE 30G X
 1/2 192, 194
 ULTRA FLO INSULIN SYRINGE 30G X
 5/16 192, 194
 ULTRA FLO INSULIN SYRINGE 31G X
 5/16 192, 194
 ULTRA THIN PEN NEEDLES 32G X 4
 MM 192, 194
 ULTRA-CARE ALCOHOL PREP PADS
 PAD 70 % 192, 194

AIP Dual Advantage 2026 Formulary Prior Authorization Criteria

ULTRACARE INSULIN SYRINGE 30G X 1/2	192, 194	UNIFINE PENTIPS PLUS 29G X 12MM	193, 194
ULTRACARE INSULIN SYRINGE 30G X 5/16	192, 194	UNIFINE PENTIPS PLUS 30G X 5 MM	193, 194
ULTRACARE INSULIN SYRINGE 31G X 5/16	192, 194	UNIFINE PENTIPS PLUS 31G X 5 MM	193, 194
ULTRACARE PEN NEEDLES 31G X 5 MM	192, 194	UNIFINE PENTIPS PLUS 31G X 6 MM	193, 194
ULTRACARE PEN NEEDLES 31G X 6 MM	192, 194	UNIFINE PENTIPS PLUS 31G X 8 MM	193, 194
ULTRACARE PEN NEEDLES 31G X 8 MM	192, 194	UNIFINE PENTIPS PLUS 32G X 4 MM	193, 194
ULTRACARE PEN NEEDLES 32G X 4 MM	192, 194	UNIFINE PENTIPS PLUS 33G X 4 MM	193, 194
ULTRACARE PEN NEEDLES 32G X 5 MM	192, 194	UNIFINE PROTECT PEN NEEDLE 30G X 5 MM	193, 194
ULTRACARE PEN NEEDLES 32G X 6 MM	192, 194	UNIFINE PROTECT PEN NEEDLE 30G X 8 MM	193, 194
ULTRACARE PEN NEEDLES 33G X 4 MM	192, 194	UNIFINE PROTECT PEN NEEDLE 32G X 4 MM	193, 194
ULTRA-THIN II INS SYR SHORT 30G X 5/16	192, 194	UNIFINE SAFECONTROL PEN NEEDLE 30G X 5 MM.....	193, 194
ULTRA-THIN II INS SYR SHORT 31G X 5/16	192, 194	UNIFINE SAFECONTROL PEN NEEDLE 30G X 8 MM.....	193, 194
ULTRA-THIN II INSULIN SYRINGE 29G X 1/2.....	192, 194	UNIFINE SAFECONTROL PEN NEEDLE 31G X 5 MM.....	193, 194
ULTRA-THIN II MINI PEN NEEDLE 31G X 5 MM.....	192, 194	UNIFINE SAFECONTROL PEN NEEDLE 31G X 6 MM.....	193, 194
ULTRA-THIN II PEN NEEDLE SHORT 31G X 8 MM.....	192, 194	UNIFINE SAFECONTROL PEN NEEDLE 31G X 8 MM.....	193, 194
ULTRA-THIN II PEN NEEDLES 29G X 12.7MM	192, 194	UNIFINE SAFECONTROL PEN NEEDLE 32G X 4 MM.....	193, 194
UNIFINE OTC PEN NEEDLES 31G X 5 MM	192, 194	UNIFINE ULTRA PEN NEEDLE 29G X 12MM	193, 194
UNIFINE OTC PEN NEEDLES 32G X 4 MM	192, 194	UNIFINE ULTRA PEN NEEDLE 31G X 5 MM	193, 194
UNIFINE PENTIPS 29G X 12MM	192, 194	UNIFINE ULTRA PEN NEEDLE 31G X 6 MM	193, 194
UNIFINE PENTIPS 30G X 5 MM.	192, 194	UNIFINE ULTRA PEN NEEDLE 31G X 8 MM	193, 194
UNIFINE PENTIPS 31G X 5 MM.	192, 194	UNIFINE ULTRA PEN NEEDLE 32G X 4 MM	193, 194
UNIFINE PENTIPS 31G X 6 MM.	192, 194	UNIFINE ULTRA PEN NEEDLE 32G X 6 MM	193, 194
UNIFINE PENTIPS 31G X 8 MM.	192, 194	UNIFINE ULTRA PEN NEEDLE 33G X 4 MM.	193, 194
UNIFINE PENTIPS 32G X 4 MM.	192, 194		
UNIFINE PENTIPS 32G X 6 MM.	192, 194		
UNIFINE PENTIPS 33G X 4 MM.	193, 194		

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

UNIFINE ULTRA PEN NEEDLE 34G X
3.5 MM 193, 194

UPTRAVI ORAL TABLET 100 MCG,
1000 MCG, 1200 MCG, 1400 MCG, 150
MCG, 1600 MCG, 200 MCG, 400 MCG,
600 MCG, 800 MCG 322

UPTRAVI TITRATION 322

ustekinumab-aauz 390, 391

V

VALCHLOR 231

VALUE HEALTH INSULIN SYRINGE
29G X 1/2 193, 194

VANFLYTA 292

VANISHPOINT INSULIN SYRINGE 29G
X 1/2 193, 194

VANISHPOINT INSULIN SYRINGE 29G
X 5/16 193, 194

VANISHPOINT INSULIN SYRINGE 30G
X 1/2 193, 194

VANISHPOINT INSULIN SYRINGE 30G
X 3/16 193, 194

VANISHPOINT INSULIN SYRINGE 30G
X 5/16 193, 194

VENCLEXTA ORAL TABLET 10 MG,
100 MG, 50 MG 403

VENCLEXTA STARTING PACK 403

VEOZAH 125, 126

VEPPANU 404

VERIFINE INSULIN PEN NEEDLE 29G
X 12MM 193, 194

VERIFINE INSULIN PEN NEEDLE 31G
X 5 MM 193, 194

VERIFINE INSULIN PEN NEEDLE 31G
X 8 MM 193, 194

VERIFINE INSULIN PEN NEEDLE 32G
X 4 MM 193, 194

VERIFINE INSULIN PEN NEEDLE 32G
X 6 MM 193, 194

VERIFINE INSULIN SYRINGE 28G X 1/2
..... 193, 194

VERIFINE INSULIN SYRINGE 29G X 1/2
..... 193, 194

VERIFINE INSULIN SYRINGE 30G X 1/2
..... 193, 194

VERIFINE INSULIN SYRINGE 30G X
5/16 193, 194

VERIFINE INSULIN SYRINGE 31G X
5/16 193, 194

VERIFINE PLUS PEN NEEDLE 31G X 5
MM 193, 194

VERIFINE PLUS PEN NEEDLE 31G X 8
MM 194

VERIFINE PLUS PEN NEEDLE 32G X 4
MM 194

VERQUVO 405

VERZENIO 6

VITRAKVI ORAL CAPSULE 100 MG, 25
MG 206

VITRAKVI ORAL SOLUTION 206

VIVIMUSTA 46

VIZIMPRO 73

VONJO 268

VOQUEZNA 408

VORANIGO 409

voriconazole oral suspension reconstituted
..... 410

VOSEVI 333, 334

VOWST 121

VP INSULIN SYRINGE 29G X 1/2 194

VUMERITY 87

VYALEV SUBCUTANEOUS SOLUTION
12-240 MG/ML 130

VYLOY 415

VYNDAMAX 347

W

WEBCOL ALCOHOL PREP LARGE PAD
70 % 194

WEBCOL ALCOHOL PREP MEDIUM
PAD 70 % 194

WEGMANS UNIFINE PENTIPS PLUS
31G X 5 MM 194

WEGMANS UNIFINE PENTIPS PLUS
31G X 6 MM 194

WEGMANS UNIFINE PENTIPS PLUS
31G X 8 MM 194

WEGMANS UNIFINE PENTIPS PLUS
32G X 4 MM 194

WELIREG 45

AIP Dual Advantage 2026 Formulary

Prior Authorization Criteria

WINREVAIR..... 340, 341

X

XALKORI ORAL CAPSULE..... 69

XALKORI ORAL CAPSULE SPRINKLE

150 MG, 20 MG, 50 MG 70

XDEMVIY 225

XERMELO 355

XIFAXAN ORAL TABLET 200 MG, 550

MG 302

XOLAIR 262, 263, 264

XOSPATA 137

XPOVIO (100 MG ONCE WEEKLY)

ORAL TABLET THERAPY PACK 50

MG 323

XPOVIO (40 MG ONCE WEEKLY) ORAL

TABLET THERAPY PACK 10 MG, 40

MG 323

XPOVIO (40 MG TWICE WEEKLY)

ORAL TABLET THERAPY PACK 40

MG 323

XPOVIO (60 MG ONCE WEEKLY) ORAL

TABLET THERAPY PACK 60 MG.. 323

XPOVIO (60 MG TWICE WEEKLY)... 323

XPOVIO (80 MG ONCE WEEKLY) ORAL

TABLET THERAPY PACK 40 MG, 80

MG 323

XPOVIO (80 MG TWICE WEEKLY)... 323

XTANDI ORAL CAPSULE..... 109

XTANDI ORAL TABLET 40 MG, 80 MG

..... 109

Y

YERVOY 198

YESINTEK 396, 397, 398, 399

YONSA..... 8

YUFLYMA (1 PEN)..... 14, 15

YUFLYMA (2 SYRINGE)..... 14, 15

YUFLYMA-CD/UC/HS STARTER .. 14, 15

yulithira oral tablet 10 mg, 2.5 mg, 5 mg, 7.5

mg 119

Z

ZEJULA ORAL TABLET..... 252

ZELBORAF 402

ZEVRX INSULIN SYRINGE 30G X 1/2

..... 194

ZEVRX INSULIN SYRINGE 30G X 5/16

..... 194

ZEVRX PEN NEEDLES 31G X 5 MM. 194

ZEVRX PEN NEEDLES 31G X 6 MM. 194

ZEVRX PEN NEEDLES 31G X 8 MM. 194

ZEVRX PEN NEEDLES 32G X 4 MM. 194

ZEVRX STERILE ALCOHOL PREP PAD

PAD 70 % 194

ZIIHERA..... 411

ZIRABEV 49

ZOLADEX..... 145

ZTALMY 134

ZURZUVAE ORAL CAPSULE 20 MG, 25

MG, 30 MG..... 417

ZYDELIG 165

ZYKADIA ORAL TABLET 63

ZYNLONTA..... 223

ZYNYZ 298